[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 642
1. Schor NF: Pharmacotherapy for adults with tumors of the central nervous system. Pharmacol Ther; 2009 Mar;121(3):253-64
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacotherapy for adults with tumors of the central nervous system.
  • Tumors of the adult central nervous system are among the most common and most chemoresistant neoplasms.
  • Malignant tumors of the brain and spinal cord collectively account for approximately 1.3% of all cancers and 2.2% of all cancer-related deaths.
  • Novel pharmacological approaches to nervous system tumors are urgently needed.
  • This review presents the current approaches and challenges to successful pharmacotherapy of adults with malignant tumors of the central nervous system and discusses novel approaches aimed at overcoming these challenges.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Relat Cancer. 2008 Sep;15(3):721-43 [18753362.001]
  • [Cites] J Neurooncol. 2002 Jun;58(2):115-23 [12164682.001]
  • [Cites] Clin Cancer Res. 2002 Aug;8(8):2725-34 [12171906.001]
  • [Cites] Anticancer Res. 2002 Jul-Aug;22(4):2029-36 [12174880.001]
  • [Cites] Cancer. 2002 Sep 1;95(5):1113-9 [12209698.001]
  • [Cites] Chemotherapy. 2002 Sep;48(4):189-95 [12218266.001]
  • [Cites] Clin Cancer Res. 2002 Sep;8(9):3008-18 [12231548.001]
  • [Cites] Glia. 2002 Oct;40(1):44-54 [12237842.001]
  • [Cites] Cancer Chemother Pharmacol. 2002 Dec;50(6):479-89 [12451475.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Feb;62(2):111-26 [12578221.001]
  • [Cites] Ann Oncol. 2003 Apr;14(4):599-602 [12649108.001]
  • [Cites] Neuroimaging Clin N Am. 2002 Nov;12(4):525-36 [12687909.001]
  • [Cites] Neuroimaging Clin N Am. 2002 Nov;12(4):583-97 [12687913.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23(2B):1631-5 [12820433.001]
  • [Cites] Curr Opin Oncol. 2003 Nov;15(6):412-8 [14624222.001]
  • [Cites] Clin Cancer Res. 2004 Dec 1;10(23):7875-83 [15585620.001]
  • [Cites] Lancet Neurol. 2005 Jan;4(1):4-5 [15620846.001]
  • [Cites] J Neurol Sci. 2005 Feb 15;228(2):143-7 [15694195.001]
  • [Cites] J Neurooncol. 2005 Feb;71(3):295-9 [15735920.001]
  • [Cites] J Neurooncol. 2005 Feb;71(3):301-5 [15735921.001]
  • [Cites] Anticancer Res. 2004 Nov-Dec;24(6):4195-203 [15736473.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2411-22 [15800333.001]
  • [Cites] Neurology. 2005 Apr 26;64(8):1444-5 [15851741.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 15;97(12):880-7 [15956649.001]
  • [Cites] Front Biosci. 2005;10:2645-68 [15970525.001]
  • [Cites] Eur J Endocrinol. 2005 Jul;153(1):135-41 [15994755.001]
  • [Cites] J Neurosurg. 2005 Jun;102(6):1170; author reply 1170-1 [16028784.001]
  • [Cites] Oncogene. 2005 Aug 4;24(33):5226-34 [15897911.001]
  • [Cites] Neurochem Int. 2005 Nov;47(6):430-41 [16087277.001]
  • [Cites] Mol Cancer Ther. 2005 Sep;4(9):1293-302 [16170020.001]
  • [Cites] J Neurooncol. 2005 Sep;74(2):113-21 [16193381.001]
  • [Cites] Cancer Lett. 2006 Jan 8;231(1):74-86 [16356833.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11419-28 [16357150.001]
  • [Cites] Cancer. 2006 Jan 1;106(1):172-9 [16323194.001]
  • [Cites] Pituitary. 2005;8(1):43-52 [16411068.001]
  • [Cites] Pituitary. 2005;8(1):53-60 [16411069.001]
  • [Cites] BMC Cancer. 2006;6:2 [16393339.001]
  • [Cites] Eur J Endocrinol. 2006 Mar;154(3):467-77 [16498061.001]
  • [Cites] Eur Spine J. 2006 Feb;15(2):203-10 [16374649.001]
  • [Cites] J Endocrinol Invest. 2006 Jan;29(1):86-93 [16553040.001]
  • [Cites] J Cell Physiol. 2006 Jul;208(1):220-8 [16575905.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4687-92 [16651420.001]
  • [Cites] Clin Cancer Res. 2006 May 1;12(9):2716-29 [16675563.001]
  • [Cites] Neurosurg Focus. 2006;20(4):E22 [16709028.001]
  • [Cites] Neurosurg Focus. 2006;20(4):E24 [16709030.001]
  • [Cites] Neurosurg Focus. 2006;20(4):E7 [16709038.001]
  • [Cites] Cell Death Differ. 2006 Jul;13(7):1238-41 [16456578.001]
  • [Cites] Oncol Rep. 2006 Jul;16(1):127-32 [16786135.001]
  • [Cites] Front Horm Res. 2006;35:129-34 [16809928.001]
  • [Cites] Expert Rev Anticancer Ther. 2006 Jul;6(7):1087-104 [16831080.001]
  • [Cites] Endocr Rev. 2006 Aug;27(5):485-534 [16705142.001]
  • [Cites] Anticancer Drugs. 2006 Aug;17(7):733-51 [16926624.001]
  • [Cites] Nat Clin Pract Neurol. 2005 Dec;1(2):88-95 [16932504.001]
  • [Cites] BMC Complement Altern Med. 2006;6:27 [16914050.001]
  • [Cites] J Neurooncol. 2006 Sep;79(3):271-9 [16645721.001]
  • [Cites] Glia. 2006 Dec;54(8):850-60 [16981197.001]
  • [Cites] Int J Oncol. 2006 Nov;29(5):1295-301 [17016664.001]
  • [Cites] Oncol Rep. 2006 Nov;16(5):1117-21 [17016602.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2006 Oct;2(10):552-61 [17024154.001]
  • [Cites] J Pharmacol Exp Ther. 2006 Dec;319(3):1424-34 [16971507.001]
  • [Cites] Expert Rev Anticancer Ther. 2006 Nov;6(11):1585-92 [17134363.001]
  • [Cites] NMR Biomed. 2006 Dec;19(8):1035-42 [16894643.001]
  • [Cites] Jpn J Clin Oncol. 2008 May;38(5):373-80 [18413337.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Sep;62(4):699-706 [18338171.001]
  • [Cites] Neurology. 2008 Jul 29;71(5):365-73 [18663182.001]
  • [Cites] J Neurooncol. 2003 Oct;65(1):77-85 [14649887.001]
  • [Cites] Pituitary. 2003;6(1):19-27 [14674720.001]
  • [Cites] Lancet Oncol. 2004 Feb;5(2):89-100 [14761812.001]
  • [Cites] Cancer. 2004 Feb 15;100(4):807-13 [14770438.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):927-31 [14967452.001]
  • [Cites] Clin Neuropathol. 2004 Jan-Feb;23(1):21-7 [14986930.001]
  • [Cites] J Neurooncol. 2004 Feb;66(3):365-75 [15015670.001]
  • [Cites] Cancer. 2004 Apr 15;100(8):1712-6 [15073861.001]
  • [Cites] Neuroendocrinology. 2004 Mar;79(3):142-8 [15103227.001]
  • [Cites] Neurosurg Focus. 2003 Nov 15;15(5):E13 [15323470.001]
  • [Cites] J Exp Clin Cancer Res. 2004 Jun;23(2):201-6 [15354403.001]
  • [Cites] Neurology. 2004 Sep 14;63(5):901-3 [15365145.001]
  • [Cites] Neurology. 2004 Sep 14;63(5):904-6 [15365146.001]
  • [Cites] Mol Cancer Ther. 2004 Sep;3(9):1127-35 [15367707.001]
  • [Cites] J Neurosurg. 2004 Oct;101(4):653-8 [15481721.001]
  • [Cites] J Neurosurg. 2004 Nov;101(5):826-31 [15540922.001]
  • [Cites] J Inorg Biochem. 2004 Dec;98(12):2168-73 [15541507.001]
  • [Cites] BMC Cancer. 2006;6:294 [17181871.001]
  • [Cites] J Clin Neurosci. 2007 Mar;14(3):261-6 [17258135.001]
  • [Cites] Br J Cancer. 2007 Mar 26;96(6):960-9 [17342095.001]
  • [Cites] Clin Neurosurg. 2006;53:345-51 [17380773.001]
  • [Cites] Curr Pharm Biotechnol. 2007 Apr;8(2):105-13 [17430159.001]
  • [Cites] J Natl Cancer Inst. 2007 Apr 18;99(8):639-52 [17440165.001]
  • [Cites] Ann Neurol. 2007 May;61(5):484-90 [17469128.001]
  • [Cites] J Mol Med (Berl). 2007 May;85(5):497-509 [17221219.001]
  • [Cites] Cancer Res. 2007 May 1;67(9):4467-73 [17483362.001]
  • [Cites] Neurology. 2007 May 22;68(21):1831-6 [17515545.001]
  • [Cites] J Neurochem. 2007 Jul;102(2):522-38 [17596214.001]
  • [Cites] Ann Endocrinol (Paris). 2007 Jun;68(2-3):118-9 [17512893.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12867-72 [17646646.001]
  • [Cites] Mol Cancer Ther. 2007 Aug;6(8):2290-302 [17699724.001]
  • [Cites] Neurol Med Chir (Tokyo). 2007 Aug;47(8):341-9; discussion 350 [17721049.001]
  • [Cites] J Neurooncol. 2007 Oct;85(1):1-10 [17429576.001]
  • [Cites] Bull Cancer. 2007 Sep;94(9):769-73 [17878096.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):643-53 [10690550.001]
  • [Cites] Acta Neuropathol. 2000 May;99(5):555-62 [10805101.001]
  • [Cites] J Clin Neurosci. 2000 Jan;7(1):20-3 [10847645.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Jun;85(6):2247-52 [10852458.001]
  • [Cites] J Neurooncol. 2000;46(2):157-71 [10894369.001]
  • [Cites] Int J Oncol. 2000 Sep;17(3):501-5 [10938390.001]
  • [Cites] N Engl J Med. 2000 Nov 9;343(19):1350-4 [11070098.001]
  • [Cites] Ann Endocrinol (Paris). 2000 Nov;61(5):411-7 [11084391.001]
  • [Cites] Cancer Treat Rev. 2000 Dec;26(6):449-62 [11139374.001]
  • [Cites] J Exp Clin Cancer Res. 2000 Sep;19(3):357-62 [11144529.001]
  • [Cites] Neurosurgery. 2001 Jan;48(1):151-7 [11152340.001]
  • [Cites] J Neurooncol. 2000 Sep;49(2):105-15 [11206006.001]
  • [Cites] J Neurooncol. 2000 Sep;49(2):117-29 [11206007.001]
  • [Cites] Jpn J Cancer Res. 2001 Feb;92(2):211-9 [11223551.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jan;86(1):140-5 [11231991.001]
  • [Cites] J Neurooncol. 2000 Dec;50(3):227-37 [11263502.001]
  • [Cites] Eur J Cancer. 2001 May;37(7):930-8 [11313183.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Aug;86(8):3809-14 [11502816.001]
  • [Cites] Cancer Gene Ther. 2001 Aug;8(8):589-98 [11571537.001]
  • [Cites] Br J Cancer. 2001 Sep 28;85(7):1077-83 [11592782.001]
  • [Cites] J Neuroimmunol. 2001 Nov 1;120(1-2):19-24 [11694315.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Nov;86(11):5256-61 [11701688.001]
  • [Cites] Curr Opin Neurol. 2001 Dec;14(6):679-82 [11723373.001]
  • [Cites] Lancet Oncol. 2001 Sep;2(9):552-60 [11905710.001]
  • [Cites] Neurology. 2002 Apr 23;58(8):1310-1 [11971113.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2277-83 [11980998.001]
  • [Cites] Med Oncol. 2002;19(1):1-9 [12025885.001]
  • [Cites] Expert Opin Investig Drugs. 2002 Jun;11(6):787-800 [12036422.001]
  • [Cites] Lancet Oncol. 2002 Jul;3(7):397-406 [12142169.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4307-15 [12154034.001]
  • (PMID = 19091301.001).
  • [ISSN] 0163-7258
  • [Journal-full-title] Pharmacology & therapeutics
  • [ISO-abbreviation] Pharmacol. Ther.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS038569; United States / NINDS NIH HHS / NS / NS038569-10; United States / NCI NIH HHS / CA / CA074289-09; United States / NCI NIH HHS / CA / R01 CA074289-09; United States / NCI NIH HHS / CA / R01 CA074289; United States / NINDS NIH HHS / NS / R01 NS038569-10
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 132
  • [Other-IDs] NLM/ NIHMS103661; NLM/ PMC2782733
  •  go-up   go-down


2. Eyenga VC, Ngah JE, Atangana R, Etom E, Ngowe MN, Bassong Y, Oyono JL, Sosso M: [Central nervous system tumours in Cameroon: histopathology and demography]. Sante; 2008 Jan-Mar;18(1):39-42
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Central nervous system tumours in Cameroon: histopathology and demography].
  • [Transliterated title] Les tumeurs du système nerveux central au Cameroun: histopathologie, démographie.
  • Tumours of the central nervous system (CNS) have not received much scientific attention in sub-Saharan Africa, especially in the central African zone.
  • The aim of this study was to determine the relative frequency and different histologic types of CNS tumours seen in the neurosurgery units of Cameroon, a multiethnic country of central Africa.
  • This retrospective study covers the decade from January 1996 through December 2006 in the three neurosurgery departments in Cameroon, at the Yaoundé General Hospital, the Yaoundé Central Hospital, and the Douala General Hospital.
  • INCLUSION CRITERIA: All cases undergoing surgery in these units for a histologically-confirmed CNS tumour.
  • The average age of patients with metastatic tumors was 42+/-18.5 years compared with 36.5+/-17.8 years for cases with primary tumors.
  • Primary tumors were malignant in 34.2% (n=12) of the children and benign in 65.8% (n=23); among adults 22.7% (n=30) were malignant and 77.3% (n=102) benign.
  • In conclusion, CNS tumors occurred mainly before the age of 55 years and had a slight predilection for girls and women.
  • Meningiomas were the most frequent tumors in adults while astrocytomas were more prevalent in children.
  • [MeSH-major] Brain Neoplasms / epidemiology. Meningeal Neoplasms / epidemiology. Meningioma / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Astrocytoma / epidemiology. Astrocytoma / pathology. Brain / pathology. Cameroon. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Male. Meninges / pathology. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18684690.001).
  • [ISSN] 1157-5999
  • [Journal-full-title] Santé (Montrouge, France)
  • [ISO-abbreviation] Sante
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


3. Vieira Santos A, Vilela P, Mateus L, Saraiva PF, Goulão A: [Central nervous system abnormalities namely secondary brain tumors]. Acta Med Port; 2006 Nov-Dec;19(6):451-4
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Central nervous system abnormalities namely secondary brain tumors].
  • [Transliterated title] Tumor do sistema nervoso central secundário a radioterapia e quimioterapia.
  • The authors speculate about the possibility that this tumor may have been radiation and/or chemotherapy induced.
  • Improvement in neuroimaging techniques, in particular magnetic resonance imaging, has helped characterize Central Nervous System abnormalities, namely secondary brain tumours.
  • [MeSH-major] Brain Neoplasms / diagnosis. Glioblastoma / diagnosis. Neoplasms, Second Primary / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy
  • [MeSH-minor] Adult. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17583602.001).
  • [ISSN] 1646-0758
  • [Journal-full-title] Acta médica portuguesa
  • [ISO-abbreviation] Acta Med Port
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Portugal
  •  go-up   go-down


Advertisement
4. Guinto-Balanzar G, Félix-Espinoza I, Ponce-de-León Sde A, Aréchiga-Ramos NC, Arteaga-Larios V, Kovacs K: [Primary central nervous system lymphoma in immunocompetent patients]. Gac Med Mex; 2005 Nov-Dec;141(6):469-76
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary central nervous system lymphoma in immunocompetent patients].
  • [Transliterated title] Linfoma primario del sistema nervioso central en pacientes inmunocompetentes.
  • Primary central nervous system lymphoma has been traditionally described in patients with immunodeficiency syndromes; however, there is an increasing number of immunocompetent patients with this type of tumor that have been reported recently.
  • The majority of tumors were histologically classified as diffuse large cells and all of them showed a positive reaction to B-cells antigens on immunohistochemistry.
  • [MeSH-major] Brain Neoplasms. Lymphoma, B-Cell
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunocompetence. Male. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16381500.001).
  • [ISSN] 0016-3813
  • [Journal-full-title] Gaceta médica de México
  • [ISO-abbreviation] Gac Med Mex
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


5. Brown M, Schrot R, Bauer K, Letendre D: Incidence of first primary central nervous system tumors in California, 2001-2005. J Neurooncol; 2009 Sep;94(2):249-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of first primary central nervous system tumors in California, 2001-2005.
  • We examined the incidence of first primary central nervous system tumors (PCNST) in California from 2001-2005.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurol Sci. 2000 Apr 1;175(1):33-9 [10785254.001]
  • [Cites] Neuroepidemiology. 2008;30(1):34-44 [18259099.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2000 Oct;69(4):464-71 [10990505.001]
  • [Cites] Neuro Oncol. 1999 Jan;1(1):14-25 [11554386.001]
  • [Cites] Cancer Causes Control. 2001 Oct;12(8):703-11 [11562110.001]
  • [Cites] Cancer Causes Control. 2002 Mar;13(2):175-82 [11936824.001]
  • [Cites] Expert Rev Anticancer Ther. 2001 Oct;1(3):395-401 [12113106.001]
  • [Cites] Br J Neurosurg. 2002 Dec;16(6):562-6 [12617237.001]
  • [Cites] Int J Epidemiol. 2003 Apr;32(2):225-33 [12714541.001]
  • [Cites] Neurosurgery. 2003 Jun;52(6):1327-33; discussion 1333-4 [12762878.001]
  • [Cites] Neuroepidemiology. 2004 Jan-Apr;23(1-2):85-93 [14739573.001]
  • [Cites] Am J Epidemiol. 1970 Mar;91(3):238-59 [4313251.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1976 Mar;39(3):290-6 [932744.001]
  • [Cites] Cancer. 1976 Nov;38(5):2135-42 [991126.001]
  • [Cites] J Neuropathol Exp Neurol. 1977 Jan;36(1):41-9 [188996.001]
  • [Cites] Surg Neurol. 1979 Oct;12(4):317-8 [524248.001]
  • [Cites] Neurosurgery. 1982 Jan;10(1):16-21 [7057973.001]
  • [Cites] Ann N Y Acad Sci. 1982;381:202-8 [6953791.001]
  • [Cites] Surg Neurol. 1984 Aug;22(2):149-56 [6740478.001]
  • [Cites] J Natl Cancer Inst. 1985 Feb;74(2):291-7 [3856043.001]
  • [Cites] J Neurooncol. 1989 Sep;7(3):211-24 [2795117.001]
  • [Cites] J Natl Med Assoc. 1992 Oct;84(10):858-63 [1404461.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] Cancer. 1995 Jan 1;75(1 Suppl):330-7 [8001004.001]
  • [Cites] J Natl Cancer Inst. 1996 May 15;88(10):675-9 [8627644.001]
  • [Cites] J Neurosurg. 1996 Jun;84(6):946-50 [8847588.001]
  • [Cites] Neuroepidemiology. 1996;15(2):103-12 [8684582.001]
  • [Cites] Cancer. 1997 Feb 15;79(4):796-803 [9024718.001]
  • [Cites] Natl Vital Stat Rep. 1998 Oct 7;47(3):1-16, 20 [9796247.001]
  • [Cites] Am J Epidemiol. 1999 Jun 1;149(11):1063-71 [10355383.001]
  • [Cites] Neuro Oncol. 2006 Jan;8(1):27-37 [16443945.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Apr;15(4):630-8 [16614102.001]
  • [Cites] Neurosurg Focus. 2006;20(4):E1 [16709014.001]
  • [Cites] J Neurooncol. 2006 Jul;78(3):303-10 [16598428.001]
  • [Cites] Cancer. 2006 Oct 15;107(8):1711-42 [16958083.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] J Neurooncol. 2007 Sep;84(2):189-99 [17431547.001]
  • [Cites] Neurol Clin. 2007 Nov;25(4):867-90, vii [17964019.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2642-52 [10861444.001]
  • (PMID = 19340398.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] ENG
  • [Grant] United States / NCCDPHP CDC HHS / DP / U58 DP000807; United States / NCI NIH HHS / CA / N01PC54404; United States / NCI NIH HHS / CA / N01PC35136; United States / NCI NIH HHS / CA / N01PC35139; United States / NCCDPHP CDC HHS / DP / 1U58DP00807-01
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2724635
  •  go-up   go-down


6. Crawford JR, Santi MR, Cornelison R, Sallinen SL, Haapasalo H, MacDonald TJ: Detection of human herpesvirus-6 in adult central nervous system tumors: predominance of early and late viral antigens in glial tumors. J Neurooncol; 2009 Oct;95(1):49-60
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of human herpesvirus-6 in adult central nervous system tumors: predominance of early and late viral antigens in glial tumors.
  • The purpose is to determine the incidence of active and latent human herpesvirus-6 (HHV-6) infection in a large cohort of adult primary and recurrent CNS tumors.
  • We screened a tissue microarray (TMA) containing more than 200 adult primary and recurrent CNS tumors with known clinical information for the presence of HHV-6 DNA by in situ hybridization (ISH) and protein by immunohistochemistry (IHC).
  • One hundred six of 224 (47%) CNS tumors were positive for HHV-6 U57 Major Capsid Protein (MCP) gene by ISH compared to 0/25 non tumor control brain (P = 0.001).
  • Fourteen of 30 (47%) tumors were HHV-6 MCP positive by nested PCR compared to 0/25 non-tumor brain controls (P = 0.001), revealing HHV-6 Variant A in 6 of 14 samples.
  • HHV-6A/B early (p41) and late (gp116/64/54) antigens were detected by IHC in 66 of 277 (24%) (P = 0.003) and 84 of 282 (35%) (P = 0.002) tumors, respectively, suggesting active infection.
  • Glial tumors were 3 times more positive by IHC compared to non glial tumors for both HHV-6 gp116/64/54 (P = 0.0002) and HHV-6 p41 (P = 0.004).
  • HHV-6 early and late antigens are detected in adult primary and recurrent CNS tumors more frequently in glial tumors.
  • We hypothesize that the glial-tropic features of HHV-6 may play an important modifying role in tumor biology that warrants further investigation.
  • [MeSH-major] Antigens, Viral. Central Nervous System Neoplasms / genetics. Central Nervous System Neoplasms / virology. Glioma / genetics. Glioma / virology. Herpesvirus 6, Human / isolation & purification
  • [MeSH-minor] Adult. Antigens, CD / metabolism. CD48 Antigen. Capsid Proteins / genetics. Capsid Proteins / metabolism. Humans. Survival Analysis. Viral Envelope Proteins / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19424665.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / K12NS052159-01A
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Viral; 0 / CD48 Antigen; 0 / Capsid Proteins; 0 / Viral Envelope Proteins
  •  go-up   go-down


7. Bellil S, Braham E, Limaiem F, Bellil K, Chelly I, Mekni A, Haouet S, Zitouna M, Jemel H, Khaldi M, Kchir N: [Central nervous system dysgerminoma: a clinicopathological study of 3 cases]. Tunis Med; 2009 Mar;87(3):207-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Central nervous system dysgerminoma: a clinicopathological study of 3 cases].
  • [Transliterated title] Dysgerminomes du système nerveux central: étude anatomo-clinique de 3 cas.
  • BACKGROUND: Intracranial germ cell tumors are rarely seen and typically localize in the pineal or suprasellar region.
  • The largest category of germ cell tumors is dysgerminoma.
  • CASE REPORT: We report three cases of central nervous system dysgerminomas.
  • Histologic examination and immunohistochemical study of surgical specimen were consistent with primary central nervous system dysgerminoma.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Dysgerminoma / pathology
  • [MeSH-minor] Child. Female. Humans. Male. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19537016.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


8. Moulignier A: [HIV and the central nervous system]. Rev Neurol (Paris); 2006 Jan;162(1):22-42
HIV InSite. treatment guidelines - Cardiac Cardiac Manifestations of HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [HIV and the central nervous system].
  • [Transliterated title] Atteintes du système nerveux central et infection par le VIH-1.
  • Central nervous system complications are common in HIV-1 infected patients and occur either as a result of concomitant immunosuppression (opportunistic infections, lymphoma and tumors), as a primary manifestation of HIV infection, or as an adverse effect of therapy (immune restoration and toxicity).
  • [MeSH-major] Central Nervous System Diseases / etiology. Encephalitis / etiology. HIV Infections / complications
  • [MeSH-minor] AIDS Dementia Complex / diagnosis. AIDS Dementia Complex / epidemiology. AIDS Dementia Complex / etiology. AIDS Dementia Complex / therapy. AIDS-Related Opportunistic Infections / diagnosis. AIDS-Related Opportunistic Infections / epidemiology. AIDS-Related Opportunistic Infections / etiology. AIDS-Related Opportunistic Infections / therapy. Adult. Animals. Brain Ischemia / etiology. Brain Neoplasms / diagnosis. Brain Neoplasms / epidemiology. Brain Neoplasms / etiology. Brain Neoplasms / therapy. Child. Cytomegalovirus Infections / complications. Cytomegalovirus Infections / epidemiology. Disease Susceptibility. Encephalitis, Viral / diagnosis. Encephalitis, Viral / epidemiology. Encephalitis, Viral / etiology. Encephalitis, Viral / therapy. Humans. Immunocompromised Host. Leukoencephalopathy, Progressive Multifocal / diagnosis. Leukoencephalopathy, Progressive Multifocal / epidemiology. Leukoencephalopathy, Progressive Multifocal / etiology. Leukoencephalopathy, Progressive Multifocal / therapy. Lymphoma, AIDS-Related / diagnosis. Lymphoma, AIDS-Related / epidemiology. Lymphoma, AIDS-Related / etiology. Lymphoma, AIDS-Related / therapy. Magnetic Resonance Imaging. Meningitis, Cryptococcal / diagnosis. Meningitis, Cryptococcal / epidemiology. Meningitis, Cryptococcal / etiology. Meningitis, Cryptococcal / therapy. Middle Aged. Myelitis, Transverse / diagnosis. Myelitis, Transverse / epidemiology. Myelitis, Transverse / etiology. Myelitis, Transverse / therapy. Neurosyphilis / diagnosis. Neurosyphilis / epidemiology. Neurosyphilis / etiology. Neurosyphilis / therapy. Toxoplasmosis, Cerebral / diagnosis. Toxoplasmosis, Cerebral / epidemiology. Toxoplasmosis, Cerebral / etiology. Tuberculosis / diagnosis. Tuberculosis / epidemiology. Tuberculosis / etiology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Encephalitis.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16446621.001).
  • [ISSN] 0035-3787
  • [Journal-full-title] Revue neurologique
  • [ISO-abbreviation] Rev. Neurol. (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 114
  •  go-up   go-down


9. Eap C, Litré CF, Noudel R, Theret E, Duntze J, Collin P, Rousseaux P: [Primitive malignant rhabdoid tumor of the central nervous system in an adolescent. A case study]. Neurochirurgie; 2010 Oct;56(5):404-7
ORBi (University of Liege). Free full Text at ORBi .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primitive malignant rhabdoid tumor of the central nervous system in an adolescent. A case study].
  • [Transliterated title] Tumeur rhabdoïde du système nerveux central chez une adolescente de 16ans : à propos d'un cas.
  • Primitive malignant rhabdoid tumors of the central nervous system are rare and have a poor prognosis.
  • Adult and adolescent cases are exceptional.
  • We report the case of a 16-year-old girl who presented an intratumoral hemorrhage in a rhabdoid tumor.
  • We discuss the different therapeutic options for this patient and review the literature on this kind of tumor.
  • [MeSH-major] Brain Neoplasms. Rhabdoid Tumor

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010. Published by Elsevier Masson SAS.
  • (PMID = 20594960.001).
  • [ISSN] 1773-0619
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


10. Buckner JC, Brown PD, O'Neill BP, Meyer FB, Wetmore CJ, Uhm JH: Central nervous system tumors. Mayo Clin Proc; 2007 Oct;82(10):1271-86
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system tumors.
  • Central nervous system tumors are relatively common in the United States, with more than 40,000 cases annually.
  • Although more than half of these tumors are benign, they can cause substantial morbidity.
  • Malignant primary brain tumors are the leading cause of death from solid tumors in children and the third leading cause of death from cancer in adolescents and adults aged 15 to 34 years.
  • Whereas magnetic resonance imaging helps define the anatomic extent of tumor, biopsy is often required to confirm the diagnosis.
  • Benign tumors are usually curable with surgical resection or radiation therapy including stereotactic radiation; however, most patients with malignant brain tumors benefit from chemotherapy either at the time of initial diagnosis or at tumor recurrence.
  • Metastases to the brain remain a frequent and morbid complication of solid tumors but are frequently controlled with surgery or radiation therapy.
  • Unfortunately, the mortality rate from malignant brain tumors remains high, despite initial disease control.
  • This article provides an overview of current diagnostic and treatment approaches for patients with primary and metastatic brain tumors.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Glioma / diagnosis. Glioma / therapy. Humans

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17908533.001).
  • [ISSN] 0025-6196
  • [Journal-full-title] Mayo Clinic proceedings
  • [ISO-abbreviation] Mayo Clin. Proc.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 52
  •  go-up   go-down


11. Chtourou I, Krichen Makni S, Bahri I, Ellouze S, Khabir A, Ben Ali H, Daoud J, Boudawara TS: [Rhabdoid tumours of the central nervous system: five case studies]. Cancer Radiother; 2006 May;10(3):112-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Rhabdoid tumours of the central nervous system: five case studies].
  • [Transliterated title] Les tumeurs rhabdoïdes du système nerveux central: à propos de cinq observations.
  • PURPOSE: The rhabdoid cerebral tumors were first identified by Briner et al. in 1985.
  • Such tumors are equally characterized by a critically and speedly mortal development.
  • The aim of the present study was to discuss the various anatomicoclinical and therapeutic aspects of these rare tumors.
  • Radiography through magnetic resonance revealed a heterogeneous tumor process localized respectively on the spine (one case), the insula (one case), the temporofrontal lobes (two cases) and the medulla (one case).
  • Histological examination of the tumors also showed a proliferation of giant cells with a hyaline-based cytoplasmic inclusion.
  • A recurrence of rhabdoid tumors occurred in two cases.
  • CONCLUSION: The cerebral rhabdoid malignant tumor constitutes one of the most aggressive and life-threatening intracranial tumors.
  • The optimal management of such tumors remains unknown.
  • [MeSH-major] Central Nervous System Neoplasms. Rhabdoid Tumor
  • [MeSH-minor] Adolescent. Adult. Child. Female. Humans. Infant. Male. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16616869.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


12. Murray G, Jiménez L, Báez F, Colón-Castillo LE, Brau RH: Descriptive profile of surgically-confirmed adult central nervous system tumors in Puerto Rico. P R Health Sci J; 2009 Dec;28(4):317-28

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Descriptive profile of surgically-confirmed adult central nervous system tumors in Puerto Rico.
  • INTRODUCTION: Published studies regarding the incidence of central nervous system (CNS) tumors in Puerto Rico (PR) are exceedingly rare.
  • The general understanding is that the incidence of these tumors in Puerto Rico is similar to the one found in the United States of America (USA).
  • The objective of this study is to describe the specific profile of all the CNS tumors that are surgically intervened in Puerto Rico, through the creation of a database.
  • METHODS: A retrospective analysis of all the surgical procedures from January 1, 2002 to May 31, 2006 for adult CNS tumors in Puerto Rico was performed.
  • The information was organized to form a database of all the CNS neoplasms.
  • RESULTS: A total of 1,018 procedures for CNS tumors were performed on 1,005 patients.
  • The incidence rate of surgically intervened CNS tumors in Puerto Rico is 6 per 100,000 people.
  • CNS tumors were more common in women than in men (58% vs. 42%), respectively.
  • CONCLUSIONS: Our results reflect a unique histopathological distribution of operated CNS tumors in Puerto Rico.
  • In this series, primary tumors are more common than metastatic tumors.
  • Benign histological tumors were more frequent than more malignant variants.
  • Although this study reflects only the histologically diagnosed tumors, it is headway towards diagnosing the incidence of all CNS tumors in Puerto Rico.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Central Nervous System Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Puerto Rico. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19999240.001).
  • [ISSN] 0738-0658
  • [Journal-full-title] Puerto Rico health sciences journal
  • [ISO-abbreviation] P R Health Sci J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Puerto Rico
  •  go-up   go-down


13. Ramírez-Bermúdez J, Aguilar-Venegas LC, Calero-Moscoso C, Ramírez-Abascal M, Nente-Chávez F, Flores-Reynoso S, Dolores-Velasco F, Ramos-Tisnado R: [Neurology-psychiatry interface in central nervous system diseases]. Gac Med Mex; 2010 Mar-Apr;146(2):108-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neurology-psychiatry interface in central nervous system diseases].
  • [Transliterated title] Interfase neurología-psiquiatría en pacientes hospitalizados por patologías del sistema nervioso central.
  • The main neurological disorders for which patients sought medical care at the neuropsychiatry service, were: brain tumors (14.2%), viral encephalitis (8.7%), ischaemic cerebrovascular disorders (7.1%), epilepsy (6.5%) and haemorragic cerebrovascular disorders (4.7%).
  • [MeSH-major] Central Nervous System Diseases. Interdisciplinary Communication. Neurology. Psychiatry
  • [MeSH-minor] Adult. Cross-Sectional Studies. Female. Humans. Male. Prospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20626125.001).
  • [ISSN] 0016-3813
  • [Journal-full-title] Gaceta médica de México
  • [ISO-abbreviation] Gac Med Mex
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


14. Sawada T, Kato Y, Kobayashi M: Expression of aquaporine-4 in central nervous system tumors. Brain Tumor Pathol; 2007;24(2):81-4
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of aquaporine-4 in central nervous system tumors.
  • Cerebral edema is associated with common brain tumors.
  • To elucidate the characterization of the expression of AQP4 and the relationship of the expression of VEGF, we investigated the expression of AQP4 in tumors of the central nervous system immunohistochemically.
  • Brain tumors and nontumorous cerebral tissue for control were evaluated by immunohistochemical staining using anti-AQP4, VEGF, CD34, and MIB-1.
  • In tumor cells, only glial tumor cells showed a positive reaction for AQP4.
  • Although endothelial cells were negative and/or weakly positive for AQP4, the positive relationship suggested the expression of VEGF in endothelial cells in neovasculature and that of AQP 4 in tumor cells.
  • APQ4 expression increased in human astrocytic tumors and edematous cerebral tissue.
  • Upregulation of APQ4 by tumor cells and reactive astroglia were major factors of cerebral edema.
  • [MeSH-major] Aquaporin 4 / biosynthesis. Brain Neoplasms / metabolism. Brain Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Astrocytes / metabolism. Brain Edema / etiology. Brain Edema / metabolism. Female. Gene Expression. Humans. Immunohistochemistry. Male. Middle Aged. Receptors, Vascular Endothelial Growth Factor / biosynthesis. Up-Regulation. Vascular Endothelial Growth Factor A / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18095136.001).
  • [ISSN] 1433-7398
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / AQP4 protein, human; 0 / Aquaporin 4; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  •  go-up   go-down


15. Inda MM, Castresana JS: RASSF1A promoter is highly methylated in primitive neuroectodermal tumors of the central nervous system. Neuropathology; 2007 Aug;27(4):341-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RASSF1A promoter is highly methylated in primitive neuroectodermal tumors of the central nervous system.
  • Although cancer is rare in children, primary brain tumors constitute the most frequent location of solid tumors in childhood.
  • Primitive neuroectodermal tumors (PNET) of the central nervous system can be divided into infratentorial PNET or medulloblastoma (MB), and supratentorial (sPNET) tumors.
  • The RASSF1A (Ras Association Domain Family Protein 1) gene, located at 3p21.3, is highly methylated in multiple primary tumor samples, including neuroblastoma.
  • Therefore, the inactivation of the RASSF1A gene seems to be an important step in the tumorigenesis of PNET of the central nervous sytem.
  • [MeSH-major] Cerebellar Neoplasms / genetics. Medulloblastoma / genetics. Neuroectodermal Tumors, Primitive / genetics. Promoter Regions, Genetic. Supratentorial Neoplasms / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. DNA Methylation. Female. Humans. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17899687.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / RASSF1 protein, human; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


16. Theeler BJ, Keylock J, Yoest S, Forouhar M: Ewing's sarcoma family tumors mimicking primary central nervous system neoplasms. J Neurol Sci; 2009 Sep 15;284(1-2):186-9
Genetic Alliance. consumer health - Ewing's Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ewing's sarcoma family tumors mimicking primary central nervous system neoplasms.
  • Ewing's sarcoma family tumors (ESFTs) and embyronal tumors of the central nervous system are malignant primitive neuroectodermal tumors (PNETs) that can arise in the central nervous system, bones, or soft tissues.
  • When ESFTs involve the central nervous system or nearby structures the diagnosis depends on cytogenetics and immunohistochemistry as these tumors can appear otherwise histologically identical to central PNETs.
  • We present two cases of isolated central nervous system presentations of ESFTs mimicking primary central nervous system neoplasms.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Neuroectodermal Tumors, Primitive / diagnosis. Sarcoma, Ewing / diagnosis. Skull Neoplasms / diagnosis. Spinal Neoplasms / diagnosis. Temporal Bone / pathology. Thoracic Vertebrae
  • [MeSH-minor] Adolescent. Adult. Antigens, CD / analysis. Biomarkers, Tumor / analysis. Calmodulin-Binding Proteins / genetics. Cell Adhesion Molecules / analysis. Diagnosis, Differential. Diffusion Magnetic Resonance Imaging. Epidural Space. Female. Headache / etiology. Humans. Male. Memory Disorders / etiology. RNA-Binding Proteins / genetics. Spinal Cord Compression / etiology. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19394051.001).
  • [ISSN] 1878-5883
  • [Journal-full-title] Journal of the neurological sciences
  • [ISO-abbreviation] J. Neurol. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / CD99 protein, human; 0 / Calmodulin-Binding Proteins; 0 / Cell Adhesion Molecules; 0 / EWSR1 protein, human; 0 / RNA-Binding Proteins
  •  go-up   go-down


17. Fuller CE, Perry A: Molecular diagnostics in central nervous system tumors. Adv Anat Pathol; 2005 Jul;12(4):180-94
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular diagnostics in central nervous system tumors.
  • Central nervous system (CNS) neoplasms can be diagnostically challenging, due to remarkably wide ranges in histologic appearance, biologic behavior, and therapeutic approach.
  • In this regard, the field is primed by recent advances in basic research, elucidating the molecular mechanisms of tumorigenesis and progression in the most common adult and pediatric brain tumors.
  • Thus far, few have made the transition into routine clinical practice, the most notable example being 1p and 19q testing in oligodendroglial tumors.
  • The goal of this article is to highlight the most common genetic alterations currently implicated in CNS tumors, focusing most on those that are either already in common use in ancillary molecular diagnostics testing or are likely to become so in the near future.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Central Nervous System Neoplasms / genetics. Ependymoma / genetics. Oligodendroglioma / genetics
  • [MeSH-minor] Animals. Biomarkers, Tumor / analysis. Biomarkers, Tumor / genetics. Chromosome Aberrations. Humans. In Situ Hybridization, Fluorescence. Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / genetics. Meningioma / diagnosis. Meningioma / genetics. Neoplasms, Germ Cell and Embryonal / diagnosis. Neoplasms, Germ Cell and Embryonal / genetics. Polymerase Chain Reaction. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16096380.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 260
  •  go-up   go-down


18. Kamoshima Y, Sawamura Y: Update on current standard treatments in central nervous system germ cell tumors. Curr Opin Neurol; 2010 Dec;23(6):571-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update on current standard treatments in central nervous system germ cell tumors.
  • PURPOSE OF REVIEW: Various approaches have been used for the management of patients with germ cell tumors (GCTs) in the central nervous system (CNS); however, the optimal treatment of both germinoma and nongerminomatous GCTs remains unknown.
  • This review discusses current management strategies and late effects of therapy for CNS GCTs.
  • SUMMARY: The 10-year survival rate of CNS germinoma is approximately 90%.
  • Most patients with CNS GCTs are children and young adults.
  • Therefore, with the improving life prognosis of young patients, secondary neoplasms, secondary cerebral vasculopathy, neurocognitive deficits, and many other adverse effects induced by the initial treatments are problems to be solved in the next decade.
  • [MeSH-major] Antineoplastic Protocols / standards. Central Nervous System Neoplasms / drug therapy. Central Nervous System Neoplasms / radiotherapy. Neoplasms, Germ Cell and Embryonal / drug therapy. Neoplasms, Germ Cell and Embryonal / radiotherapy
  • [MeSH-minor] Adolescent. Antineoplastic Agents / chemistry. Antineoplastic Agents / pharmacology. Antineoplastic Combined Chemotherapy Protocols / standards. Child. Germinoma / drug therapy. Germinoma / mortality. Germinoma / radiotherapy. Humans. Survival Rate / trends. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20885323.001).
  • [ISSN] 1473-6551
  • [Journal-full-title] Current opinion in neurology
  • [ISO-abbreviation] Curr. Opin. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


19. Wu W, Shi JX, Cheng HL, Wang HD, Hang CH, Shi QL, Yin HX: Hemangiopericytomas in the central nervous system. J Clin Neurosci; 2009 Apr;16(4):519-23

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hemangiopericytomas in the central nervous system.
  • Hemangiopericytomas, which are more aggressive than meningiomas, are rare in the central nervous system (CNS).
  • We analyzed the clinical, radiological and histological features and treatment of 26 patients with hemangiopericytomas in the CNS.
  • Most tumors were located in the parasagittal and falx regions.
  • The tumors were dense or mixed as assessed by CT scans, and most were homogeneously enhanced.
  • Most tumors were isointense on T1-weighted MRI, and high or mixed intensity on T2-weighted MRI; they were homogeneously or heterogeneously enhanced.
  • Histological examination indicated numerous small vascular spaces in the tumor.
  • All tumors were immunohistochemically positive for vimentin.
  • Surgical removal and post-operative radiotherapy are thus critical for the treatment of this tumor.
  • [MeSH-major] Central Nervous System Neoplasms. Hemangiopericytoma
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging / methods. Male. Middle Aged. Neurosurgical Procedures / methods. Radiotherapy. Retrospective Studies. Tomography, X-Ray Computed / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19246200.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


20. Sakurada K, Saino M, Mouri W, Sato A, Kitanaka C, Kayama T: Nestin expression in central nervous system germ cell tumors. Neurosurg Rev; 2008 Apr;31(2):173-6; discussion 176-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nestin expression in central nervous system germ cell tumors.
  • Central nervous system (CNS) germ cell tumors constitute a unique class of rare tumors that mainly affect children and adolescents.
  • These tumors are believed to originate from displaced primordial germ cells.
  • Recently, results of treatment of germ cell tumors have improved with use of radiotherapy and combination chemotherapy.
  • However, some tumors have proven refractory to intensive treatment with surgery, radiation, and combination chemotherapy.
  • Nestin is an intermediate filament protein expressed in undifferentiated cells during CNS development and in CNS tumors and is used as a marker of immature elements of tumors, including brain tumor stem cells.
  • In this study, we examined for the first time nestin expression in 19 CNS germ cell tumors (nine pure germinomas, five germinomas with syncytiotrophoblastic giant cells, one yolk sac tumor, one choriocarcinoma, one embryonal carcinoma, and two mature teratomas).
  • Clinically, nestin-negative tumors did not exhibit dissemination, while all tumors that exhibited dissemination also strongly expressed nestin protein.
  • These findings suggest that the detection of nestin expression could be useful in the management of CNS germ cell tumors, as an auxiliary predictor of dissemination and/or progression.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Biomarkers, Tumor / genetics. Central Nervous System Neoplasms / genetics. Intermediate Filament Proteins / biosynthesis. Intermediate Filament Proteins / genetics. Neoplasms, Germ Cell and Embryonal / genetics. Nerve Tissue Proteins / biosynthesis. Nerve Tissue Proteins / genetics
  • [MeSH-minor] Adolescent. Adult. Child. Choriocarcinoma / genetics. Choriocarcinoma / metabolism. Choriocarcinoma / pathology. Endodermal Sinus Tumor / genetics. Endodermal Sinus Tumor / metabolism. Endodermal Sinus Tumor / pathology. Female. Germinoma / genetics. Germinoma / metabolism. Germinoma / pathology. Giant Cell Tumors / genetics. Giant Cell Tumors / metabolism. Giant Cell Tumors / pathology. Humans. Hypopituitarism / etiology. Immunoenzyme Techniques. Magnetic Resonance Imaging. Male. Nestin. Teratoma / genetics. Teratoma / metabolism. Teratoma / pathology. Vision Disorders / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1999 Feb;90(2):258-64 [9950496.001]
  • [Cites] Cell Mol Life Sci. 2004 Oct;61(19-20):2510-22 [15526158.001]
  • [Cites] J Clin Pathol. 2005 Feb;58(2):222-3 [15677549.001]
  • [Cites] APMIS. 2002 Jun;110(6):499-507 [12193211.001]
  • [Cites] Neurosci Lett. 2006 May 29;400(1-2):80-5 [16529857.001]
  • [Cites] Neurosurg Focus. 1998 Jul 15;5(1):e7 [17140188.001]
  • [Cites] J Histochem Cytochem. 2002 Feb;50(2):147-58 [11799134.001]
  • [Cites] Lab Invest. 2002 Mar;82(3):345-51 [11896213.001]
  • [Cites] Mol Cancer. 2006 Dec 02;5:67 [17140455.001]
  • [Cites] Neurol Res. 1989 Jun;11(2):118-26 [2569683.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 20;101(3):781-6 [14711994.001]
  • [Cites] J Neurooncol. 2001 Sep;54(3):311-6 [11767296.001]
  • [Cites] J Invest Dermatol. 2006 Jan;126(1):142-53 [16417230.001]
  • (PMID = 18092184.001).
  • [ISSN] 0344-5607
  • [Journal-full-title] Neurosurgical review
  • [ISO-abbreviation] Neurosurg Rev
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin
  •  go-up   go-down


21. Metellus P, Bouvier C, Guyotat J, Fuentes S, Jouvet A, Vasiljevic A, Giorgi R, Dufour H, Grisoli F, Figarella-Branger D: Solitary fibrous tumors of the central nervous system: clinicopathological and therapeutic considerations of 18 cases. Neurosurgery; 2007 Apr;60(4):715-22; discussion 722
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary fibrous tumors of the central nervous system: clinicopathological and therapeutic considerations of 18 cases.
  • OBJECTIVE: This is a retrospective study of 18 patients harboring a solitary fibrous tumor of the central nervous system.
  • METHODS: Between 1999 and 2004, 18 patients harboring central nervous system solitary fibrous tumors were surgically treated at our two institutions.
  • Gross total resection was achieved in 10 cases (55.6%); tumor recurrence or progression occurred in nine cases (50%).
  • CONCLUSION: Prognosis of solitary fibrous tumors of the central nervous system remains unclear; consequently, careful and close monitoring of patients and long-term follow-up are mandatory.
  • In other respects, the role of postoperative radiotherapy in atypical or incompletely resected solitary fibrous tumors of the central nervous system remains to be determined and, therefore, warrants larger series with longer follow-up periods.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Brain Neoplasms / surgery. Neoplasms, Fibrous Tissue / radiotherapy. Neoplasms, Fibrous Tissue / surgery. Spinal Neoplasms / radiotherapy. Spinal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17415209.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Yasuda K, Taguchi H, Sawamura Y, Ikeda J, Aoyama H, Fujieda K, Ishii N, Kashiwamura M, Iwasaki Y, Shirato H: Low-dose craniospinal irradiation and ifosfamide, cisplatin and etoposide for non-metastatic embryonal tumors in the central nervous system. Jpn J Clin Oncol; 2008 Jul;38(7):486-92
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-dose craniospinal irradiation and ifosfamide, cisplatin and etoposide for non-metastatic embryonal tumors in the central nervous system.
  • OBJECTIVE: The current study was conducted to evaluate the effects of low-dose craniospinal irradiation (CSI) combined with chemotherapy on non-metastatic embryonal tumors in the central nervous system (CNS), including medulloblastoma and supra-tentorial primitive neuroectodermal tumors (ST-PNET).
  • The dose to the primary tumor bed was 39.6-54 Gy.
  • CONCLUSION: Low-dose CSI and ICE chemotherapy may have a role as a treatment option for a subset of patients with non-metastatic embryonal tumors in the CNS.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Brain Neoplasms / therapy. Cranial Irradiation. Medulloblastoma / therapy. Neuroectodermal Tumors, Primitive / therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cisplatin / administration & dosage. Combined Modality Therapy. Dose-Response Relationship, Radiation. Etoposide / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Infant. Male. Radiotherapy Dosage. Supratentorial Neoplasms / pathology. Supratentorial Neoplasms / therapy. Survival Analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18573848.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


23. Plesec TP, Prayson RA: Frozen section discrepancy in the evaluation of central nervous system tumors. Arch Pathol Lab Med; 2007 Oct;131(10):1532-40

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frozen section discrepancy in the evaluation of central nervous system tumors.
  • CONTEXT: Frozen section (FS) evaluation of central nervous system (CNS) lesions provides an assessment of specimen adequacy and facilitates triage for ancillary studies.
  • DESIGN: All CNS FS cases involving a tumor diagnosis at FS or permanent section (N = 2156) from September 1997 until June 2005 were retrospectively reviewed.
  • Nine (15.8%) of 57 discrepancies involved errors in the diagnosis of CNS lymphoma.
  • Four (7.0%) of 57 discrepancies involved errors in the overgrading of tumors.
  • CONCLUSIONS: Frozen section of CNS neoplastic processes can be highly accurate.
  • Approximately 80% of the discrepant cases were classified into 5 categories: spindle cell lesions, astrocytoma versus oligodendroglioma, differential diagnosis of CNS lymphoma, reactive versus neoplastic process, and tumor overgrading.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Diagnostic Errors / statistics & numerical data. Frozen Sections / methods. Pathology, Surgical / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Intraoperative Period. Male. Middle Aged. Reproducibility of Results. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17922589.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


24. Erickson ML, Johnson R, Bannykh SI, de Lotbiniere A, Kim JH: Malignant rhabdoid tumor in a pregnant adult female: literature review of central nervous system rhabdoid tumors. J Neurooncol; 2005 Sep;74(3):311-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant rhabdoid tumor in a pregnant adult female: literature review of central nervous system rhabdoid tumors.
  • Rhabdoid tumors of the central nervous system are uncommon, aggressive childhood malignancies.
  • The 13 described adult cases comprise both primary CNS tumors and malignant transformation of previously existing gliomas, meningiomas, and astrocytomas.
  • Central nervous system rhabdoid lesions of adults have been diagnosed as primary malignant rhabdoid tumors, atypical teratoid/rhabdoid tumors, and more recently, rhabdoid glioblastomas.
  • Pathologic evaluation revealed histology, electron microscopy and immunohistochemistry consistent with the diagnosis of malignant rhabdoid tumor.
  • FISH studies were negative for the INI-1 genetic mutations and chromosome 22q deletion associated with childhood atypical rhabdoid/rhabdoid tumor in 75% of cases.
  • We briefly describe the characteristics and current understanding of rhabdoid tumors, and review the literature comparing the 12 other cases of central nervous system rhabdoid tumors in adults.
  • Furthermore, we consider and discuss the implications of this case being the second presentation of MRT during pregnancy in only six adult female patients.
  • [MeSH-major] Brain Neoplasms / pathology. Pregnancy Complications, Neoplastic / pathology. Rhabdoid Tumor / pathology
  • [MeSH-minor] Adult. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Magnetic Resonance Imaging. Microscopy, Electron, Transmission. Pregnancy


25. Villano JL, Virk IY, Ramirez V, Propp JM, Engelhard HH, McCarthy BJ: Descriptive epidemiology of central nervous system germ cell tumors: nonpineal analysis. Neuro Oncol; 2010 Mar;12(3):257-64
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Descriptive epidemiology of central nervous system germ cell tumors: nonpineal analysis.
  • Central nervous system (CNS) germ cell tumors (GCT) have not been epidemiologically well described.
  • Our study describes 2 population-based series of nonpineal CNS GCT.
  • Data on all primary (malignant and nonmalignant) CNS (ICD-O-3 sites: C70.0-C72.9, C75.1-C75.3) GCT diagnosed between 2000 and 2004 from the Central Brain Tumor Registry of the United States (CBTRUS) and on all malignant GCT diagnosed between 1992 and 2005 from the Surveillance, Epidemiology, and End Results (SEER) were analyzed.
  • For children and young adults, most tumors were malignant (86.8% and 89.0%, respectively), whereas for adults, more than half were nonmalignant (56.8%).
  • In SEER, the frequency of malignant GCT in the CNS (2.5%) was greater than that in the mediastinum (2.1%).
  • Of 408 malignant CNS GCT, 216 (52.9%) were nonpineal.
  • Overall relative survival for nonpineal CNS malignant GCT was 85.3% at 2 years, 77.3% at 5 years, and 67.6% at 10 years.
  • Nonpineal CNS GCT show no significant gender preference, yet have outcomes similar to pineal GCT.
  • [MeSH-major] Central Nervous System Neoplasms / epidemiology. Neoplasms, Germ Cell and Embryonal / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Child. Child, Preschool. Female. Humans. Incidence. Infant. Infant, Newborn. Male. Registries. SEER Program. United States / epidemiology. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2585-92 [10561326.001]
  • [Cites] Neuro Oncol. 2008 Apr;10(2):121-30 [18287340.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Mar 15;46(5):1171-6 [10725628.001]
  • [Cites] Oncologist. 2000;5(4):312-20 [10964999.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Sep;59(9):815-21 [11005262.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7268-76 [11585765.001]
  • [Cites] Int J Clin Oncol. 2001 Aug;6(4):183-91 [11706556.001]
  • [Cites] Brain Tumor Pathol. 2001;18(2):115-22 [11908867.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Oct;57(4):487-500 [12354131.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):846-53 [14990640.001]
  • [Cites] Pediatr Blood Cancer. 2004 Aug;43(2):126-33 [15236278.001]
  • [Cites] Am J Clin Pathol. 1976 Apr;65(4):450-4 [178171.001]
  • [Cites] J Neurosurg. 1985 Aug;63(2):155-67 [2991485.001]
  • [Cites] Int J Androl. 1987 Feb;10(1):43-9 [3034798.001]
  • [Cites] J Neurosurg. 1987 Jul;67(1):65-70 [2439668.001]
  • [Cites] AJNR Am J Neuroradiol. 1989 Sep-Oct;10(5):1039-44 [2476011.001]
  • [Cites] Pediatr Pathol. 1990;10(1-2):231-41 [2156245.001]
  • [Cites] Chest. 1991 Feb;99(2):472-9 [1846573.001]
  • [Cites] J Neurosurg. 1991 Apr;74(4):545-51 [1848284.001]
  • [Cites] Hematol Oncol Clin North Am. 1991 Dec;5(6):1189-209 [1663939.001]
  • [Cites] Radiat Med. 1992 Mar-Apr;10(2):55-61 [1320768.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jan 1;28(1):229-45 [8270446.001]
  • [Cites] Neuropediatrics. 1994 Feb;25(1):26-32 [8208347.001]
  • [Cites] Med Pediatr Oncol. 1995 Jun;24(6):368-72 [7536294.001]
  • [Cites] J Neurosurg. 1997 Mar;86(3):446-55 [9046301.001]
  • [Cites] J Neurooncol. 1997 Mar;32(1):71-80 [9049865.001]
  • [Cites] Cancer. 1997 Aug 15;80(4):681-90 [9264351.001]
  • [Cites] Cancer. 1997 Nov 1;80(9):1792-7 [9351549.001]
  • [Cites] Childs Nerv Syst. 1999 Mar;15(2-3):119-26; discussion 127 [10230668.001]
  • [Cites] J Neurosurg. 1999 Jan;90(1):133-7 [10413166.001]
  • [Cites] Bull N Y Acad Med. 1950 Jul;26(7):440-60 [15426876.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):834-8 [15944708.001]
  • [Cites] J Neurosurg. 2005 Dec;103(6 Suppl):524-30 [16383251.001]
  • [Cites] Obstet Gynecol. 2006 May;107(5):1075-85 [16648414.001]
  • [Cites] Urology. 2006 Aug;68(2):402-5; discussion 405 [16904461.001]
  • [Cites] Neurology. 2007 May 15;68(20):1668-73 [17502547.001]
  • [Cites] Childs Nerv Syst. 2008 Jan;24(1):71-8 [17906866.001]
  • [Cites] J Neurooncol. 1999 Aug;44(1):71-6 [10582672.001]
  • (PMID = 20167813.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2940596
  •  go-up   go-down


26. Bauchet L, Rigau V, Mathieu-Daudé H, Fabbro-Peray P, Palenzuela G, Figarella-Branger D, Moritz J, Puget S, Bauchet F, Pallusseau L, Duffau H, Coubes P, Trétarre B, Labrousse F, Dhellemmes P, Société Française de Neurochirurgie Pédiatrique, Société Française de Neurochirurgie, Société Française de Neuropathologie, Association des Neuro-Oncologues d'Expression Française: Clinical epidemiology for childhood primary central nervous system tumors. J Neurooncol; 2009 Mar;92(1):87-98

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical epidemiology for childhood primary central nervous system tumors.
  • This work was conducted by the French Brain Tumor Data Bank (FBTDB) and aims to prospectively record all primary central nervous system tumors (PCNST), in France, for which histological diagnosis is available.
  • The Tumor Registry from Herault was authorized to compile the data files with personal identifiers.
  • About 1,017 cases (533 boys and 484 girls) of newly diagnosed childhood PCNST have been recorded (gliomas: 52%, all other neuroepithelial tumors: 31%, craniopharyngioma: 5%, germ cell tumors, meningioma and neurinoma: approximately 3% each, all histological subtypes have been detailed).
  • Tumor resections were performed in 83.3%, and biopsies in 16.7%.
  • The distributions by histology, cryopreservation of the samples, age, sex, tumor site and surgery have been detailed.
  • The long term goals of the FBTDB are to create a national registry and a network to perform epidemiological studies, to implement clinical and basic research protocols, and to evaluate and harmonize the healthcare of children and adult patients affected by PCNST.
  • [MeSH-major] Central Nervous System Neoplasms / epidemiology. Registries
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. France / epidemiology. Humans. Infant. Infant, Newborn. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19020806.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Investigator] Aghakhani N; Ali Benali M; Alliez B; Amat D; Amlashi A; Arbez-Gindre F; Arbion F; Assaker R; Aubriot Lorton MH; Auque J; Autricque A; Auvigne I; Averous G; Baldet P; Bataille B; Bazin A; Beaurain J; Benezech J; Bergemer Fouquet A; Besson G; Beuvon F; Billotet C; Blond S; Boetto S; Boissonnet H; Bonyhay G; Bouillot P; Bourgeois P; Bouvier C; Brassier G; Broche C; Brunon J; Cabal P; Cahn V; Caire F; Calvet P; Cazals-Hatem D; Chapon F; Chazal J; Civit T; Colnat S; Colombat M; Comoy J; Couvelard A; Czorny A; Dam Hieu P; Daumas-Duport C; Dautheribes M; David P; Debono B; Delage Corre M; Delhaye M; Delisle MB; Delsol G; Derlon JM; Desenclos C; Desplat A; Devaux B; Di Rocco F; Diaz A; Diebold MD; Dorfmuller G; Dran G; Dufour T; Dumas B; Dumollard JM; Durand L; Duthel R; Eimer S; El Fertit H; Emery E; Espagno C; Esposito P; Etchandy MP; Eyremandi RP; Faillot T; Felix S; Fernandez C; Fesselet J; Fontaine D; Fournier D; François P; Froelich S; Fuentes JM; Fuentes S; Gadan R; Gaspard C; Gay G; Gigaud M; Gil Robles S; Godard J; Gontier MF; Goujon JM; Gray F; Grignon Y; Grisoli F; Guarnieri J; Guyotat J; Hallacq P; Hamlat A; Hayek G; Heitzmann A; Hennequin V; Huot JC; Irthum B; Jacquet G; Jan M; Jaubert F; Jouanneau E; Jouvet A; Justrabo E; Kalamarides M; Kehrli P; Kemeny JL; Keravel Y; Kerdraon R; Khalil T; Khouri K; Khouri S; Klein O; Kujas M; Lacroix C; Lagarrigue J; Langlois O; Lapierre F; Laquerriere A; Laurent MC; Le Gall F; Le Guerinel C; Le Houcq M; Lechapt E; Legars D; Lemaire JJ; Lena G; Lepeintre JF; Leriche B; Lescure JP; Levillain P; Liguoro D; Lioret E; Listrat A; Loiseau H; Lonjon M; Lopes M; Lot G; Louis E; Maheut-Lourmière J; Maillard A; Maitre F; Maitrot D; Majek-Zakine E; Mandonnet E; Manzo N; Marchal JC; Marie B; Maurage CA; Menei P; Mercier P; Mergey E; Metellus P; Michalak S; Michiels JF; Milinkevitch S; Mineo JF; Miquel C; Mireau E; Mohr M; Mokhtari K; Morandi X; Morar S; Moreau JJ; Moreno S; Mourier KL; Mottolese C; Nataf F; Neuville A; Nogues L; Noudel R; Nuti C; Page P; Paquis P; Parent M; Parker F; Pasqualini F; Patey M; Pelissou-Guyotat I; Peoc'h M; Peragut JC; Peruzzi P; Pierre-Kahn A; Pinelli C; Polivka M; Pommepuy I; Ponnelle T; Porhiel V; Proust F; Quintin-Roue I; Ragragui O; Rasendrarijao D; Raynaud P; Redondo A; Renjard L; Reyns N; Richard S; Richaud J; Riem T; Riffaud L; Ringenbach F; Robert G; Roche PH; Rodriguez MA; Roujeau T; Rousseaux P; Rousselet MC; Roux FE; Roux FX; Ruchoux MM; Sabatier J; Sabatier P; Saïkali S; Saint Andre JP; Saint Pierre G; Saint-Rose C; San Galli F; Sautreaux JL; Sawan B; Scavarda D; Segnarbieux F; Seigneuret E; Sindou M; Sorbara R; Sorin A; Stilhart B; Straub P; Taha S; Ternier JP; Tortel MC; Toussaint P; Touzet G; Tremoulet M; Trouillas J; Tubiana A; Uro-Coste E; Vandenbos F; Varlet P; Velut S; Vidal J; Viennet G; Vignaud JM; Vignes JR; Vinchon M; Vital A; Wager M; Weinbreck N; Zerah M
  •  go-up   go-down


27. Goodwin TL, Sainani K, Fisher PG: Incidence patterns of central nervous system germ cell tumors: a SEER Study. J Pediatr Hematol Oncol; 2009 Aug;31(8):541-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence patterns of central nervous system germ cell tumors: a SEER Study.
  • BACKGROUND: Incidence patterns of central nervous system (CNS) germ cell tumors (GCTs) have been reported, but the influence of underlying host risk factors has not been rigorously explored.
  • We aimed to determine in a large, population-based cancer registry how age, sex, and race, influence the occurrence of CNS GCTs in the pediatric population.
  • The cases were limited to only those with the International Classification of Childhood Cancer Xa: intracranial and intraspinal germ-cell tumors.
  • Incidence rates (per 10,000) for each sex and race were plotted for single-age groups, and then stratified by tumor location and pathology subtype.
  • Males had significantly higher rates of CNS GCTs than females.
  • Tumor location differed strikingly by sex (P<0.0001) with pineal location more common in males (61.0% vs. 15.5%).
  • Asian race was associated with a higher rate of CNS GCTs than other races.
  • CONCLUSIONS: Males have higher incidence of CNS GCTs, primarily germinomas, than females, starting in the second decade.
  • Pineal location is strongly associated with male sex, with pineal germinomas representing over half of all CNS GCTs in males.
  • These findings suggest a robust but poorly understood influence of sex, either genetic or hormonal, and race on the occurrence of CNS GCTs.
  • [MeSH-major] Central Nervous System Neoplasms / epidemiology. Neoplasms, Germ Cell and Embryonal / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Child. Child, Preschool. Female. Humans. Incidence. Male. Middle Aged. Registries. Retrospective Studies. Sex Factors. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19636276.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Gyure KA: Newly defined central nervous system neoplasms. Am J Clin Pathol; 2005 Jun;123 Suppl:S3-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Newly defined central nervous system neoplasms.
  • In recent years, numerous new entities or variants of recognized central nervous system tumors have been described in the literature, and the morphologic spectrum of these neoplasms is delineated incompletely.
  • The clinicopathologic features and differential diagnosis of 4 new entities, including the chordoid glioma of the third ventricle, cerebellar liponeurocytoma, atypical teratoid/rhabdoid tumor, and papillary glioneuronal tumor, are discussed in this review.
  • [MeSH-major] Central Nervous System Neoplasms / classification. Central Nervous System Neoplasms / diagnosis
  • [MeSH-minor] Adult. Cerebellar Neoplasms / classification. Cerebellar Neoplasms / diagnosis. Child. Chordoma / classification. Chordoma / diagnosis. Diagnosis, Differential. Female. Ganglioglioma / classification. Ganglioglioma / diagnosis. Glioma / diagnosis. Glioma / pathology. Humans. Hypothalamic Neoplasms / classification. Hypothalamic Neoplasms / diagnosis. Male. Medulloblastoma / classification. Medulloblastoma / diagnosis. Prognosis. Rhabdoid Tumor / classification. Rhabdoid Tumor / diagnosis. Teratoma / classification. Teratoma / diagnosis. Third Ventricle / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16100866.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 81
  •  go-up   go-down


29. Schneider DT, Zahn S, Sievers S, Alemazkour K, Reifenberger G, Wiestler OD, Calaminus G, Göbel U, Perlman EJ: Molecular genetic analysis of central nervous system germ cell tumors with comparative genomic hybridization. Mod Pathol; 2006 Jun;19(6):864-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular genetic analysis of central nervous system germ cell tumors with comparative genomic hybridization.
  • The limited information available to date regarding the genetic alterations in germ cell tumors of the central nervous system has raised concerns about their biologic relationship to other germ cell tumor entities.
  • We investigated fresh-frozen or archival tumor samples from 19 patients with central nervous system germ cell tumors (CNS-GCTs), including seven germinomas, eight malignant nongerminomatous germ cell tumors and four teratomas, using chromosomal comparative genomic hybridization to determine recurrent chromosomal imbalances.
  • All 15 malignant CNS-GCTs and two of four teratomas showed multiple chromosomal imbalances.
  • Chromosomal gains (median: 4 gains/tumor, range: 0-9 gains/tumor) were observed more frequently than losses (median: 1.6 losses/tumor, range: 0-6 losses/tumor).
  • Gain of 12p, which is considered characteristic for germ cell tumors of the adult testis, was detected in 11 of 19 tumors and 10 of 15 malignant CNS-GCTs.
  • In one tumor, gain of 12p was confined to an amplicon at 12p12, corresponding to the commonly amplified region on 12p.
  • Notably, we observed no difference in the genetic profiles of germinomatous and nongerminomatous CNS-GCTs; however, the average number of imbalances was higher in the latter group.
  • A meta-analysis comparing 116 malignant gonadal and extragonadal germ cell tumors revealed that the genomic alterations in CNS-GCTs are virtually indistinguishable from those found in their gonadal or other extragonadal counterparts of the corresponding age group.
  • These data strongly argue in favor of common pathogenetic mechanisms in gonadal and extragonadal germ cell tumors.
  • [MeSH-major] Central Nervous System Neoplasms / genetics. Genetic Testing / methods. Neoplasms, Germ Cell and Embryonal / genetics. Oligonucleotide Array Sequence Analysis / methods
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. DNA, Neoplasm / analysis. Female. Humans. Infant, Newborn. Male. Meta-Analysis as Topic

  • MedlinePlus Health Information. consumer health - Genetic Testing.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16607373.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


30. Freeman BB 3rd, Daw NC, Geyer JR, Furman WL, Stewart CF: Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients. Cancer Invest; 2006 Apr-May;24(3):310-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients.
  • EGFR expression has been noted in neuroblastoma and rhabdomyosarcoma cell lines and in tumor specimens from children with Wilms tumor, osteosarcoma, and glioma.
  • Thus, gefitinib, the first marketed EGFR tyrosine kinase inhibitor, was chosen for study in children with refractory solid tumors and central nervous system (CNS) malignancies.
  • This review discusses findings from 3 clinical trials of gefitinib in children with refractory solid tumors and CNS malignancies, focusing on the clinical pharmacology of the compound.
  • Finally, the future for the use of gefitinib in pediatrics is similar to that of other molecularly targeted agents and awaits definition of tumors and patient populations in which it will be most advantageous.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Central Nervous System Neoplasms / drug therapy. Quinazolines / therapeutic use
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Camptothecin / therapeutic use. Child. Clinical Trials as Topic. Drug Resistance, Neoplasm. Humans. Receptor, Epidermal Growth Factor / drug effects. Receptor, Epidermal Growth Factor / metabolism

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16809160.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; 7673326042 / irinotecan; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib; XT3Z54Z28A / Camptothecin
  • [Number-of-references] 67
  •  go-up   go-down


31. Hu SW, Tsai KB, Yang SF, Lee KS, Chai CY: Unusual solitary fibrous tumors in the central nervous system: a report of two cases. Kaohsiung J Med Sci; 2005 Apr;21(4):179-84

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual solitary fibrous tumors in the central nervous system: a report of two cases.
  • Solitary fibrous tumors (SFTs) are uncommon, and most are found in the pleura.
  • SFTs of the central nervous system (CNS) are very rare.
  • Most neurosurgeons do not believe that SFTs can present as primary CNS neoplasms.
  • We report two cases, so that surgeons may recognize that this is an entity different from other spindle-cell CNS tumors.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Neoplasms, Fibrous Tissue / pathology
  • [MeSH-minor] Adult. Antigens, CD34 / analysis. Female. Humans. Male. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15909674.001).
  • [ISSN] 1607-551X
  • [Journal-full-title] The Kaohsiung journal of medical sciences
  • [ISO-abbreviation] Kaohsiung J. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


32. Delmaire C, Gauvrit JY, Hajj E, Ares GS, Ayachi M, Reyns N, Dubois F, Pruvo JP: [Midline tumors of the central nervous system]. J Radiol; 2006 Jun;87(6 Pt 2):764-78
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Midline tumors of the central nervous system].
  • Different types of tumors can arise from these structures including tumors of the trigone and septum, tumors of the falx, third ventricular tumors and pinal region tumors.
  • These tumors share similar features: minimal clinical symptoms despite their occasional large size, mild non-specific intracranial hypertension syndrome, value of MRI for depiction of tumor location, stereotactic biopsy, relative difficulty of surgical management.
  • [MeSH-major] Brain Neoplasms / diagnosis. Magnetic Resonance Imaging
  • [MeSH-minor] Adult. Cerebral Ventricle Neoplasms / diagnosis. Female. Humans. Pineal Gland

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16778746.001).
  • [ISSN] 0221-0363
  • [Journal-full-title] Journal de radiologie
  • [ISO-abbreviation] J Radiol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 30
  •  go-up   go-down


33. Gill P, Litzow M, Buckner J, Arndt C, Moynihan T, Christianson T, Ansell S, Galanis E: High-dose chemotherapy with autologous stem cell transplantation in adults with recurrent embryonal tumors of the central nervous system. Cancer; 2008 Apr 15;112(8):1805-11
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose chemotherapy with autologous stem cell transplantation in adults with recurrent embryonal tumors of the central nervous system.
  • BACKGROUND: Embryonal central nervous system (CNS) tumors (medulloblastoma, cerebral neuroblastoma, pineoblastoma, and primitive neuroectodermal tumors) are rare in adults.
  • The purpose of the current study was to evaluate adult patients with embryonal CNS tumors who were treated with HDC with ASCT and compare their outcomes with those of patients who received conventional-dose chemotherapy.
  • METHODS: The authors reviewed the medical records of 23 adult patients (age >or= 18 years) who were treated at the Mayo Clinic for recurrent embryonal CNS tumors between 1976 and 2004.
  • CONCLUSIONS: Improvements in the median TTP and survival noted with the administration of HDC with ASCT, as well as the acceptable toxicity of this regimen, supports consideration of its use in adults with recurrent embryonal CNS tumors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / drug therapy. Medulloblastoma / drug therapy. Neoadjuvant Therapy. Neoplasm Recurrence, Local / drug therapy. Stem Cell Transplantation / methods
  • [MeSH-minor] Adult. Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Carmustine / administration & dosage. Cisplatin / administration & dosage. Cohort Studies. Disease Progression. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Lomustine / administration & dosage. Male. Middle Aged. Procarbazine / administration & dosage. Retrospective Studies. Survival Rate. Thiotepa / administration & dosage. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. THIO-TEPA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer. 2008 Apr 15;112(8):1643-5 [18306390.001]
  • (PMID = 18300237.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 35S93Y190K / Procarbazine; 6PLQ3CP4P3 / Etoposide; 7BRF0Z81KG / Lomustine; 905Z5W3GKH / Thiotepa; Q20Q21Q62J / Cisplatin; U68WG3173Y / Carmustine
  •  go-up   go-down


34. Gläsker S, Van Velthoven V: Risk of hemorrhage in hemangioblastomas of the central nervous system. Neurosurgery; 2005 Jul;57(1):71-6; discussion 71-6
MedlinePlus Health Information. consumer health - Bleeding.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of hemorrhage in hemangioblastomas of the central nervous system.
  • OBJECTIVE: Hemangioblastomas are benign vascular tumors of the central nervous system.
  • Several cases of spontaneous hemorrhage within these tumors have been reported.
  • However, the risk of hemorrhage in these tumors remains unknown.
  • METHODS: To clarify the incidence of hemorrhage in hemangioblastomas, we reviewed our large clinical database of 277 patients with central nervous system hemangioblastomas for the incidence of spontaneous or perioperative hemorrhage.
  • Clinical characteristics such as tumor size, tumor location, von Hippel-Lindau disease status, and clinical symptoms before hemorrhage were correlated with hemorrhage risk.
  • The average diameter of tumors that bled was 3 cm in our series and 2.3 cm in the literature review, whereas the average diameter of hemangioblastomas in major series ranges from 0.8 to 1.1 cm.
  • An important indicator for the probability of hemorrhage is tumor size, as spontaneous or postoperative hemorrhage occurred exclusively in extraordinarily large tumors.
  • Hemangioblastomas smaller than 1.5 cm (the vast majority of these tumors) harbor virtually no risk of spontaneous hemorrhage.
  • [MeSH-major] Central Nervous System Neoplasms / physiopathology. Hemangioblastoma / physiopathology. Hemorrhage / etiology. Risk
  • [MeSH-minor] Adult. Aged. Clinical Trials as Topic. Female. Humans. Magnetic Resonance Imaging / methods. Male. Middle Aged. Neurosurgery / methods. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15987542.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 27
  •  go-up   go-down


35. Eshelman-Kent D, Gilger E, Gallagher M: Transitioning survivors of central nervous system tumors: challenges for patients, families, and health care providers. J Pediatr Oncol Nurs; 2009 Sep-Oct;26(5):280-94
MedlinePlus Health Information. consumer health - Family Issues.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transitioning survivors of central nervous system tumors: challenges for patients, families, and health care providers.
  • Survivors of central nervous system tumors (SCNST) are a growing group of cancer survivors who require risk-based, long-term health care due to the chemotherapy, surgery, and radiation they have received.Although treatment strategies are being developed to reduce morbidity and mortality, ultimately this subgroup of pediatric cancer survivors often faces moderate to severe late effects of their treatment.As a result, they will need lifelong health care that includes risk-based health care due to cancer treatment exposures as well as primary adult health care, including primary and secondary preventative care.
  • [MeSH-major] Central Nervous System Neoplasms / therapy. Family. Health Personnel. Survivors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19837958.001).
  • [ISSN] 1043-4542
  • [Journal-full-title] Journal of pediatric oncology nursing : official journal of the Association of Pediatric Oncology Nurses
  • [ISO-abbreviation] J Pediatr Oncol Nurs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 137
  •  go-up   go-down


36. Brown M, Schrot R, Bauer K, Dodge J: Incidence of first primary central nervous system tumors in California, 2001-2005: children, adolescents and teens. J Neurooncol; 2009 Sep;94(2):263-73

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of first primary central nervous system tumors in California, 2001-2005: children, adolescents and teens.
  • This study used data from the California Cancer Registry to comprehensively examine first primary central nervous system tumors (PCNST) by the International Classification of Childhood Cancers (ICCC) diagnostic groups and to compare their incidence by age groups, sex, race/ethnicity, socioeconomic status and tumor behavior.
  • [MeSH-major] Central Nervous System Neoplasms / epidemiology. Glioblastoma / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Factors. California / epidemiology. Child. Child, Preschool. Female. Humans. Incidence. Infant. Infant, Newborn. Male. Time Factors. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19340399.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NCCDPHP CDC HHS / DP / 1U58DP00807-01
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


37. Bhagavathi S, Wilson JD: Primary central nervous system lymphoma. Arch Pathol Lab Med; 2008 Nov;132(11):1830-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary central nervous system lymphoma.
  • Primary central nervous system lymphoma (PCNSL) is an uncommon extranodal non-Hodgkin lymphoma.
  • The differential diagnosis of PCNSL includes central nervous system gliomas, metastatic tumors, demyelinating disorders, subacute infarcts, and space-occupying lesions due to an infectious etiology.
  • Primary central nervous system lymphomas are treated with combined radiotherapies and chemotherapies.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Lymphoma / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / pathology. Middle Aged. Prognosis

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18976024.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 24
  •  go-up   go-down


38. Phi JH, Park SH, Paek SH, Kim SK, Lee YJ, Park CK, Cho BK, Lee DH, Wang KC: Expression of Sox2 in mature and immature teratomas of central nervous system. Mod Pathol; 2007 Jul;20(7):742-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Sox2 in mature and immature teratomas of central nervous system.
  • This study was undertaken to investigate the expression pattern of Sox2 in mature and immature teratomas of the central nervous system.
  • Sox2 immunohistochemistry was performed in 14 cases of central nervous system teratoma: five mature, five immature teratomas, and four mixed germ cell tumors with a prominent teratoma component.
  • Since Sox2 is strongly expressed in the primitive neuroepithelial tissues of central nervous system immature teratomas, it may be a useful biomarker for the diagnosis and quantitative grading of central nervous system immature teratomas.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. HMGB Proteins / biosynthesis. Teratoma / pathology. Transcription Factors / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Fluorescent Antibody Technique. Glial Fibrillary Acidic Protein / analysis. Humans. Immunohistochemistry. Infant. Male. Microscopy, Confocal. SOXB1 Transcription Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17464316.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / HMGB Proteins; 0 / SOX2 protein, human; 0 / SOXB1 Transcription Factors; 0 / Transcription Factors
  •  go-up   go-down


39. Behdad A, Perry A: Central nervous system primitive neuroectodermal tumors: a clinicopathologic and genetic study of 33 cases. Brain Pathol; 2010 Mar;20(2):441-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system primitive neuroectodermal tumors: a clinicopathologic and genetic study of 33 cases.
  • Central nervous system (CNS) primitive neuroectodermal tumors (PNETs) include supratentorial, brain stem, and spinal cord tumors with medulloblastoma-like histopathology.
  • After re-diagnosis of three infantile cases as atypical teratoid/rhabdoid tumor (AT/RT), 33 remaining CNS PNETs were retrieved for clinicopathologic and fluorescence in situ hybridization studies.
  • We conclude that in CNS PNET: (i) routine application of INI1 immunohistochemistry helps rule out AT/RT, particularly in infants;.
  • (iii) involvement of CNS parenchyma by Ewing sarcoma/peripheral PNET is rare enough that EWS gene testing is not necessary unless significant dural involvement is present; and (iv) both anaplastic/large cell features and polysomies of 2 and 8 are associated with more aggressive clinical behavior.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Neuroectodermal Tumors, Primitive / genetics. Neuroectodermal Tumors, Primitive / pathology. Spinal Cord Neoplasms / genetics. Spinal Cord Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aneuploidy. Child. Child, Preschool. Chromosomes, Human, Pair 2. Chromosomes, Human, Pair 22. Chromosomes, Human, Pair 8. Female. Humans. Infant. Male. Middle Aged. Nuclear Proteins / genetics. Oncogene Proteins / genetics. RNA-Binding Protein EWS / genetics. Rhabdoid Tumor / diagnosis. Rhabdoid Tumor / genetics. Rhabdoid Tumor / pathology. Teratoma / diagnosis. Teratoma / genetics. Teratoma / pathology. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19725831.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / MYCN protein, human; 0 / Nuclear Proteins; 0 / Oncogene Proteins; 0 / RNA-Binding Protein EWS
  •  go-up   go-down


40. Ulbright TM, Hattab EM, Zhang S, Ehrlich Y, Foster RS, Einhorn LH, Cheng L: Primitive neuroectodermal tumors in patients with testicular germ cell tumors usually resemble pediatric-type central nervous system embryonal neoplasms and lack chromosome 22 rearrangements. Mod Pathol; 2010 Jul;23(7):972-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primitive neuroectodermal tumors in patients with testicular germ cell tumors usually resemble pediatric-type central nervous system embryonal neoplasms and lack chromosome 22 rearrangements.
  • Primitive neuroectodermal tumors (PNETs) are one of the most frequent types of 'non-germ cell' tumor in patients with testicular germ cell tumors and have a guarded prognosis when present in metastatic sites after cisplatin-based chemotherapy.
  • Improved treatments, including targeted therapy, require understanding the biology of these neoplasms.
  • We therefore analyzed the morphologic, immunohistochemical and molecular biologic features of 14 PNETs from 14 patients with concurrent or previous testicular germ cell tumors; 12 tumors were from metastatic sites and 2 were primary in the testis.
  • Using standard light microscopic criteria for central nervous system and peripheral PNETs, we classified nine tumors as medulloepithelioma, three as medulloblastoma/supratentorial PNET, one as neuroblastic tumor with abundant neuropil and true rosettes and one as small cell embryonal tumor/PNET (Ewing sarcoma-like).
  • INI1 was diffusely and strongly positive in all tumors whereas the other stains, except for cytoplasmic WT1 (which showed substantial reactivity in most tumors), were mostly focal to negative, including CD99 (eight negative, six focal) and Fli-1 (all negative).
  • Only 1 tumor, classified as medulloepithelioma, was scored positive for chromosome 22 translocation (22% rearranged cells) and the remaining 13 were negative, including the one case that resembled peripheral PNET.
  • We conclude that PNETs derived from testicular germ cell tumors mostly resemble central nervous system PNETs and generally lack the chromosome 22 translocation of peripheral PNETs.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / pathology. Neoplasms, Multiple Primary / pathology. Neuroectodermal Tumors, Primitive, Peripheral / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Chromosomes, Human, Pair 22 / genetics. Gene Rearrangement. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Young Adult

  • Genetic Alliance. consumer health - Chromosome 22.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20348883.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


41. Uematsu Y, Fukai J, Okita R, Owai Y, Fujita K, Tanaka Y, Itakura T: Intra-axial pseudotumors in the central nervous system: clinicopathological analysis. Brain Tumor Pathol; 2010 Oct;27(2):71-80

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intra-axial pseudotumors in the central nervous system: clinicopathological analysis.
  • Intra-axial pseudotumors in the central nervous system often mimic malignant brain tumors and cause difficulty in diagnosis and treatment.
  • MRI demonstrated perifocal edema and ring-like or solid enhancement, mimicking the malignant tumors.
  • These results suggested that intra-axial pseudotumors in the central nervous system contain various kinds of pathology, and detailed clinicopathological analysis is important from the point of view of differential diagnosis.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Pseudotumor Cerebri / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Brain Abscess / pathology. Brain Neoplasms / diagnosis. Brain Neoplasms / pathology. Cell Count. Cerebral Angiography. Coloring Agents. Demyelinating Diseases / pathology. Female. Gliosis / pathology. Histiocytosis, Non-Langerhans-Cell / pathology. Humans. Image Processing, Computer-Assisted. Immunohistochemistry. Magnetic Resonance Imaging. Male. Middle Aged. Tissue Fixation. Tomography, Emission-Computed, Single-Photon. Vasculitis, Central Nervous System / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21046308.001).
  • [ISSN] 1861-387X
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Coloring Agents
  •  go-up   go-down


42. Wentworth S, Pinn M, Bourland JD, Deguzman AF, Ekstrand K, Ellis TL, Glazier SS, McMullen KP, Munley M, Stieber VW, Tatter SB, Shaw EG: Clinical experience with radiation therapy in the management of neurofibromatosis-associated central nervous system tumors. Int J Radiat Oncol Biol Phys; 2009 Jan 1;73(1):208-13
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical experience with radiation therapy in the management of neurofibromatosis-associated central nervous system tumors.
  • PURPOSE: Patients with neurofibromatosis (NF) develop tumors of the central nervous system (CNS).
  • METHODS AND MATERIALS: Eighteen patients with NF with CNS tumors were treated from 1986 to 2007.
  • Progression was defined as growth or recurrence of an irradiated tumor on serial imaging.
  • RESULTS: Eighty-two tumors in 18 patients were irradiated, with an average of five tumors/patient.
  • Tumor types included acoustic neuroma (16%), ependymoma (6%), low-grade glioma (11%), meningioma (60%), and schwanomma/neurofibroma (7%).
  • CONCLUSIONS: RT provided local control, OS, and PFS rates similar to or better than published data for tumors in non-NF patients.
  • Radiation therapy should be considered in NF patients with imaging progression of CNS tumors.
  • [MeSH-major] Brain Neoplasms / mortality. Brain Neoplasms / radiotherapy. Neurofibromatoses / mortality. Neurofibromatoses / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Humans. Middle Aged. North Carolina / epidemiology. Survival Analysis. Survival Rate. Treatment Outcome. Young Adult


43. Salvati M, Caroli E, Frati A, Piccirilli M, Agrillo A, Brogna C, Occhiogrosso G, Giangaspero F: Central nervous system mesenchymal chondrosarcoma. J Exp Clin Cancer Res; 2005 Jun;24(2):317-24
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system mesenchymal chondrosarcoma.
  • Central nervous system mesenchymal chondrosarcomas are rare malignant tumors that constitute a separate entity from the classical chondrosarcoma and myxoid variant.
  • Clinical behaviour of central nervous system chondrosarcomas is still unknown.
  • We describe two rare examples of intracranial mesenchymal chondrosarcoma with a review of the literature, in an attempt to clarify the clinical characteristics, prognosis and treatment of choice of these unusual tumors.
  • Although clinical behaviour of central nervous system chondrosarcomas remains to be defined, data from our series as well as literature show that radical removal is the best therapeutic choice.
  • [MeSH-major] Brain Neoplasms / diagnosis. Chondrosarcoma, Mesenchymal / diagnosis
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents. Cartilage / pathology. Cell Differentiation. Central Nervous System Neoplasms / diagnosis. Central Nervous System Neoplasms / mortality. Central Nervous System Neoplasms / therapy. Chemotherapy, Adjuvant. Child. Child, Preschool. Female. Humans. Infant. Magnetic Resonance Imaging. Male. Middle Aged. Prognosis. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16110767.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


44. Yoo KH, Lee SH, Lee J, Sung KW, Jung HL, Koo HH, Lim DH, Kim JH, Shin HJ: Improved outcome of central nervous system germ cell tumors: implications for the role of risk-adapted intensive chemotherapy. J Korean Med Sci; 2010 Mar;25(3):458-65
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved outcome of central nervous system germ cell tumors: implications for the role of risk-adapted intensive chemotherapy.
  • To determine the impact of treatment protocols on the outcome of central nervous system germ cell tumors (CNS-GCTs), we reviewed the medical records of 53 patients who received front-line chemotherapy from September 1997 to September 2006.
  • Our data suggest that risk-adapted intensive chemotherapy may improve the outcome of patients with malignant CNS-GCTs.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / therapy. Neoplasms, Germ Cell and Embryonal / therapy. Radiotherapy
  • [MeSH-minor] Adolescent. Biomarkers, Tumor / metabolism. Child. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Male. Risk Factors. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 1995 Mar;36(3):459-64; discussion 464-6 [7538635.001]
  • [Cites] J Clin Oncol. 1996 Nov;14(11):2908-15 [8918487.001]
  • [Cites] J Neurooncol. 1997 Mar;32(1):71-80 [9049865.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Sep 1;39(2):419-26 [9308946.001]
  • [Cites] J Neurooncol. 1998 May;37(3):229-39 [9524081.001]
  • [Cites] Scand Audiol. 1999;28(3):139-43 [10489862.001]
  • [Cites] Cancer. 2005 Nov 15;104(10):2156-67 [16220552.001]
  • [Cites] Pediatr Blood Cancer. 2007 Mar;48(3):285-91 [16598761.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2585-92 [10561326.001]
  • [Cites] Oncologist. 2000;5(4):312-20 [10964999.001]
  • [Cites] Childs Nerv Syst. 2002 Feb;18(1-2):30-7 [11935241.001]
  • [Cites] Cancer. 2003 Jul 15;98(2):369-76 [12872359.001]
  • [Cites] Neurol Med Chir (Tokyo). 2003 Sep;43 Suppl:i-vii, 1-111 [14705327.001]
  • [Cites] Radiology. 1978 Sep;128(3):745-51 [674649.001]
  • [Cites] Med Pediatr Oncol. 1981;9(4):361-5 [6167845.001]
  • [Cites] Cancer. 1985 Mar 1;55(5):932-40 [2981605.001]
  • [Cites] J Neurooncol. 1985;3(2):147-52 [3897472.001]
  • [Cites] Acta Oncol. 1988;27(1):43-50 [2835067.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Aug;15(2):285-90 [3403311.001]
  • [Cites] J Neurosurg. 1989 May;70(5):676-81 [2540291.001]
  • [Cites] Neurol Res. 1989 Jun;11(2):118-26 [2569683.001]
  • [Cites] Pharmacol Toxicol. 1992 Feb;70(2):143-7 [1508841.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jul 15;32(4):943-9 [7607968.001]
  • [Cites] Radiother Oncol. 1996 Jan;38(1):19-23 [8850422.001]
  • (PMID = 20191048.001).
  • [ISSN] 1598-6357
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2826748
  • [Keywords] NOTNLM ; Central Nervous System / Drug Therapy / Neoplasms, Germ Cell and Embryonal / Survival
  •  go-up   go-down


45. Combs SE, Thilmann C, Debus J, Schulz-Ertner D: Precision radiotherapy for hemangiopericytomas of the central nervous system. Cancer; 2005 Dec 1;104(11):2457-65
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Precision radiotherapy for hemangiopericytomas of the central nervous system.
  • The present analysis evaluates the role of precision RT in the management of HAP of the central nervous system (CNS) and represents one of the largest series of HAP treated with RT that can be found in the literature.
  • METHODS: Of 37 consecutive patients with histologically confirmed HAP who were treated at the institution between 1984 and 2004, the majority, 25 tumors, was localized within the skull base (n = 25) and 4 tumors were localized at the spine.
  • CONCLUSION: High-precision RT is an effective and safe treatment modality for patients with HAP of the CNS and the spine and achieves highly acceptable tumor control, while sparing normal tissue.
  • [MeSH-major] Central Nervous System Neoplasms / radiotherapy. Hemangiopericytoma / radiotherapy. Radiotherapy / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Combined Modality Therapy. Disease-Free Survival. Dose Fractionation. Follow-Up Studies. Humans. Middle Aged. Retrospective Studies. Stereotaxic Techniques. Survival Analysis. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16222690.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Cheng YC, Lirng JF, Chang FC, Guo WY, Teng MM, Chang CY, Wong TT, Ho DM: Neuroradiological findings in atypical teratoid/rhabdoid tumor of the central nervous system. Acta Radiol; 2005 Feb;46(1):89-96
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroradiological findings in atypical teratoid/rhabdoid tumor of the central nervous system.
  • PURPOSE: To evaluate the computed tomography (CT) and magnetic resonance imaging (MRI) findings of atypical teratoid tumor/rhabdoid tumor (AT/RT) of the central nervous system (CNS).
  • MATERIAL AND METHODS: Twenty cases of CNS AT/RT have been found over the past 23 years in our hospital; these involving 11 boys and 9 girls whose mean age at diagnosis was 5.5 years.
  • However, AT/RT should still remain in the differential diagnosis of brain tumors in young children, especially those located in the cerebellar hemisphere and with eccentric cysts.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Central Nervous System Neoplasms / radiography. Rhabdoid Tumor / pathology. Rhabdoid Tumor / radiography. Teratoma / pathology. Teratoma / radiography
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Infant. Magnetic Resonance Imaging. Male. Prognosis. Retrospective Studies. Survival Rate. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15841745.001).
  • [ISSN] 0284-1851
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Sweden
  •  go-up   go-down


47. Sukov WR, Cheville JC, Giannini C, Carlson AW, Shearer BM, Sinnwell JP, Ketterling RP: Isochromosome 12p and polysomy 12 in primary central nervous system germ cell tumors: frequency and association with clinicopathologic features. Hum Pathol; 2010 Feb;41(2):232-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isochromosome 12p and polysomy 12 in primary central nervous system germ cell tumors: frequency and association with clinicopathologic features.
  • Germ cell tumors arising within the central nervous system are rare neoplasms that typically occur along midline structures in children and young adults.
  • Although isochromosome 12p is established as a frequent chromosomal abnormality in testicular germ cell tumors, studies examining isochromosome 12p in primary central nervous system germ cell tumors are limited.
  • Herein, we studied 24 primary central nervous system germ cell tumors from 23 patients using fluorescence in situ hybridization to determine the frequency of isochromosome 12p in these neoplasms.
  • Of the 24 primary central nervous system germ cell tumors, fluorescence in situ hybridization detected isochromosome 12p in 6 (25%) tumors, whereas 11 (46%) tumors showed polysomy (multiple copies) of chromosome 12.
  • The remaining 7 tumors yielded a normal result by fluorescence in situ hybridization.
  • Clinical follow-up of this patient cohort indicated 8 patients (32%) developed a recurrence, although no association was demonstrated between the presence or absence of chromosomal 12 abnormalities and tumor relapse.
  • We confirm that isochromosome 12p is less frequent in primary central nervous system germ cell tumors relative to testicular germ cell tumors, and although our numbers are limited, the presence or absence of isochromosome 12p does not appear to impact tumor recurrence.
  • Similarly, although polysomy 12 was identified in nearly half of our central nervous system germ cell tumors, no prognostic significance was attributed to this abnormality.
  • These results suggest that fluorescence in situ hybridization studies for isochromosome 12p or polysomy 12 may have limited use in the evaluation of these rare neoplasms.
  • [MeSH-major] Central Nervous System Neoplasms / genetics. Chromosomes, Human, Pair 12 / genetics. Isochromosomes / genetics. Neoplasms, Germ Cell and Embryonal / genetics
  • [MeSH-minor] Adolescent. Adult. Child. Chromosome Mapping. Female. Gene Amplification. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 19801160.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Alameda F, Lloreta J, Ariza A, Salido M, Espinet B, Baro T, Garcia-Fructoso G, Galito E, Munne A, Cruz Sanchez FF, Sole F, Serrano S: Primitive neuroectodermal tumor of the central nervous system with glial differentiation: a FISH study of an adult case. Clin Neuropathol; 2007 Jan-Feb;26(1):12-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primitive neuroectodermal tumor of the central nervous system with glial differentiation: a FISH study of an adult case.
  • Primitive neuroectodermal tumors (PNETs) of the central nervous system (CNS), a rare occurrence in adults, may show glial differentiation and can be misinterpreted as pure astrocytic neoplasms.
  • Few fluorescence in situ hybridization (FISH) studies have been carried out on these tumors; isochromosome 17q was found to be the major chromosomal abnormality.
  • We present the case of an adult in which we performed a FISH study of both the glial and neuronal components.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Chromosomes, Human, Pair 17 / genetics. Neuroectodermal Tumors, Primitive / genetics. Neuroectodermal Tumors, Primitive / pathology. Trisomy / genetics
  • [MeSH-minor] Adult. Humans. In Situ Hybridization, Fluorescence. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17290931.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


49. Shukla K, Parikh B, Shukla J, Trivedi P, Shah B: Accuracy of cytologic diagnosis of central nervous system tumours in crush preparation. Indian J Pathol Microbiol; 2006 Oct;49(4):483-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accuracy of cytologic diagnosis of central nervous system tumours in crush preparation.
  • The aim of this study was to assess the usefulness and accuracy of cytologic smears by making crush preparation as a diagnostic method, in central nervous system tumors.
  • 278 patients with central nervous system tumors were investigated.
  • The most common tumor in intracranial cavity was astrocytoma (56.68%), followed by meningioma (6.88%), medulloblastoma (5.66%) and ependymoma (5.56%).
  • The most common tumor in intraspinal cavity was ependymoma (38.46%), followed by meningioma (23.07%) and schwannoma (23.07%).
  • In conclusion, crush preparation is an effective, simple, rapid, relatively safe and reliable technique for the diagnosis of central nervous system tumors.
  • [MeSH-major] Astrocytoma. Central Nervous System Neoplasms / diagnosis. Cytodiagnosis. Ependymoma. Medulloblastoma. Meningioma. Neurilemmoma
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Cytological Techniques / methods. Female. Humans. Male. Middle Aged. Reproducibility of Results

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17183833.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] India
  •  go-up   go-down


50. Paul T, Challa S, Tandon A, Panigrahi M, Purohit A: Primary central nervous system lymphomas: Indian experience, and review of literature. Indian J Cancer; 2008 Jul-Sep;45(3):112-8
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary central nervous system lymphomas: Indian experience, and review of literature.
  • Primary central nervous system lymphomas (PCNSLs) are a rare form of non-Hodgkin's lymphoma which arise within and remain confined primarily to the central nervous system (CNS).
  • They generally account for 1-2% of all primary brain tumors and are reported to be on the rise due to the Acquired Immune Deficiency Syndrome (AIDS) epidemic.
  • RESULTS: In a 19-year study period, there were 56 patients of PCNSLs, accounting for 1.07% of all intracranial neoplasms.
  • [MeSH-major] Brain Neoplasms / pathology. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD20 / metabolism. Antigens, CD3 / metabolism. Antigens, CD45 / metabolism. Child. Female. Humans. Immunocompetence. Immunoenzyme Techniques. India / epidemiology. Male. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19018115.001).
  • [ISSN] 0019-509X
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD3; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


51. Fine HA, Kim L, Albert PS, Duic JP, Ma H, Zhang W, Tohnya T, Figg WD, Royce C: A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors. Clin Cancer Res; 2007 Dec 1;13(23):7101-6
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors.
  • PURPOSE: Inhibition of angiogenesis represents a promising new therapeutic strategy for treating primary malignant brain tumors.
  • Lenalidomide, a potent analogue of the antiangiogenic agent thalidomide, has shown significant activity in several hematologic malignancies, and therefore we chose to explore its tolerability and activity in patients with primary central nervous system tumors.
  • EXPERIMENTAL DESIGN: A phase I interpatient dose escalation trial of lenalidomide in patients with recurrent primary central nervous system tumors was conducted.
  • In the group of 24 patients with recurrent glioblastoma, the median time to tumor progression was <2 months and only 12.5% of patients were progression-free at 6 months.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Central Nervous System Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Thalidomide / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Dose-Response Relationship, Drug. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18056189.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 4Z8R6ORS6L / Thalidomide; F0P408N6V4 / lenalidomide
  •  go-up   go-down


52. Telarović S, Telarović S, Relja M, Franinović-Marković J: Impact of war on central nervous system tumors incidence--a 15-year retrospective study in Istria County, Croatia. Coll Antropol; 2006 Mar;30(1):149-55

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of war on central nervous system tumors incidence--a 15-year retrospective study in Istria County, Croatia.
  • The aim of study was to analyze epidemiological features of central nervous system (CNS) tumors diagnosed in Istria County, Croatia, with a particular emphasis on incidence dynamics during the wartime (1991-1995).
  • The data were extracted from the medical records of patients with CNS tumors admitted to the Department of Neurology of Pula General Hospital in the period from the 1st January 1986 to the 31st December 2000, N = 364.
  • The analyzed tumor-related variables included clinical manifestation, localization, and applied diagnostic and therapeutic methods.
  • Primary tumors were separated from the metastatic, and the latter were analysed with respect to their site of origin.
  • The lowest incidence of CNS tumors (10 patients) was reported in 1990, and the highest (42 patients) in 1993.
  • The incidence dynamics of CNS tumors showed a rapidly progressive increase over the 1991-1995 period, followed by the return to average values.
  • Therefore, we analyzed other factors that may have contributed towards the rapid increase in the number of CNS tumors, such as its coincidence with the war or psychotrauma.
  • The results confirm the observational clinical hypothesis of an extreme increase in the number of CNS tumors during the period under consideration.
  • [MeSH-major] Central Nervous System Neoplasms / etiology. Warfare
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Combined Modality Therapy. Croatia / epidemiology. Female. Humans. Incidence. Male. Medical Records. Middle Aged. Retrospective Studies. Sex Distribution

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16617590.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


53. Silvestre DC, Gil GA, Tomasini N, Bussolino DF, Caputto BL: Growth of peripheral and central nervous system tumors is supported by cytoplasmic c-Fos in humans and mice. PLoS One; 2010;5(3):e9544
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth of peripheral and central nervous system tumors is supported by cytoplasmic c-Fos in humans and mice.
  • Herein we examined phospholipid synthesis status in brain tumors from human patients and from NPcis mice, an animal model of the human disease Neurofibromatosis Type 1 (NF1).
  • PRINCIPAL FINDINGS: In human samples, c-Fos expression was at the limit of detection in non-pathological specimens, but was abundantly expressed associated to ER membranes in tumor cells.
  • This was also observed in CNS of adult tumor-bearing NPcis mice but not in NPcis fos(-/-) KO mice.
  • A glioblastoma multiforme and a malignant PNS tumor from a NF1 patient (MPNST) showed a 2- and 4- fold c-Fos-dependent phospholipid synthesis activation, respectively.
  • CONCLUSIONS: Results highlight a role of cytoplasmic c-Fos as an activator of phospholipid synthesis in events demanding high rates of membrane biogenesis as occurs for the exacerbated growth of tumors cells.
  • They also disclose this protein as a potential target for controlling tumor growth in the nervous system.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Cytoplasm / metabolism. Proto-Oncogene Proteins c-fos / biosynthesis

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1999 Dec 10;286(5447):2172-6 [10591652.001]
  • [Cites] J Neurosci Res. 2009 Aug 1;87(10):2273-81 [19267420.001]
  • [Cites] Neurochem Res. 2000 Jan;25(1):153-62 [10685615.001]
  • [Cites] Nat Genet. 2000 Sep;26(1):109-13 [10973261.001]
  • [Cites] Genes Dev. 2000 Nov 1;14(21):2695-700 [11069886.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Jan 12;280(1):9-13 [11162469.001]
  • [Cites] Cell. 2001 Feb 23;104(4):593-604 [11239415.001]
  • [Cites] FASEB J. 2001 Mar;15(3):556-8 [11259365.001]
  • [Cites] Am J Hum Genet. 2001 May;68(5):1110-8 [11283797.001]
  • [Cites] Mol Cell Biol. 2001 Jul;21(13):4369-78 [11390664.001]
  • [Cites] Cancer Res. 2002 Mar 1;62(5):1573-7 [11894862.001]
  • [Cites] Brain Res Dev Brain Res. 2002 Apr 30;135(1-2):71-7 [11978395.001]
  • [Cites] Science. 2002 May 3;296(5569):920-2 [11988578.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):616-26 [12154354.001]
  • [Cites] Trends Mol Med. 2003 Jan;9(1):19-23 [12524206.001]
  • [Cites] Cancer Cell. 2003 Nov;4(5):371-81 [14667504.001]
  • [Cites] Mol Biol Cell. 2004 Apr;15(4):1881-94 [14767061.001]
  • [Cites] Glia. 1989;2(4):223-30 [2527821.001]
  • [Cites] Nature. 1989 Aug 17;340(6234):568-71 [2505081.001]
  • [Cites] J Neurochem. 1990 Dec;55(6):1855-60 [2230799.001]
  • [Cites] Biochim Biophys Acta. 1991 Dec 10;1072(2-3):129-57 [1751545.001]
  • [Cites] Neuron. 1992 Jan;8(1):13-23 [1730004.001]
  • [Cites] Cell. 1992 Nov 13;71(4):577-86 [1423615.001]
  • [Cites] Nature. 1992 Dec 24-31;360(6406):741-5 [1465144.001]
  • [Cites] Trends Neurosci. 1995 Feb;18(2):66-7 [7537412.001]
  • [Cites] Oncogene. 1996 Feb 1;12(3):507-13 [8637706.001]
  • [Cites] J Neurosci Res. 1996 Jan 1;43(1):93-8 [8838579.001]
  • [Cites] Am J Hum Genet. 1997 Sep;61(3):512-9 [9326316.001]
  • [Cites] Brain Res Mol Brain Res. 1998 Jul 15;58(1-2):10-5 [9685570.001]
  • [Cites] J Neurochem. 1999 Sep;73(3):1228-35 [10461916.001]
  • [Cites] Toxicol Appl Pharmacol. 2006 Aug 1;214(3):263-9 [16473383.001]
  • [Cites] Oncogene. 2007 May 24;26(24):3551-8 [17160021.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):10631-4 [18006802.001]
  • [Cites] J Biol Chem. 2008 Nov 7;283(45):31163-71 [18784083.001]
  • [Cites] J Neurosci Res. 2009 Mar;87(4):857-65 [18951474.001]
  • [Cites] Nature. 2009 Apr 30;458(7242):1127-30 [19407794.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • (PMID = 20209053.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-fos
  • [Other-IDs] NLM/ PMC2832012
  •  go-up   go-down


54. Pakasa NM, Pasquier B, Chambonnière ML, Morrison AL, Khaddage A, Perret AG, Dumollard JM, Barral FG, Péoc'h M: Atypical presentations of solitary fibrous tumors of the central nervous system: an analysis of unusual clinicopathological and outcome patterns in three new cases with a review of the literature. Virchows Arch; 2005 Jul;447(1):81-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical presentations of solitary fibrous tumors of the central nervous system: an analysis of unusual clinicopathological and outcome patterns in three new cases with a review of the literature.
  • Central nervous system (CNS) solitary fibrous tumors (SFTs) are rare mesenchymal neoplasms recognized less than a decade ago.
  • Approximately 60 cases of SFT have been reported in the central nervous system.
  • We describe three atypical SFTs of the CNS, two intracranial and one within the spine.
  • The intraspinal tumor occurred at T5-T7 in a patient with multiple café-au-lait spots, was predominantly myxoid and developed a second similar lesion at S3-S5 14 years later.
  • The MiB 1 index was lower in the second tumor.
  • These atypical presentations gave us an opportunity to provide further information about the natural histological course of CNS SFTs.
  • [MeSH-major] Brain Neoplasms / pathology. Fibroma / pathology. Sella Turcica / pathology. Spinal Cord Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Female. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasms, Second Primary

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1999 Dec;30(12):1464-73 [10667425.001]
  • [Cites] Pathol Int. 2000 Oct;50(10):808-17 [11107053.001]
  • [Cites] Virchows Arch. 2004 May;444(5):459-64 [15014990.001]
  • [Cites] Neurosurgery. 2004 Jan;54(1):213-6; discussion 216-7 [14683560.001]
  • [Cites] J Neurosurg. 2004 Apr;100(4 Suppl Spine):358-63 [15070144.001]
  • [Cites] APMIS. 2000 Sep;108(9):617-25 [11110050.001]
  • [Cites] Histopathology. 1993 Mar;22(3):282-4 [8495961.001]
  • [Cites] J Neurosurg. 2000 Apr;92(2 Suppl):217-20 [10763696.001]
  • [Cites] Neurol Med Chir (Tokyo). 2004 May;44(5):249-54 [15200060.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Nov;131(1):69-73 [11734322.001]
  • [Cites] Pediatr Dev Pathol. 2001 May-Jun;4(3):267-75 [11370264.001]
  • [Cites] Neurosurgery. 2004 Apr;54(4):1004-9; discussion 1009 [15046670.001]
  • [Cites] J Neurosurg. 2000 Sep;93(3):490-3 [10969951.001]
  • [Cites] Am J Clin Pathol. 1996 Aug;106(2):217-24 [8712177.001]
  • [Cites] Ann Pathol. 1999 Dec;19(6):532-5 [10617813.001]
  • [Cites] Surg Neurol. 2004 Feb;61(2):174-8; discussion 178-9 [14751636.001]
  • [Cites] Neurosurgery. 1996 Jul;39(1):182-5 [8805158.001]
  • [Cites] Neuroradiology. 1981 Mar;21(2):55-65 [6259553.001]
  • [Cites] Am J Surg Pathol. 2002 Oct;26(10):1330-42 [12360048.001]
  • [Cites] Neurosurg Rev. 2004 Oct;27(4):246-51 [15138847.001]
  • [Cites] J Neurooncol. 2001 Aug;54(1):57-69 [11763424.001]
  • [Cites] Acta Neuropathol. 2001 Oct;102(4):349-54 [11603810.001]
  • [Cites] Am J Surg Pathol. 1997 Nov;21(11):1354-60 [9351573.001]
  • [Cites] Ann Diagn Pathol. 2003 Jun;7(3):169-73 [12808569.001]
  • [Cites] Am J Pathol. 1999 Jun;154(6):1841-7 [10362810.001]
  • [Cites] Int J Surg Pathol. 2002 Jul;10(3):217-21 [12232579.001]
  • [Cites] Arch Pathol Lab Med. 2003 Apr;127(4):432-9 [12683870.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Jun;135(2):160-4 [12127400.001]
  • [Cites] Am J Surg Pathol. 1997 Apr;21(4):477-83 [9130996.001]
  • [Cites] J Neuroimaging. 2004 Jul;14(3):281-4 [15228772.001]
  • (PMID = 15926073.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen
  •  go-up   go-down


55. Kim LJ, Albuquerque FC, Aziz-Sultan A, Spetzler RF, McDougall CG: Low morbidity associated with use of n-butyl cyanoacrylate liquid adhesive for preoperative transarterial embolization of central nervous system tumors. Neurosurgery; 2006 Jul;59(1):98-104; discussion 98-104
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low morbidity associated with use of n-butyl cyanoacrylate liquid adhesive for preoperative transarterial embolization of central nervous system tumors.
  • OBJECTIVE: To determine the safety and efficacy of preoperative embolization of central nervous system tumors with n-butyl cyanoacrylate (NBCA) liquid adhesive.
  • METHODS: Over a 6-year period, 35 consecutive patients (12 women, 23 men; mean age, 42 yr; range, 6 mo-75 yr) with a central nervous system tumor underwent preoperative embolization with NBCA.
  • Tumor type, location, endovascular and surgical treatment, percent of tumor embolization, estimated blood loss, and neurological deficits related to embolization were evaluated retrospectively.
  • The mean percent of tumor embolized was 68%, but this did not significantly correlate with operative blood loss (Pearson's correlation coefficient, r = 0.049).
  • CONCLUSION: In experienced hands, central nervous system tumors can be embolized with NBCA liquid adhesive with a high degree of safety and efficacy.
  • [MeSH-major] Central Nervous System Neoplasms / therapy. Cyanoacrylates / adverse effects. Embolization, Therapeutic / adverse effects. Embolization, Therapeutic / methods. Tissue Adhesives / adverse effects
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Enbucrilate. Female. Humans. Infant. Male. Middle Aged. Nervous System Diseases / etiology. Nervous System Diseases / physiopathology. Neurosurgical Procedures. Recovery of Function. Retreatment. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16823305.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyanoacrylates; 0 / Tissue Adhesives; F8CEP82QNP / Enbucrilate
  •  go-up   go-down


56. Liu HY, Zhang XL, Chen YP, Qiu SJ: [Characteristic imaging features of primary central nervous system lymphoma in comparison with pathological findings]. Nan Fang Yi Ke Da Xue Xue Bao; 2009 Feb;29(2):333-6
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Characteristic imaging features of primary central nervous system lymphoma in comparison with pathological findings].
  • OBJECTIVE: To investigate the imaging features of primary central nervous system lymphoma (PCNSL).
  • RESULTS: Among the 13 patients with PCNSL, 11 were identified to have solitary tumor foci and the other 2 had multiple lesions.
  • Supratentorial tumors were found in 9 patients, infratentorial tumors in 3 patients, and both supratentorial and infratentorial tumors in 1 patient.
  • In 6 cases, the tumor presented isodensity or slight hypodensity on plain CT images, with mild or moderate enhancement after contrast agent injection.
  • Pathologically, the tumors appeared pinkish or grey-white, soft, with rich blood supply and without capsules.
  • The tumor cells were found to cluster around the blood vessels under microscope.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Lymphoma / diagnosis. Lymphoma / pathology. Magnetic Resonance Imaging. Tomography, X-Ray Computed
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Retrospective Studies. Supratentorial Neoplasms / diagnosis. Supratentorial Neoplasms / pathology. Young Adult

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19246316.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


57. Iqbal M, Shah A, Wani MA, Kirmani A, Ramzan A: Cytopathology of the central nervous system. Part I. Utility of crush smear cytology in intraoperative diagnosis of central nervous system lesions. Acta Cytol; 2006 Nov-Dec;50(6):608-16

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytopathology of the central nervous system. Part I. Utility of crush smear cytology in intraoperative diagnosis of central nervous system lesions.
  • OBJECTIVE: To evaluate the utility of rapid intraoperative crush smear cytologic diagnosis of central and peripheral nervous system lesions and to determine the accuracy and relevance of the accuracy of the intraoperative cytologic diagnosis when compared to the final paraffin section diagnosis.
  • CONCLUSION: In the expert hands of a pathologist with good exposure neurosurgical specimens, crush smear cytology is an accura and reliable procedure for the intraoperative diagnosis central nervous system tumors.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Histological Techniques / methods. Peripheral Nervous System Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Biopsy / methods. Biopsy / standards. Child. Child, Preschool. Female. Humans. Infant. Intraoperative Period. Male. Middle Aged. Paraffin Embedding. Reproducibility of Results

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17152270.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Valentin MD, Canalle R, Queiroz Rde P, Tone LG: Frequency of polymorphisms and protein expression of cyclin-dependent kinase inhibitor 1A (CDKN1A) in central nervous system tumors. Sao Paulo Med J; 2009 Sep;127(5):288-94
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequency of polymorphisms and protein expression of cyclin-dependent kinase inhibitor 1A (CDKN1A) in central nervous system tumors.
  • CONTEXT AND OBJECTIVE: Genetic investigation of central nervous system (CNS) tumors provides valuable information about the genes regulating proliferation, differentiation, angiogenesis, migration and apoptosis in the CNS.
  • The aim of our study was to determine the prevalence of genetic polymorphisms (codon 31 and 3' untranslated region, 3'UTR) and protein expression of the cyclin-dependent kinase inhibitor 1A (CDKN1A) gene in patients with and without CNS tumors.
  • METHODS: 41 patients with CNS tumors and a control group of 161 subjects without cancer and paires for sex, age and ethnicity were genotyped using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).
  • Protein analysis was performed on 36 patients with CNS tumors, using the Western Blotting technique.
  • These frequencies were not statistically different (P > 0.05) from those seen in the patients with CNS tumors (19.4% and 0.0%, codon 31; 15.8% and 2.6%, 3'UTR site).
  • CONCLUSION: No significant differences in protein expression patterns or polymorphisms of CDKN1A in relation to the three types of CNS tumors were observed among Brazilian subjects.
  • [MeSH-major] Brain Neoplasms / genetics. Cyclin-Dependent Kinase Inhibitor p21 / genetics. Neoplasm Proteins / genetics. Polymorphism, Genetic / genetics
  • [MeSH-minor] 3' Untranslated Regions / genetics. Adolescent. Child. Child, Preschool. Codon / genetics. Epidemiologic Methods. Female. Humans. Infant. Male. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20169278.001).
  • [ISSN] 1806-9460
  • [Journal-full-title] São Paulo medical journal = Revista paulista de medicina
  • [ISO-abbreviation] Sao Paulo Med J
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / 3' Untranslated Regions; 0 / CDKN1A protein, human; 0 / Codon; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Neoplasm Proteins
  •  go-up   go-down


59. Kashyap R, Ryan C, Sharma R, Maloo MK, Safadjou S, Graham M, Tretheway D, Jain A, Orloff M: Liver grafts from donors with central nervous system tumors: a single-center perspective. Liver Transpl; 2009 Oct;15(10):1204-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver grafts from donors with central nervous system tumors: a single-center perspective.
  • However, it has become a common practice to accept organs from donors that have low-grade tumors or tumors with low metastatic potential.
  • The aim of this study was to analyze our experience with the use of liver grafts from donors with central nervous system (CNS) tumors.
  • A retrospective review of 1173 liver transplants performed between 1992 and 2006 identified 42 donors diagnosed with a CNS tumor.
  • Thirty-two tumors were malignant, and 10 tumors were benign.
  • Twenty (47.6%) of the CNS tumors were glioblastoma multiforme (astrocytoma grade IV), 11 (26.2%) were other astrocytomas, and 1 (2.4%) was an anaplastic ependymoma.
  • Twenty (62.5%) neoplasms were grade IV tumors, 8 (25%) were grade II tumors, and 4 (12.5%) were grade III tumors.
  • The rate of recurrence for the entire group was 2.4% (all CNS tumors).
  • There was no difference in survival between recipients of grafts from donors with CNS tumors and recipients of grafts from donors without CNS tumors (1 year: 82% versus 83.3%, P = not significant; 3 years: 77.4% versus 72%, P = not significant).
  • In conclusion, in our experience, despite violation of the blood-brain barrier and high-grade CNS tumors, recurrence was uncommon.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Liver Diseases / therapy. Liver Transplantation / methods. Tissue and Organ Procurement / methods
  • [MeSH-minor] Adult. Blood-Brain Barrier. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Retrospective Studies. Time Factors. Tissue Donors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 AASLD
  • [CommentIn] Liver Transpl. 2010 Jul;16(7):916 [20583090.001]
  • [CommentIn] Liver Transpl. 2010 Jul;16(7):914-5 [20583288.001]
  • (PMID = 19790151.001).
  • [ISSN] 1527-6473
  • [Journal-full-title] Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • [ISO-abbreviation] Liver Transpl.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Kim EY, Kim SS: Magnetic resonance findings of primary central nervous system T-cell lymphoma in immunocompetent patients. Acta Radiol; 2005 Apr;46(2):187-92
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance findings of primary central nervous system T-cell lymphoma in immunocompetent patients.
  • PURPOSE: To describe the MR findings of primary central nervous system T-cell lymphoma (T-PCNSL) in immunocompetent patients.
  • The number, location, shape, enhancement pattern, and signal intensity of the tumors were determined.
  • All tumors showed iso- to low T1 and iso- to slightly high T2 signal intensity to the adjacent gray matter.
  • The lower rCBV ratio of the tumor might be helpful in differentiating T-PCNSL from other brain tumors such as high-grade glioma.
  • [MeSH-major] Brain Neoplasms / pathology. Immunocompetence. Lymphoma, T-Cell, Peripheral / pathology
  • [MeSH-minor] Adolescent. Adult. Cerebrovascular Circulation / physiology. Diagnosis, Differential. Diffusion Magnetic Resonance Imaging. Female. Humans. Male. Middle Aged. Reproducibility of Results

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15902895.001).
  • [ISSN] 0284-1851
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Sweden
  •  go-up   go-down


61. Sigauke E, Rakheja D, Maddox DL, Hladik CL, White CL, Timmons CF, Raisanen J: Absence of expression of SMARCB1/INI1 in malignant rhabdoid tumors of the central nervous system, kidneys and soft tissue: an immunohistochemical study with implications for diagnosis. Mod Pathol; 2006 May;19(5):717-25
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Absence of expression of SMARCB1/INI1 in malignant rhabdoid tumors of the central nervous system, kidneys and soft tissue: an immunohistochemical study with implications for diagnosis.
  • Malignant rhabdoid tumors are high-grade neoplasms of the central nervous system (CNS), kidneys and soft tissue that usually occur in children.
  • The histologic diagnosis of malignant rhabdoid tumor depends on identification of characteristic rhabdoid cells-large cells with eccentrically located nuclei and abundant, eosinophilic cytoplasm-and immunohistochemistry with antibodies to vimentin, keratin and epithelial membrane antigen.
  • In most malignant rhabdoid tumors, the SMARCB1/INI1 gene, located in chromosome band 22q11.2, is inactivated by deletions and/or mutations, so genetic diagnosis is often possible.
  • We assessed SMARCB1/INI1 expression in 17 rhabdoid tumors and 57 other tumors of the CNS, kidney or soft tissue using immunohistochemistry.
  • In total, 12 brain, three renal and two soft tissue rhabdoid tumors were examined along with four glioblastomas, four pilocytic astrocytomas, four oligodendrogliomas, two ependymomas, two choroid plexus papillomas, five pituitary adenomas, four germinomas, four renal carcinomas with Xp11.2 translocations, two clear cell sarcomas, two Wilms' tumors, one renal medullary carcinoma, two desmoplastic small round cell tumors, two alveolar rhabdomyosarcomas, two embryonal rhabdomyosarcomas, one low-grade chondrosarcoma, two extraskeletal myxoid chondrosarcomas, one mesenchymal chondrosarcoma, four malignant peripheral nerve sheath tumors, five metastatic carcinomas and four epithelioid sarcomas, two primary and two metastatic.
  • The neoplastic cells of all rhabdoid tumors, the four epithelioid sarcomas and the renal medullary carcinoma did not express SMARCB1/INI1 by immunohistochemistry; neoplastic cells of all other tumors expressed SMARCB1/INI1.
  • Immunohistochemistry to assess expression of SMARCB1/INI1 may be useful in the diagnosis of rhabdoid tumors of the CNS, kidneys and soft tissue.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. DNA-Binding Proteins / biosynthesis. Kidney Neoplasms / pathology. Rhabdoid Tumor / pathology. Soft Tissue Neoplasms / pathology. Transcription Factors / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Child. Child, Preschool. Chromosomal Proteins, Non-Histone. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Infant. Infant, Newborn. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16528370.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromosomal Proteins, Non-Histone; 0 / DNA-Binding Proteins; 0 / SMARCB1 protein, human; 0 / Transcription Factors
  •  go-up   go-down


62. Wang Z, Fan QH, Yu MN, Zhang WM: [Clinicopathologic and immunohistochemical study of atypical teratoid/rhabdoid tumor of central nervous system]. Zhonghua Bing Li Xue Za Zhi; 2006 Aug;35(8):458-61
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic and immunohistochemical study of atypical teratoid/rhabdoid tumor of central nervous system].
  • OBJECTIVE: To study the clinicopathologic features and differential diagnosis of atypical teratoid/rhabdoid tumor (AT/RT) occurring in the central nervous system.
  • The tumor cells were positive for vimentin, CD99, epithelial membrane antigen, cytokeratin, glial fibrillary acidic protein, S-100 protein, neurofilament, desmin and smooth muscle actin.
  • CONCLUSIONS: AT/RT is a highly malignant tumor occurring in the central nervous system.
  • The tumor is characterized by a heterogeneous histologic and immunohistochemical phenotype.
  • It needs to be distinguished from a number of central nervous system tumors, including medulloblastoma, primitive neuroectodermal tumor, germ cell neoplasm and rhabdoid meningioma.
  • [MeSH-major] Brain Neoplasms / pathology. Rhabdoid Tumor / pathology. Teratoma / pathology
  • [MeSH-minor] Actins / analysis. Adult. Antigens, CD / analysis. Cell Adhesion Molecules / analysis. Child, Preschool. Desmin / analysis. Glial Fibrillary Acidic Protein / analysis. Humans. Immunohistochemistry. Keratins / analysis. Male. Mucin-1 / analysis. Muscle, Smooth / chemistry. Neurofilament Proteins / analysis. S100 Proteins / analysis. Vimentin / analysis

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17069697.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Actins; 0 / Antigens, CD; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules; 0 / Desmin; 0 / Glial Fibrillary Acidic Protein; 0 / Mucin-1; 0 / Neurofilament Proteins; 0 / S100 Proteins; 0 / Vimentin; 68238-35-7 / Keratins
  •  go-up   go-down


63. Kim KE, Kim KU, Kim DC, Park JI, Han JY: Cytogenetic characterizations of central nervous system tumors: the first comprehensive report from a single institution in Korea. J Korean Med Sci; 2009 Jun;24(3):453-60

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic characterizations of central nervous system tumors: the first comprehensive report from a single institution in Korea.
  • The World Health Organization (WHO) classification of central nervous system (CNS) tumors incorporates morphology, cytogenetics, molecular genetics, and immunologic markers.
  • Despite the relatively large number of CNS tumors with clonal chromosome abnormalities, only few studies have investigated cytogenetic abnormalities for CNS tumors in Korea.
  • Thus, we investigated 119 CNS tumors by conventional G-banded karyotypes to characterize patterns of chromosomal abnormalities involving various CNS tumors, and 92.4% of them were cultured and karyotyped successfully.
  • Totally, 51.8% of karyotypable CNS tumors showed abnormal cytogenetic results, including neuroepithelial tumors (75.0%), meningeal tumors (71.1%), pituitary adenomas (4.2%), schwannomas (44.4%), and metastatic tumors (100.0%).
  • Abnormal karyotypes were more complex at high-grade tumors, suggesting that the karyotype reflects the biologic nature of the tumor.
  • More detailed cytogenetic and molecular characterizations of CNS tumors contribute to better diagnostic criteria and deeper insights of tumorigenesis, eventually resulting in development of novel therapeutic strategies.
  • [MeSH-major] Asian Continental Ancestry Group / genetics. Central Nervous System Neoplasms / genetics. Chromosome Aberrations
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Glioblastoma / genetics. Humans. Karyotyping. Korea. Male. Meningeal Neoplasms / genetics. Middle Aged. Neurilemmoma / genetics. Pituitary Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2000 Jun;48(2):95-101 [11083072.001]
  • [Cites] Expert Rev Neurother. 2004 Jul;4(4):649-63 [15853584.001]
  • [Cites] Br J Cancer. 2001 Jan;84(2):199-201 [11161377.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Mar;33(3):279-84 [11807985.001]
  • [Cites] J Neurosurg. 2002 Mar;96(3):559-64 [11892633.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Jun;135(2):147-59 [12127399.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Apr 1;142(1):1-7 [12660025.001]
  • [Cites] Adv Anat Pathol. 2003 Jul;10(4):212-7 [12826827.001]
  • [Cites] Childs Nerv Syst. 2003 Jun;19(5-6):270-85 [12761644.001]
  • [Cites] J Med Genet. 2003 Nov;40(11):802-6 [14627667.001]
  • [Cites] Neurosurg Rev. 2004 Jan;27(1):58-64 [12845540.001]
  • [Cites] Cancer Genet Cytogenet. 2004 May;151(1):36-51 [15120909.001]
  • [Cites] Hum Mol Genet. 1994 Aug;3(8):1393-9 [7987321.001]
  • [Cites] Oncogene. 1995 Apr 20;10(8):1521-8 [7731706.001]
  • [Cites] Genes Chromosomes Cancer. 1995 Oct;14(2):85-96 [8527398.001]
  • [Cites] Cancer Genet Cytogenet. 1996 Sep;90(2):109-17 [8830718.001]
  • [Cites] Cancer Res. 1996 Nov 15;56(22):5141-5 [8912848.001]
  • [Cites] Cancer Genet Cytogenet. 1997 May;95(1):1-8 [9140447.001]
  • [Cites] Cancer Res. 1997 Jul 1;57(13):2765-80 [9205089.001]
  • [Cites] Cancer Genet Cytogenet. 1997 Aug;97(1):39-53 [9242217.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jan 19;96(2):598-603 [9892679.001]
  • [Cites] J Pathol. 1999 Aug;188(4):395-9 [10440750.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):137-60 [15674475.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):183-202 [15674477.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2653-61 [15805262.001]
  • [Cites] Acta Neurochir (Wien). 2000;142(10):1099-104; discussion 1104-5 [11129530.001]
  • (PMID = 19543509.001).
  • [ISSN] 1598-6357
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2698192
  • [Keywords] NOTNLM ; Central Nervous System Neoplasms / Chromosome Abnormality / Karyotype / Solid Tumor / WHO Classification
  •  go-up   go-down


64. Assanasen T, Shuangshoti S, Nilyai S, Wannakrairot P, Ruangvejvorachai P, Sawatdee R, Sangprakarn S: Overexpression of c-Myc in primary central nervous system lymphoma of Thais. J Med Assoc Thai; 2006 Sep;89 Suppl 3:S40-6
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of c-Myc in primary central nervous system lymphoma of Thais.
  • BACKGROUND: c-Myc protooncogenes have been implicated in the tumourigenesis of extracerebral lymphomas, however only afew studies on this oncogenic molecule have been available for primary central nervous system lymphoma (PCNSL).
  • OBJECTIVE: To determine the prevalence ofprotein overexpression and gene amplification of c-Myc in PCNSL and to correlate with histological and immunophenotypic subtypes of malignant lymphoma according to WHO classification of tumors of haematopoietic and lymphoid tissue 2001.
  • [MeSH-major] Central Nervous System Neoplasms / metabolism. Lymphoma / metabolism. Proto-Oncogene Proteins c-myc / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Female. Gene Amplification. Gene Expression Regulation, Neoplastic. Humans. Immunocompetence. Immunohistochemistry. In Situ Hybridization. Male. Middle Aged. Prevalence. Thailand

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17718267.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-myc
  •  go-up   go-down


65. Swain RS, Tihan T, Horvai AE, Di Vizio D, Loda M, Burger PC, Scheithauer BW, Kim GE: Inflammatory myofibroblastic tumor of the central nervous system and its relationship to inflammatory pseudotumor. Hum Pathol; 2008 Mar;39(3):410-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory myofibroblastic tumor of the central nervous system and its relationship to inflammatory pseudotumor.
  • Inflammatory myofibroblastic tumor (IMT) is a distinctive spindle cell lesion and occurs primarily in soft tissue.
  • IMT in the central nervous system (CNS) is rare, its characteristics are poorly defined, and its relation to similar tumors at other sites is unclear.
  • To better characterize IMT within the CNS, we studied clinicopathologic features of 6 IMTs and compared them with 18 nonneoplastic lesions originally classified as IP.
  • All tumors were composed of neoplastic spindle cells and a variable amount of inflammatory infiltrate.
  • We suggest that IMT in the CNS is distinct from the nonneoplastic IP, and distinguishing IMT from nonneoplastic lesions should enable better decisions for patient management.
  • [MeSH-major] Central Nervous System Neoplasms / classification. Central Nervous System Neoplasms / pathology. Granuloma, Plasma Cell / classification. Granuloma, Plasma Cell / pathology. Myofibroma / classification. Myofibroma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Infant. Male. Middle Aged

  • Genetic Alliance. consumer health - Inflammatory myofibroblastic tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18261625.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Myung J, Kim B, Yoon BW, Lee SK, Sung JJ, Chung CK, Chang KH, Park SH: B-cell dominant lymphocytic primary angiitis of the central nervous system: four biopsy-proven cases. Neuropathology; 2010 Apr;30(2):123-30
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B-cell dominant lymphocytic primary angiitis of the central nervous system: four biopsy-proven cases.
  • We report four cases of biopsy-proven B-cell-rich primary angiitis of the central nervous system (PACNS).
  • Radiological studies initially indicated tumors such as glioma (n = 2) or lymphoma (n = 1), except in one case, in which the radiological analysis indicated vasculitis or demyelinating disease.
  • [MeSH-major] B-Lymphocytes / pathology. Brain / pathology. Brain Neoplasms / pathology. Lymphoma, B-Cell / pathology. Vasculitis, Central Nervous System / pathology
  • [MeSH-minor] Adult. Antineoplastic Agents, Hormonal / therapeutic use. Cyclophosphamide / therapeutic use. Diagnosis, Differential. Female. Humans. Immunosuppressive Agents / therapeutic use. Magnetic Resonance Imaging. Male. Medical Records. Prednisolone / therapeutic use. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19737359.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Immunosuppressive Agents; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


67. Jahnke K, Kraemer DF, Knight KR, Fortin D, Bell S, Doolittle ND, Muldoon LL, Neuwelt EA: Intraarterial chemotherapy and osmotic blood-brain barrier disruption for patients with embryonal and germ cell tumors of the central nervous system. Cancer; 2008 Feb 1;112(3):581-8
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraarterial chemotherapy and osmotic blood-brain barrier disruption for patients with embryonal and germ cell tumors of the central nervous system.
  • BACKGROUND: The rate of durable responses in embryonal and certain germ cell tumors of the central nervous system (CNS) is unsatisfactory.
  • Intraarterial chemotherapy and osmotic blood-brain barrier disruption (IA/BBBD) increases drug delivery to the CNS.
  • The median OS was 2.8 years for all patients, 2.5 years for supratentorial and disseminated primitive neuroectodermal tumors (PNETs, n = 29), 1.7 years for medulloblastomas (n = 12), and 5.4 years for germ cell tumors (n = 13).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Blood-Brain Barrier / physiopathology. Central Nervous System Neoplasms / drug therapy. Neoplasms, Germ Cell and Embryonal / drug therapy
  • [MeSH-minor] Adolescent. Adult. Carboplatin / administration & dosage. Carboplatin / adverse effects. Child. Child, Preschool. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Disease Progression. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Humans. Infant. Infusions, Intra-Arterial / methods. Male. Methotrexate / administration & dosage. Methotrexate / adverse effects. Middle Aged. Prospective Studies. Survival Analysis. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18072268.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS33618; United States / NINDS NIH HHS / NS / NS44687
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


68. Levy O, Deangelis LM, Filippa DA, Panageas KS, Abrey LE: Bcl-6 predicts improved prognosis in primary central nervous system lymphoma. Cancer; 2008 Jan 1;112(1):151-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bcl-6 predicts improved prognosis in primary central nervous system lymphoma.
  • BACKGROUND: In systemic non-Hodgkin lymphoma (NHL), tumors that resemble germinal center B-cells are less aggressive than tumors that resemble postgerminal center B-cells.
  • However, the value of B-cell differentiation markers in primary central nervous system lymphoma (PCNSL) is less clear.
  • There was a nonsignificant trend toward improved overall survival in patients who had bcl-6 expressing tumors.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Lymphoma / diagnosis. Proto-Oncogene Proteins c-bcl-6 / analysis
  • [MeSH-minor] Adult. Age Factors. Aged. Biomarkers, Tumor / analysis. Disease-Free Survival. Female. Humans. Immunohistochemistry. Immunophenotyping. Male. Middle Aged. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17999414.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-bcl-6
  •  go-up   go-down


69. Chen MJ, Santos Ada S, Sakuraba RK, Lopes CP, Gonçalves VD, Weltman E, Ferrigno R, Cruz JC: Intensity-modulated and 3D-conformal radiotherapy for whole-ventricular irradiation as compared with conventional whole-brain irradiation in the management of localized central nervous system germ cell tumors. Int J Radiat Oncol Biol Phys; 2010 Feb 1;76(2):608-14
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity-modulated and 3D-conformal radiotherapy for whole-ventricular irradiation as compared with conventional whole-brain irradiation in the management of localized central nervous system germ cell tumors.
  • PURPOSE: To compare the sparing potential of cerebral hemispheres with intensity-modulated radiotherapy (IMRT) and three-dimensional conformal radiotherapy (3D-CRT) for whole-ventricular irradiation (WVI) and conventional whole-brain irradiation (WBI) in the management of localized central nervous system germ cell tumors (CNSGCTs).
  • CONCLUSIONS: Although IMRT is associated with increased radiation doses to peripheral areas of the body, its use can spare a significant amount of normal central nervous system tissue compared with 3D-CRT or WBI in the setting of CNSGCT treatment.
  • [MeSH-major] Central Nervous System Neoplasms / radiotherapy. Cranial Irradiation. Neoplasms, Germ Cell and Embryonal / radiotherapy. Radiotherapy, Conformal
  • [MeSH-minor] Adolescent. Cerebrum / radiation effects. Child. Female. Humans. Male. Pinealoma / pathology. Pinealoma / radiography. Pinealoma / radiotherapy. Radiation Injuries / prevention & control. Radiotherapy Dosage. Radiotherapy Planning, Computer-Assisted / methods. Radiotherapy, Intensity-Modulated. Tumor Burden. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 19879065.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


70. Shibamoto Y, Ogino H, Hasegawa M, Suzuki K, Nishio M, Fujii T, Kato E, Ishihara S, Sougawa M, Kenjo M, Kawamura T, Hayabuchi N: Results of radiation monotherapy for primary central nervous system lymphoma in the 1990s. Int J Radiat Oncol Biol Phys; 2005 Jul 1;62(3):809-13
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of radiation monotherapy for primary central nervous system lymphoma in the 1990s.
  • PURPOSE: Results of radiation therapy for primary central nervous system lymphoma (PCNSL) were poor in the 1970-1980s, with most reported 5-year survival rates being less than 10%.
  • The data were analyzed in relation to patient and tumor characteristics.
  • Multiple tumors were seen in 34%.
  • The median radiation dose to the tumor site was 50 Gy (range, 8-74 Gy).
  • [MeSH-major] Central Nervous System Neoplasms / radiotherapy. Lymphoma / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Multivariate Analysis. Survival Rate / trends

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15936564.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


71. Takei H, Bhattacharjee MB, Rivera A, Dancer Y, Powell SZ: New immunohistochemical markers in the evaluation of central nervous system tumors: a review of 7 selected adult and pediatric brain tumors. Arch Pathol Lab Med; 2007 Feb;131(2):234-41
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New immunohistochemical markers in the evaluation of central nervous system tumors: a review of 7 selected adult and pediatric brain tumors.
  • CONTEXT: Immunohistochemistry (IHC) has become an important tool in the diagnosis of brain tumors.
  • We discuss (1) placental alkaline phosphatase, c-Kit, and OCT4 for germinoma, (2) alpha-inhibin and D2-40 for capillary hemangioblastoma, (3) phosphohistone-H3 (PHH3), MIB-1/Ki-67, and claudin-1 for meningioma, (4) PHH3, MIB-1/Ki-67, and p53 for astrocytoma, (5) synaptophysin, microtubule-associated protein 2, neurofilament protein, and neuronal nuclei for medulloblastoma, (6) INI1 for atypical teratoid/rhabdoid tumor, and (7) epithelial membrane antigen for ependymoma.
  • All the markers presented here are used mainly for supporting or confirming the diagnosis, with the exception of the proliferation markers (MIB-1/Ki-67 and PHH3), which are primarily used to support grading and are reportedly associated with prognosis in certain categories of brain tumors.
  • In addition, IHC is also of great help in predicting the prognosis for certain brain tumors.
  • [MeSH-major] Biomarkers, Tumor / analysis. Central Nervous System Neoplasms / diagnosis. Central Nervous System Neoplasms / metabolism. Immunohistochemistry
  • [MeSH-minor] Adult. Antibodies. Astrocytoma / diagnosis. Astrocytoma / metabolism. Child. Diagnosis, Differential. Ependymoma / diagnosis. Ependymoma / metabolism. Germinoma / diagnosis. Germinoma / metabolism. Hemangioblastoma / diagnosis. Hemangioblastoma / metabolism. Humans. Medulloblastoma / diagnosis. Medulloblastoma / metabolism. Meningioma / diagnosis. Meningioma / metabolism. Rhabdoid Tumor / diagnosis. Rhabdoid Tumor / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17284108.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Biomarkers, Tumor
  • [Number-of-references] 96
  •  go-up   go-down


72. Mei K, Liu A, Allan RW, Wang P, Lane Z, Abel TW, Wei L, Cheng H, Guo S, Peng Y, Rakheja D, Wang M, Ma J, Rodriguez MM, Li J, Cao D: Diagnostic utility of SALL4 in primary germ cell tumors of the central nervous system: a study of 77 cases. Mod Pathol; 2009 Dec;22(12):1628-36
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic utility of SALL4 in primary germ cell tumors of the central nervous system: a study of 77 cases.
  • Primary germ cell tumors of the central nervous system (CNS) sometimes pose diagnostic difficulty.
  • In this study we analyzed the diagnostic utility of a novel marker, SALL4, in 77 such tumors (59 pure and 18 mixed) consisting of the following tumors/tumor components: 49 germinomas, 7 embryonal carcinomas, 27 yolk sac tumors, 3 choriocarcinomas, and 14 teratomas.
  • We also stained SALL4 in 99 primary non-germ cell tumors to test SALL4 specificity.
  • We compared SALL4 with OCT4 in all germ cell tumors and compared SALL4 with alpha-fetoprotein and glypican-3 in all yolk sac tumors.
  • Strong SALL4 staining was observed in all 49 germinomas (4+ in 48, 3+ in 1), 7 embryonal carcinomas (all 4+), and 27 yolk sac tumors (1+ in 1, 2+ in 2, 3+ in 7, 4+ in 17).
  • All germinomas and embryonal carcinomas showed strong OCT4 staining (4+ in all except 1 germinoma with 3+), whereas other germ cell tumors were negative.
  • Out of 27 yolk sac tumors, 26 showed positive alpha-fetoprotein staining (1+ in 9, 2+ in 7, 3+ in 5, and 4+ in 5).
  • All yolk sac tumors showed positive glypican-3 staining (1+ in 6, 2+ in 6, 3+ in 7, and 4+ in 8).
  • The mean percentage of yolk sac tumor cells stained was 84% with SALL4, 45% with alpha-fetoprotein, and 63% with glypican-3 (P<0.01).
  • No non-germ cell tumors showed SALL4 staining.
  • Our results indicate that SALL4 is a novel sensitive diagnostic marker for primary germ cell tumors of the CNS with high specificity.
  • SALL4 is a more sensitive marker than alpha-fetoprotein and glypican-3 for yolk sac tumors.
  • [MeSH-major] Biomarkers, Tumor / analysis. Central Nervous System Neoplasms / chemistry. Neoplasms, Germ Cell and Embryonal / chemistry. Transcription Factors / analysis
  • [MeSH-minor] Adolescent. Adult. Child. Female. Glypicans / analysis. Humans. Immunohistochemistry. Infant, Newborn. Male. Octamer Transcription Factor-3 / analysis. Predictive Value of Tests. Sensitivity and Specificity. Young Adult. alpha-Fetoproteins / analysis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19820689.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AFP protein, human; 0 / Biomarkers, Tumor; 0 / GPC3 protein, human; 0 / Glypicans; 0 / Octamer Transcription Factor-3; 0 / POU5F1 protein, human; 0 / SALL4 protein, human; 0 / Transcription Factors; 0 / alpha-Fetoproteins
  •  go-up   go-down


73. Aigner L, Bogdahn U: TGF-beta in neural stem cells and in tumors of the central nervous system. Cell Tissue Res; 2008 Jan;331(1):225-41
MedlinePlus Health Information. consumer health - Stem Cells.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TGF-beta in neural stem cells and in tumors of the central nervous system.
  • Mechanisms that regulate neural stem cell activity in the adult brain are tightly coordinated.
  • Signals provided by proteins of the transforming growth factor (TGF)-beta family might represent a system by which neural stem cells are controlled under physiological conditions but released from this control after transformation to cancer stem cells.
  • It is induced in the adult brain after injury or hypoxia and during neurodegeneration when it modulates and dampens inflammatory responses.
  • Similar to its effect on neural stem cells, TGF-beta reveals anti-proliferative control on most cell types; however, paradoxically, many brain tumors escape from TGF-beta control.
  • Moreover, brain tumors develop mechanisms that change the anti-proliferative influence of TGF-beta into oncogenic cues, mainly by orchestrating a multitude of TGF-beta-mediated effects upon matrix, migration and invasion, angiogenesis, and, most importantly, immune escape mechanisms.
  • Thus, TGF-beta is involved in tumor progression.
  • [MeSH-major] Central Nervous System Neoplasms / metabolism. Neurons / cytology. Stem Cells / metabolism. Transforming Growth Factor beta / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17710437.001).
  • [ISSN] 1432-0878
  • [Journal-full-title] Cell and tissue research
  • [ISO-abbreviation] Cell Tissue Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Transforming Growth Factor beta
  • [Number-of-references] 205
  •  go-up   go-down


74. Jeon YK, Chang KH, Suh YL, Jung HW, Park SH: Inflammatory myofibroblastic tumor of the central nervous system: clinicopathologic analysis of 10 cases. J Neuropathol Exp Neurol; 2005 Mar;64(3):254-9
Genetic Alliance. consumer health - Inflammatory myofibroblastic tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory myofibroblastic tumor of the central nervous system: clinicopathologic analysis of 10 cases.
  • To verify the pathologic features, anaplastic lymphoma kinase (ALK) expression and biologic behavior of inflammatory myofibroblastic tumors (IMTs) of the central nervous system (CNS), we analyzed 10 cases of IMTs-CNS (8 cranial, 1 spinal, and 1 orbital).
  • Our series of IMTs of the CNS showed a male predominance (male:female = 6:4) and a wide age range (10-60 years; mean age, 46.7 years).
  • ALK expression was not found in our IMTs of the CNS.
  • Pathologically, IMT-CNS could be subclassified into PCG-like and FHC.
  • Although our cases did not show ALK immunoreactivity, some IMTs-CNS can recur, which suggests the neoplastic potential of these tumors.
  • The rearrangement of the ALK gene in IMTs-CNS should be verified by an examination of more cases.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Neoplasms, Muscle Tissue / complications. Neoplasms, Muscle Tissue / pathology
  • [MeSH-minor] Actins / metabolism. Adult. Aged. Female. Granuloma, Plasma Cell / metabolism. Granuloma, Plasma Cell / pathology. Granuloma, Plasma Cell / physiopathology. Humans. Immunohistochemistry / methods. Inflammation / etiology. Inflammation / pathology. Magnetic Resonance Imaging / methods. Male. Middle Aged. Sex Factors. Staining and Labeling / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15804057.001).
  • [ISSN] 0022-3069
  • [Journal-full-title] Journal of neuropathology and experimental neurology
  • [ISO-abbreviation] J. Neuropathol. Exp. Neurol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins
  •  go-up   go-down


75. Saddawi-Konefka R, Crawford JR: Chronic viral infection and primary central nervous system malignancy. J Neuroimmune Pharmacol; 2010 Sep;5(3):387-403

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic viral infection and primary central nervous system malignancy.
  • Primary central nervous system (CNS) tumors cause significant morbidity and mortality in both adults and children.
  • In primary CNS malignancies, two families of viruses, namely polyomavirus and herpesvirus, have been detected with varied frequencies in a number of pediatric and adult histological tumor subtypes.
  • However, establishing a link between chronic viral infection and primary CNS malignancy has been an area of considerable controversy, due in part to variations in detection frequencies and methodologies used among researchers.
  • Since a latent viral neurotropism can be seen with a variety of viruses and a widespread seropositivity exists among the population, it has been difficult to establish an association between viral infection and CNS malignancy based on epidemiology alone.
  • The overall goals of this review are to summarize the many human investigations that have studied viral infection in primary CNS tumors, discuss potential neuro-oncomodulatory mechanisms of viral-associated CNS disease and propose future research directions to establish a more firm association between chronic viral infections and primary CNS malignancies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2009 Jan 2;323(5910):30-1 [19119195.001]
  • [Cites] Indian J Pathol Microbiol. 2009 Jan-Mar;52(1):42-5 [19136778.001]
  • [Cites] Virology. 2009 Feb 20;384(2):266-73 [18995875.001]
  • [Cites] Virology. 2009 Feb 20;384(2):294-303 [19070883.001]
  • [Cites] J Natl Cancer Inst. 2009 Apr 1;101(7):488-97 [19318640.001]
  • [Cites] Folia Microbiol (Praha). 2003;48(3):291-318 [12879740.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5192-200 [12910256.001]
  • [Cites] Pathology. 2003 Jun;35(3):248-53 [14506971.001]
  • [Cites] Curr Top Microbiol Immunol. 2004;273:215-44 [14674603.001]
  • [Cites] Trends Mol Med. 2004 Jan;10(1):19-23 [14720582.001]
  • [Cites] FEMS Microbiol Rev. 2004 Feb;28(1):59-77 [14975530.001]
  • [Cites] Virology. 2004 Jan 5;318(1):1-9 [15015494.001]
  • [Cites] Cell Mol Life Sci. 2004 Jun;61(11):1307-16 [15170509.001]
  • [Cites] Semin Cancer Biol. 2004 Oct;14(5):387-96 [15288264.001]
  • [Cites] Herpes. 2004 Jun;11 Suppl 2:120A-127A [15319099.001]
  • [Cites] N Engl J Med. 2005 Feb 24;352(8):768-76 [15728809.001]
  • [Cites] Apoptosis. 2005 Mar;10(2):251-65 [15843887.001]
  • [Cites] Am J Epidemiol. 2005 May 15;161(10):929-38 [15870157.001]
  • [Cites] J Neurosurg. 2005 Apr;102(3 Suppl):294-8 [15881753.001]
  • [Cites] Mod Pathol. 2005 Jun;18(6):838-43 [15578071.001]
  • [Cites] J Virol. 2003 Jun;77(12):7007-16 [12768019.001]
  • [Cites] Int J Cancer. 2003 Aug 10;106(1):140-2; author reply 143-5 [12794770.001]
  • [Cites] J Med Virol. 2003 Sep;71(1):115-23 [12858417.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):4181-7 [12874024.001]
  • [Cites] Nature. 2003 Jul 24;424(6947):456-61 [12879076.001]
  • [Cites] Am J Pathol. 1999 Jul;155(1):285-92 [10393860.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11519-24 [10500209.001]
  • [Cites] Proc Soc Exp Biol Med. 1962 Nov;111:343-4 [14002172.001]
  • [Cites] Clin Microbiol Rev. 2005 Jan;18(1):217-45 [15653828.001]
  • [Cites] Br J Cancer. 2005 Feb 28;92(4):747-50 [15700045.001]
  • [Cites] J Cell Physiol. 2005 Aug;204(2):402-6 [15690396.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7951-7 [16258095.001]
  • [Cites] Brain Res Brain Res Rev. 2005 Dec 1;50(1):69-85 [15982744.001]
  • [Cites] Acta Neuropathol. 2006 Apr;111(4):388-96 [16557392.001]
  • [Cites] Adv Exp Med Biol. 2006;577:1-18 [16626024.001]
  • [Cites] Adv Exp Med Biol. 2006;577:310-8 [16626045.001]
  • [Cites] Adv Exp Med Biol. 2006;577:319-41 [16626046.001]
  • [Cites] Adv Exp Med Biol. 2006;577:342-56 [16626047.001]
  • [Cites] Sci STKE. 2006 May 16;2006(335):re4 [16705130.001]
  • [Cites] Cancer Res. 2008 Feb 1;68(3):724-30 [18245472.001]
  • [Cites] Science. 1978 Sep 29;201(4362):1246-9 [211583.001]
  • [Cites] Acta Neurochir (Wien). 1978;43(3-4):239-49 [212932.001]
  • [Cites] Neurology. 1979 Dec;29(12):1590-4 [228217.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Oct;78(10):6446-50 [6273871.001]
  • [Cites] Prog Clin Biol Res. 1983;105:227-37 [6304760.001]
  • [Cites] J Virol. 1984 Mar;49(3):848-56 [6321769.001]
  • [Cites] J Neurovirol. 2006 Apr;12(2):90-9 [16798670.001]
  • [Cites] Pediatr Infect Dis J. 2006 Sep;25(9):841-2 [16940845.001]
  • [Cites] J Neurovirol. 2007;13(1):85; author reply 86-7 [17454453.001]
  • [Cites] J Virol. 2007 Jul;81(14):7629-35 [17494079.001]
  • [Cites] Yale J Biol Med. 2006 Dec;79(3-4):115-22 [17940621.001]
  • [Cites] J Neurooncol. 2007 Dec;85(3):271-80 [17589804.001]
  • [Cites] J Virol. 2000 Feb;74(3):1158-67 [10627526.001]
  • [Cites] J Clin Pathol. 1999 Aug;52(8):620-3 [10645234.001]
  • [Cites] Brain Pathol. 2000 Jan;10(1):85-92 [10668898.001]
  • [Cites] Hum Pathol. 2000 Mar;31(3):394-5 [10746685.001]
  • [Cites] Tissue Antigens. 2000 May;55(5):412-21 [10885561.001]
  • [Cites] J Infect Dis. 2000 Sep;182(3):643-51 [10950755.001]
  • [Cites] Ann Neurol. 2000 Dec;48(6):932-6 [11117551.001]
  • [Cites] J Med Virol. 2001 Jan;63(1):45-51 [11130886.001]
  • [Cites] J Gen Virol. 2001 Mar;82(Pt 3):493-7 [11172089.001]
  • [Cites] J Mol Diagn. 2001 Feb;3(1):1-10 [11227065.001]
  • [Cites] Semin Cancer Biol. 2001 Feb;11(1):49-61 [11243899.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):4287-93 [11358858.001]
  • [Cites] J Virol. 2001 Jul;75(13):6022-32 [11390604.001]
  • [Cites] Neuropathology. 2001 Jun;21(2):129-37 [11396678.001]
  • [Cites] Acta Vet Hung. 2000;48(4):477-84 [11402664.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):7829-34 [11427719.001]
  • [Cites] Am J Epidemiol. 2001 Jul 15;154(2):161-5 [11447050.001]
  • [Cites] J Neurosurg. 2001 Jul;95(1):96-101 [11453404.001]
  • [Cites] Mol Pathol. 2001 Oct;54(5):331-7 [11577176.001]
  • [Cites] Dis Markers. 2001;17(3):149-51 [11790879.001]
  • [Cites] Oncogene. 2002 Feb 14;21(8):1141-9 [11850833.001]
  • [Cites] J Natl Cancer Inst. 2002 Feb 20;94(4):267-73 [11854388.001]
  • [Cites] J Med Virol. 2002 Apr;66(4):497-505 [11857528.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2836-41 [11867723.001]
  • [Cites] J Virol. 2002 Apr;76(8):3731-8 [11907212.001]
  • [Cites] Neurology. 2002 Mar 26;58(6):895-900 [11914404.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3347-50 [12067971.001]
  • [Cites] Neuro Oncol. 2002 Jul;4(3):165-70 [12084346.001]
  • [Cites] Int J Cancer. 2002 Oct 1;101(4):348-52 [12209959.001]
  • [Cites] Neuro Oncol. 2002 Oct;4(4):278-99 [12356358.001]
  • [Cites] J Virol. 2002 Dec;76(24):12803-12 [12438605.001]
  • [Cites] Nat Rev Cancer. 2002 Dec;2(12):957-64 [12459734.001]
  • [Cites] J Virol. 2003 Jan;77(1):631-41 [12477866.001]
  • [Cites] J Virol. 2003 Mar;77(5):2807-18 [12584304.001]
  • [Cites] J Virol. 2003 May;77(9):5039-45 [12692206.001]
  • [Cites] J Neurovirol. 2003 Apr;9(2):173-82 [12707848.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 May;12(5):460-3 [12750243.001]
  • [Cites] Neuro Oncol. 2008 Feb;10(1):10-8 [17951512.001]
  • [Cites] Int J Cancer. 2008 Jul 15;123(2):247-50 [18449881.001]
  • [Cites] Brain Res. 2008 Jul 24;1221:108-14 [18565499.001]
  • [Cites] Acta Neuropathol. 2008 Jul;116(1):79-86 [18351367.001]
  • [Cites] N Engl J Med. 2008 Jul 31;359(5):539-41 [18669440.001]
  • [Cites] J Clin Microbiol. 2008 Aug;46(8):2700-6 [18550745.001]
  • [Cites] Pediatrics. 2008 Sep;122(3):513-20 [18762520.001]
  • [Cites] Nature. 2008 Sep 18;455(7211):391-5 [18701889.001]
  • [Cites] Cancer. 2008 Oct 1;113(7 Suppl):1953-68 [18798534.001]
  • [Cites] Ann Neurol. 2008 Oct;64(4):379-87 [18688812.001]
  • [Cites] Br J Cancer. 2009 Apr 21;100(8):1292-302 [19293793.001]
  • [Cites] Med Microbiol Immunol. 2009 May;198(2):79-81 [19198878.001]
  • [Cites] Semin Cancer Biol. 2009 Aug;19(4):270-5 [19416753.001]
  • [Cites] Semin Cancer Biol. 2009 Aug;19(4):252-60 [19505653.001]
  • [Cites] Semin Cancer Biol. 2009 Aug;19(4):261-9 [19505654.001]
  • [Cites] Rev Med Virol. 2009 Jul;19(4):185-99 [19530118.001]
  • [Cites] PLoS Pathog. 2009 Jul;5(7):e1000523 [19649277.001]
  • [Cites] J Clin Virol. 2009 Sep;46(1):37-42 [19505845.001]
  • [Cites] J Neurooncol. 2009 Oct;95(1):49-60 [19424665.001]
  • [Cites] Herpes. 2008 Nov;15(2):28-32 [19856545.001]
  • [Cites] J Biol Chem. 2004 Sep 10;279(37):38325-30 [15247271.001]
  • [Cites] Lancet. 1971 Jun 19;1(7712):1253-7 [4104714.001]
  • [Cites] Lancet. 1971 Jun 19;1(7712):1257-60 [4104715.001]
  • [Cites] Science. 1973 Aug 17;181(4100):674-6 [4353360.001]
  • [Cites] Int J Cancer. 1978 Jan 15;21(1):12-7 [203540.001]
  • [Cites] Virology. 1984 Jul 30;136(2):359-67 [6087549.001]
  • [Cites] J Gen Virol. 1986 Sep;67 ( Pt 9):1759-816 [3018124.001]
  • [Cites] Int J Cancer. 1987 Jan 15;39(1):60-7 [3025111.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Jan;84(1):16-20 [3025851.001]
  • [Cites] Virology. 1987 Sep;160(1):268-70 [2820135.001]
  • [Cites] Lancet. 1988 May 14;1(8594):1065-7 [2896909.001]
  • [Cites] J Gen Virol. 1988 Jul;69 ( Pt 7):1531-74 [2839594.001]
  • [Cites] J Clin Microbiol. 1989 Apr;27(4):651-3 [2542358.001]
  • [Cites] Mol Cell Biol. 1990 Jan;10(1):120-30 [2136765.001]
  • [Cites] J Cell Biochem. 1990 Jan;42(1):13-31 [2153691.001]
  • [Cites] J Gen Virol. 1990 Nov;71 ( Pt 11):2731-6 [2174963.001]
  • [Cites] Virology. 1991 Jan;180(1):49-57 [1845837.001]
  • [Cites] Adv Cancer Res. 1991;57:47-85 [1835254.001]
  • [Cites] N Engl J Med. 1992 Apr 9;326(15):988-93 [1312224.001]
  • [Cites] J Virol. 1994 Jun;68(6):3917-24 [8189528.001]
  • [Cites] N Engl J Med. 1994 Aug 18;331(7):432-8 [8035839.001]
  • [Cites] J Neurooncol. 1994;20(1):55-8 [7807184.001]
  • [Cites] Int J Cancer. 1995 Jun 9;61(6):756-60 [7790107.001]
  • [Cites] Virology. 1995 Oct 1;212(2):710-7 [7571441.001]
  • [Cites] J Virol. 1995 Nov;69(11):6697-704 [7474079.001]
  • [Cites] J Med Virol. 1995 Sep;47(1):105-11 [8551252.001]
  • [Cites] J Virol. 1996 Apr;70(4):2378-86 [8642665.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7352-7 [8692997.001]
  • [Cites] Virology. 1996 Aug 15;222(2):365-74 [8806520.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4820-5 [8841004.001]
  • [Cites] Oncogene. 1997 Jan 23;14(3):359-67 [9018122.001]
  • [Cites] Intervirology. 1996;39(4):259-69 [9078467.001]
  • [Cites] Am J Epidemiol. 1997 Apr 1;145(7):594-7 [9098175.001]
  • [Cites] J Neurovirol. 1997 May;3 Suppl 1:S78-9 [9179802.001]
  • [Cites] J Virol. 1997 Jul;71(7):5620-3 [9188637.001]
  • [Cites] J Clin Invest. 1997 Oct 15;100(8):2054-61 [9329970.001]
  • [Cites] J Gen Virol. 1997 Dec;78 ( Pt 12):3341-8 [9400986.001]
  • [Cites] Clin Infect Dis. 1998 Jan;26(1):132-7 [9455521.001]
  • [Cites] J Virol. 1998 Mar;72(3):2010-21 [9499055.001]
  • [Cites] Adv Virus Res. 1998;50:69-99 [9520997.001]
  • [Cites] Virology. 1998 Apr 10;243(2):492-6 [9568046.001]
  • [Cites] J Neurovirol. 1998 Apr;4(2):242-5 [9584961.001]
  • [Cites] Brain Pathol. 1999 Jan;9(1):33-42 [9989448.001]
  • [Cites] Mol Cell Biol. 1999 May;19(5):3607-13 [10207084.001]
  • (PMID = 20387126.001).
  • [ISSN] 1557-1904
  • [Journal-full-title] Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology
  • [ISO-abbreviation] J Neuroimmune Pharmacol
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / 1R01AI074626-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2914282
  •  go-up   go-down


76. Armstrong GT, Whitton JA, Gajjar A, Kun LE, Chow EJ, Stovall M, Leisenring W, Robison LL, Sklar CA: Abnormal timing of menarche in survivors of central nervous system tumors: A report from the Childhood Cancer Survivor Study. Cancer; 2009 Jun 1;115(11):2562-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abnormal timing of menarche in survivors of central nervous system tumors: A report from the Childhood Cancer Survivor Study.
  • To the authors' knowledge, data regarding the risk of altered timing of menarche after higher dose radiotherapy (RT), as used in the treatment of central nervous system (CNS) tumors, are limited.
  • METHODS: The authors evaluated 235 female survivors of CNS tumors, diagnosed between 1970 and 1986, and >1000 sibling controls who were participants in the Childhood Cancer Survivor Study, and provided self-reported data concerning age at menarche.
  • RESULTS: Survivors of CNS tumors were more likely to have onset of menarche before age 10 years compared with their siblings (11.9% vs 1.0%) (odds ratio [OR], 14.1; 95% confidence interval [95% CI], 7.0-30.9).
  • In addition, survivors of CNS tumors were more likely than siblings to have onset of menarche after age 16 years (10.6% vs 1.9%) (OR, 6.6; 95% CI, 3.4-11.4).
  • CONCLUSIONS: Survivors of CNS tumors are at a significantly increased risk of both early and late menarche associated with RT exposure and age at treatment.

  • Genetic Alliance. consumer health - Childhood Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 American Cancer Society.
  • [Cites] Pediatr Res. 2000 May;47(5):586-91 [10813581.001]
  • [Cites] Pediatr Blood Cancer. 2008 Apr;50(4):854-8 [17729247.001]
  • [Cites] Klin Padiatr. 2001 Jul-Aug;213(4):239-43 [11528557.001]
  • [Cites] Am J Epidemiol. 2002 Apr 1;155(7):672-9 [11914195.001]
  • [Cites] Med Pediatr Oncol. 2002 Apr;38(4):229-39 [11920786.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3255-61 [12947060.001]
  • [Cites] Growth Horm IGF Res. 2004 Jun;14 Suppl A:S118-24 [15135792.001]
  • [Cites] J Clin Epidemiol. 2004 Sep;57(9):933-44 [15504636.001]
  • [Cites] J Clin Endocrinol Metab. 1982 Jun;54(6):1164-8 [6804477.001]
  • [Cites] J Pediatr. 1985 Jan;106(1):156-60 [3965676.001]
  • [Cites] Horm Res. 1985;22(1-2):78-82 [4029883.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1987 Spring;9(1):15-22 [3109271.001]
  • [Cites] Arch Dis Child. 1987 Nov;62(11):1107-12 [3479948.001]
  • [Cites] Biometrics. 1988 Dec;44(4):1049-60 [3233245.001]
  • [Cites] N Engl J Med. 1989 Jul 20;321(3):143-51 [2501681.001]
  • [Cites] Clin Endocrinol (Oxf). 1989 Sep;31(3):363-73 [2559824.001]
  • [Cites] Pediatr Hematol Oncol. 1987;4(1):1-5 [3152908.001]
  • [Cites] Ann Hum Biol. 1991 Mar-Apr;18(2):155-66 [2024949.001]
  • [Cites] Eur J Pediatr. 1991 Jul;150(9):630-3 [1915514.001]
  • [Cites] N Engl J Med. 1993 Jan 14;328(2):87-94 [8416438.001]
  • [Cites] Pediatr Res. 1993 Jun;33(6):577-82 [8378115.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Jun;78(6):1282-6 [8200926.001]
  • [Cites] J Pediatr Hematol Oncol. 1995 May;17(2):167-71 [7749768.001]
  • [Cites] Arch Pediatr Adolesc Med. 1996 Jun;150(6):589-92 [8646307.001]
  • [Cites] J Pediatr. 1997 Oct;131(4):598-602 [9386666.001]
  • [Cites] Med Pediatr Oncol. 1998 Jun;30(6):351-6 [9589084.001]
  • [Cites] Eur J Pediatr. 1998 Sep;157(9):703-7 [9776525.001]
  • [Cites] J Bone Miner Metab. 2005;23(6):470-5 [16261454.001]
  • [Cites] J Clin Endocrinol Metab. 2006 May;91(5):1723-8 [16492690.001]
  • [Cites] Radiat Res. 2006 Jul;166(1 Pt 2):141-57 [16808603.001]
  • [Cites] Pediatrics. 2008 Feb;121 Suppl 3:S218-30 [18245514.001]
  • [Cites] Eur J Cancer. 2001 Mar;37(5):605-12 [11290436.001]
  • (PMID = 19309737.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA055727-14; United States / NCI NIH HHS / CA / U24 CA055727; United States / NCI NIH HHS / CA / U24 CA055727-14; United States / NCI NIH HHS / CA / U24 CA55727
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS113297; NLM/ PMC2746632
  •  go-up   go-down


77. Carrasco-Gonzaléz A, Lafuente-Sánchez JV, Pomposo-Gaztelu I, Figols-Ladrón de Guevara J, Aurrecoechea-Obieta J, Canales-Llantada LM, Garibi JM: [Neuronal tumors: gangliocytoma]. Rev Neurol; 2008 Feb 1-15;46(3):155-9
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neuronal tumors: gangliocytoma].
  • INTRODUCTION: Gangliocytomas are neuronal tumors of the central nervous system.
  • These tumors usually appear in the supratentorial compartment in the temporal lobe.
  • [MeSH-major] Brain Neoplasms. Ganglioneuroma. Spinal Cord Neoplasms
  • [MeSH-minor] Adult. Child, Preschool. Female. Humans. Male

  • Genetic Alliance. consumer health - Gangliocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18297623.001).
  • [ISSN] 1576-6578
  • [Journal-full-title] Revista de neurologia
  • [ISO-abbreviation] Rev Neurol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


78. Zhou J, Li NY, Zhou XJ, Zhou HB, Wu B, Jiang SJ, Ma HH, Zhang RS: [Clinicopathologic study of von Hippel-Lindau syndrome-related and sporadic hemangioblastomas of central nervous system]. Zhonghua Bing Li Xue Za Zhi; 2010 Mar;39(3):145-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic study of von Hippel-Lindau syndrome-related and sporadic hemangioblastomas of central nervous system].
  • OBJECTIVE: To study clinicopathologic features, diagnosis, treatment and prognosis of von Hippel-Lindau (VHL) syndrome-related and sporadic hemangioblastomas of the central nervous system (CNS-HB).
  • METHODS: Histopathological, ultrastructural, immunohistochemical (EnVision method) and clinical features of 21 VHL syndrome and 63 sporadic CNS-HB cases were studied with correlation of the available follow-up information.
  • RESULTS: Twenty-one VHL patients accompanied with a total of 87 CNS-HBs, including one patient of developing 12 HBs within 13 years.
  • There were 10 patients presenting other lesions related to VHL, including 6 retinal HBs, 4 pancreatic tumors (endocrine tumor and microcystic cystadenoma), 1 clear renal cell carcinoma, 4 renal cysts and 1 endolymphatic sac tumor.
  • One patient developed 5 different tumors related to VHL within a period of 4 years.
  • In the 63 cases of sporadic CNS-HB (34 male and 29 female), the mean age was 43.0 years.
  • Histologically, the tumors showed large and vacuolated stromal cells.
  • Some tumors showed atypical nuclei.
  • Tumor cells of HB stained positive for vimentin, EGFR, Inhibin alpha and D2-40, but negative for CD34 and CD68.
  • The syndrome is characterized by development of various benign and malignant tumors.
  • The most common tumor is CNS-HB, which occurs predominantly in the cerebellum.
  • Patients with VHL syndrome tend to present at a younger age than patients with sporadic CNS-HBs, and VHL related HB occurs more predominantly in the brain stem and spinal cord.
  • Prognosis of CNS-HB patients is not correlated with the nuclear atypicality, expression for Ki-67 and involvement of the brain tissue.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Hemangioblastoma / pathology. von Hippel-Lindau Disease / pathology
  • [MeSH-minor] Adolescent. Adult. Carcinoma, Renal Cell / metabolism. Carcinoma, Renal Cell / pathology. Carcinoma, Renal Cell / surgery. Child. Female. Follow-Up Studies. Glial Fibrillary Acidic Protein / metabolism. Humans. Inhibins / metabolism. Ki-67 Antigen / metabolism. Male. Middle Aged. Neoplasm Recurrence, Local. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery. Receptor, Epidermal Growth Factor / metabolism. Retinal Neoplasms / metabolism. Retinal Neoplasms / pathology. Retinal Neoplasms / surgery. Survival Analysis. Vimentin / metabolism. Young Adult

  • Genetic Alliance. consumer health - Von Hippel-Lindau syndrome.
  • MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20450758.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Ki-67 Antigen; 0 / Vimentin; 0 / inhibin-alpha subunit; 57285-09-3 / Inhibins; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


79. Mekni A, Kourda J, Chelly I, Ferchichi L, Bellil K, Hammouda KB, Kchir N, Zitouna M, Khaldi M, Haouet S: Hemangiopericytoma in the central nervous system. A study of eight cases. Neurochirurgie; 2008 Feb;54(1):15-20
Genetic Alliance. consumer health - Hemangiopericytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hemangiopericytoma in the central nervous system. A study of eight cases.
  • Most hemangiopericytomas (HPC) are located in the musculoskeletal system and the skin, while the location in the central nervous system (CNS) is rare.
  • The latter represents 2 to 4% in large series of meningeal tumors, thus accounting for less than 1% of all CNS tumors.
  • In the central nervous system, tumors with a hemangiopericytomatous histolopathological pattern can be either hemangiopericytomas or solitary fibrous tumors.
  • CNS-HPCs have a relentless tendency for local recurrence and metastases outside the CNS.
  • Metastasis can also appear many years after adequate treatment of the primary tumor.
  • We present a pathological study of eight patients with CNS-HPC and compare our results with corresponding published data.
  • The CNS-HPC group consisted of three males and five females with a mean age of 36.75 years.
  • The tumors were supratentorial in four cases, infratentorial in two cases, tentorial in one case and located in the spinal cord in the last one.
  • Histologically, CNS-HPCs were similar to their soft tissue counterparts.
  • Our study presents the pathological features of CNS-HPC as a distinct entity from both meningioma and solitary fibrous tumors.
  • [MeSH-major] Central Nervous System Neoplasms / surgery. Hemangiopericytoma / surgery
  • [MeSH-minor] Adult. Antigens, CD34 / metabolism. Female. Humans. Immunohistochemistry. Infratentorial Neoplasms / pathology. Infratentorial Neoplasms / surgery. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Neuroglia / pathology. Neurosurgical Procedures. Spinal Cord Neoplasms / pathology. Spinal Cord Neoplasms / surgery. Supratentorial Neoplasms / pathology. Supratentorial Neoplasms / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18308345.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


80. Mekni A, Kourda J, Hammouda KB, Tangour M, Kchir N, Zitouna M, Haouet S: Solitary fibrous tumour of the central nervous system: pathological study of eight cases and review of the literature. Pathology; 2009;41(7):649-54
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary fibrous tumour of the central nervous system: pathological study of eight cases and review of the literature.
  • AIMS: Solitary fibrous tumours (SFT) of the central nervous system are rare neoplasms that usually present as dura-based masses and clinically resemble meningiomas.
  • [MeSH-major] Brain Neoplasms / pathology. Solitary Fibrous Tumors / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Diagnosis, Differential. Disease-Free Survival. Dura Mater / pathology. Female. Hemangiopericytoma / diagnosis. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Meningioma / diagnosis. Middle Aged. Radiosurgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19672786.001).
  • [ISSN] 1465-3931
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


81. Yokosuka K, Ishii R, Suzuki Y, Hirano K, Ishii N, Sekihara Y, Hamazaki S, Nishimura H: Extraneural metastasis of high grade glioma without simultaneous central nervous system recurrence: case report. Neurol Med Chir (Tokyo); 2007 Jun;47(6):273-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraneural metastasis of high grade glioma without simultaneous central nervous system recurrence: case report.
  • He had undergone a shunt operation and three tumor removals during a 6-year period.
  • Autopsy revealed tumor masses in the peritoneum, pleura, bone marrow, lymph nodes, and other organs, but no recurrent tumor of the primary lesion or metastases to other areas in the central nervous system.
  • Systemic metastases from primary intracranial tumors are rare, but are likely to become more frequent as the prognosis of patients with brain tumors improves and the duration of survival lengthens.
  • [MeSH-major] Bone Marrow Neoplasms / secondary. Brain Neoplasms / pathology. Glioma / secondary. Neoplasm Metastasis / physiopathology. Peritoneal Neoplasms / secondary. Pleural Neoplasms / secondary
  • [MeSH-minor] Adult. Central Nervous System / pathology. Drug Therapy. Fatal Outcome. Humans. Lymph Nodes / pathology. Male. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / physiopathology. Pulvinar / pathology. Pulvinar / physiopathology. Radiotherapy. Survival Rate

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17587781.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


82. Gilheeney SW, Khakoo Y, Souweidane M, Wolden S, Boulad F, Dunkel IJ: Thiotepa/topotecan/carboplatin with autologous stem cell rescue in recurrent/refractory/poor prognosis pediatric malignancies of the central nervous system. Pediatr Blood Cancer; 2010 Apr;54(4):591-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thiotepa/topotecan/carboplatin with autologous stem cell rescue in recurrent/refractory/poor prognosis pediatric malignancies of the central nervous system.
  • BACKGROUND: Thiotepa and carboplatin are known to be active in central nervous system tumors.
  • We present ten patients with recurrent or progressive central nervous system malignancies treated on a myeloablative regimen using these drugs.
  • CONCLUSION: Thiotepa/topotecan/carboplatin may help consolidate remission of poor prognosis pediatric central nervous system tumors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Carboplatin / administration & dosage. Carboplatin / adverse effects. Child. Child, Preschool. Combined Modality Therapy. Female. Hematopoietic Stem Cell Transplantation. Humans. Male. Neoplasm Recurrence, Local / drug therapy. Prognosis. Thiotepa / administration & dosage. Thiotepa / adverse effects. Topotecan / administration & dosage. Topotecan / adverse effects. Young Adult

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. THIO-TEPA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19998470.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 7M7YKX2N15 / Topotecan; 905Z5W3GKH / Thiotepa; BG3F62OND5 / Carboplatin
  •  go-up   go-down


83. Hambardzumyan D, Amankulor NM, Helmy KY, Becher OJ, Holland EC: Modeling Adult Gliomas Using RCAS/t-va Technology. Transl Oncol; 2009 May;2(2):89-95
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modeling Adult Gliomas Using RCAS/t-va Technology.
  • Malignant gliomas remain the most devastating childhood and adult tumors of the central nervous system.
  • Although adult and pediatric gliomas are histologically indistinguishable, they differ in location, behavior, and molecular characteristics.
  • Such differences between adult and pediatric gliomas may predict different therapeutic responses.
  • Therefore, accurate genetically engineered models of adult and pediatric gliomas may help understand the biology of these tumors and evaluate therapeutic agents in preclinical studies.
  • Here, we demonstrate that, in adult mice, gliomas may arise not only when injected in the subventricular zone but also when injected in the cortex and cerebellum.
  • Our work demonstrates a versatile and highly reproducible adult mouse model of glioma, which can be easily incorporated into preclinical studies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Cell. 2009 Jan 6;15(1):45-56 [19111880.001]
  • [Cites] J Neurooncol. 1999;44(3):243-53 [10720204.001]
  • [Cites] Neuro Oncol. 2007 Jul;9(3):319-25 [17522333.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5579-82 [17575119.001]
  • [Cites] J Neurosurg. 2006 Nov;105(5 Suppl):418-24 [17328268.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):890-900 [17283119.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5288-97 [17000661.001]
  • [Cites] Cancer Cell. 2006 May;9(5):391-403 [16697959.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3355-8, discussion 3358-9 [16585152.001]
  • [Cites] Cancer Lett. 2006 Feb 8;232(2):139-47 [16139423.001]
  • [Cites] J Neurooncol. 2005 Dec;75(3):267-72 [16195804.001]
  • [Cites] Cancer Cell. 2005 Oct;8(4):323-35 [16226707.001]
  • [Cites] Neuro Oncol. 2005 Oct;7(4):436-51 [16212809.001]
  • [Cites] Neoplasia. 2005 Apr;7(4):356-68 [15967113.001]
  • [Cites] Diagn Interv Radiol. 2005 Jun;11(2):83-6 [15957093.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Neurosurgery. 1998 Feb;42(2):341-6 [9482185.001]
  • [Cites] Cancer Res. 1996 Jan 1;56(1):150-3 [8548755.001]
  • [Cites] Cancer Res. 1994 May 15;54(10):2794-9 [8168112.001]
  • [Cites] J Neurooncol. 1994;21(2):177-85 [7861194.001]
  • [Cites] Cancer Res. 1994 Dec 15;54(24):6321-4 [7987821.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jan 18;91(2):484-8 [8290551.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 May 20;26(2):239-44 [8387988.001]
  • [Cites] Cancer Res. 1992 Jun 1;52(11):3213-9 [1317261.001]
  • [Cites] Cancer Res. 1991 Apr 15;51(8):2164-72 [2009534.001]
  • [Cites] Cancer Res. 1988 Jul 15;48(14):3910-8 [2454731.001]
  • [Cites] Nature. 1985 Jan 10-18;313(5998):144-7 [2981413.001]
  • [Cites] Ann Neurol. 1989 Oct;26(4):531-4 [2684003.001]
  • [Cites] Arch Otolaryngol. 1976 Nov;102(11):663-8 [985197.001]
  • [Cites] PLoS Biol. 2003 Dec;1(3):E59 [14691534.001]
  • [Cites] Neurosurgery. 2003 Sep;53(3):685-94; discussion 695 [12943584.001]
  • [Cites] Oncogene. 2003 Jul 31;22(31):4918-23 [12894235.001]
  • [Cites] Adv Anat Pathol. 2003 Jul;10(4):212-7 [12826827.001]
  • [Cites] Oncogene. 2003 Apr 17;22(15):2361-73 [12700671.001]
  • [Cites] Neoplasia. 2002 Nov-Dec;4(6):480-5 [12407441.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5551-8 [12359767.001]
  • [Cites] Cancer. 2002 Jul 15;95(2):249-57 [12124823.001]
  • [Cites] Brain Res Bull. 2002 Apr;57(6):751-8 [12031271.001]
  • [Cites] Brain Pathol. 2002 Jan;12(1):117-32 [11770894.001]
  • [Cites] J Neurooncol. 2001 Jul;53(3):297-305 [11718262.001]
  • [Cites] Brain. 2001 Dec;124(Pt 12):2528-39 [11701605.001]
  • [Cites] Genes Dev. 2001 Aug 1;15(15):1913-25 [11485986.001]
  • [Cites] Nat Rev Genet. 2001 Feb;2(2):120-9 [11253051.001]
  • [Cites] Semin Oncol. 2000 Jun;27(3 Suppl 6):1-10 [10866344.001]
  • [Cites] Cancer Res. 2008 Apr 1;68(7):2241-9 [18381430.001]
  • (PMID = 19412424.001).
  • [ISSN] 1936-5233
  • [Journal-full-title] Translational oncology
  • [ISO-abbreviation] Transl Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01 CA141502
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2670576
  •  go-up   go-down


84. Sundaram C, Uppin SG, Uppin MS, Rekha JS, Panigrahi MK, Purohit AK, Rammurti S: A clinicopathological and immunohistochemical study of central nervous system hemangiopericytomas. J Clin Neurosci; 2010 Apr;17(4):469-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A clinicopathological and immunohistochemical study of central nervous system hemangiopericytomas.
  • Hemangiopericytomas (HPC) of the central nervous system (CNS) are uncommon dural-based tumors that mimic meningiomas clinically and radiologically.
  • Because there are few reports about these tumors from India, we aimed to study the clinico-pathological and immunohistochemical features of CNS HPC.
  • During 2000 to 2008 all 23 patients diagnosed with HPC of CNS at our Institution were reviewed in the study (11 males and 12 females, mean age of 46 years).
  • There were 14 patients with grade II and nine with grade III tumors.
  • Immunohistochemistry with antibodies to epithelial membrane antigen (EMA), vimentin, S-100, CD34 and Ki-67 was done on routinely processed, paraffin-embedded sections of 20 tumors.
  • The mean Ki-67 labeling index was 4.25% in grade II tumors and 7.8% in grade III tumors.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Hemangiopericytoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / analysis. Child. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Meningeal Neoplasms / pathology. Meningioma / pathology. Middle Aged. Tomography, X-Ray Computed. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 20167500.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


85. Pećina-Slaus N, Niku Eva-Martić T, Beros V, Tomas D: Genetic alterations of E-cadherin and beta-catenin in germinoma and teratoma: report of two central nervous system cases. Pathol Oncol Res; 2007;13(4):370-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic alterations of E-cadherin and beta-catenin in germinoma and teratoma: report of two central nervous system cases.
  • The genetic basis as well as mechanisms of development of germ cell tumors of the CNS are still unexplained.
  • In the present article changes of Ecadherin (CDH1) and beta-catenin (CTNNB1) genes in two CNS germ cell tumors are reported.
  • A case of germinoma of the central nervous system and a case of spinal channel teratoma were tested for loss of heterozygosity (LOH) of E-cadherin gene by PCR amplification of tetranucleotide polymorphism (D16S752).
  • Both germ cell tumors analyzed demonstrated LOH of the CDH1 gene.
  • Our findings may contribute to better understanding of the genetic profile of germ cell tumors.
  • [MeSH-major] Cadherins / genetics. Central Nervous System Neoplasms / genetics. Germinoma / genetics. Teratoma / genetics. beta Catenin / genetics
  • [MeSH-minor] Adolescent. Adult. Brain Neoplasms / genetics. Brain Neoplasms / pathology. Female. Humans. Loss of Heterozygosity. Male. Mutation. Pineal Gland / pathology. Pinealoma / genetics. Pinealoma / pathology. Spinal Cord Neoplasms / genetics. Spinal Cord Neoplasms / pathology

  • Genetic Alliance. consumer health - Germinoma.
  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18158575.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cadherins; 0 / beta Catenin
  •  go-up   go-down


86. McGrail M, Batz L, Noack K, Pandey S, Huang Y, Gu X, Essner JJ: Expression of the zebrafish CD133/prominin1 genes in cellular proliferation zones in the embryonic central nervous system and sensory organs. Dev Dyn; 2010 Jun;239(6):1849-57
ZFIN. ZFIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the zebrafish CD133/prominin1 genes in cellular proliferation zones in the embryonic central nervous system and sensory organs.
  • The expression patterns of the zebrafish prominin1a and b genes were analyzed during embryogenesis using whole mount in situ hybridization. prominin1a and b show novel complementary and overlapping patterns of expression in proliferating zones in the developing sensory organs and central nervous system.
  • Initial analyses of prominin1a and b in neoplastic tissue show increased expression of both genes in a subpopulation of cells in malignant peripheral nerve sheath tumors in tp53 mutants.
  • Based on these analyses, the zebrafish prominin1 genes will be useful markers for examining proliferating cell populations in adult organs, tissues, and tumors.
  • [MeSH-major] Cell Proliferation. Central Nervous System / embryology. Central Nervous System / metabolism. Zebrafish / embryology. Zebrafish / genetics

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20503380.001).
  • [ISSN] 1097-0177
  • [Journal-full-title] Developmental dynamics : an official publication of the American Association of Anatomists
  • [ISO-abbreviation] Dev. Dyn.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Glycoproteins; 0 / Peptides
  •  go-up   go-down


87. De Vry J, Martínez-Martínez P, Losen M, Temel Y, Steckler T, Steinbusch HW, De Baets MH, Prickaerts J: In vivo electroporation of the central nervous system: a non-viral approach for targeted gene delivery. Prog Neurobiol; 2010 Nov;92(3):227-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo electroporation of the central nervous system: a non-viral approach for targeted gene delivery.
  • Among the most frequently electroporated target tissues are skin, muscle, eye, and tumors.
  • Moreover, different regions in the central nervous system (CNS), including the developing neural tube and the spinal cord, as well as prenatal and postnatal brain have been successfully electroporated.
  • Here, we present a comprehensive review of the literature describing electroporation of the CNS with a focus on the adult brain.
  • Improving the knowledge about in vivo electroporation will pave the way for electroporation-enhanced gene therapy to treat brain carcinomas, as well as CNS disorders such as Alzheimer's disease, Parkinson's disease, and depression.
  • [MeSH-major] Central Nervous System / metabolism. Electroporation / methods. Gene Transfer Techniques. Genetic Therapy / methods

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20937354.001).
  • [ISSN] 1873-5118
  • [Journal-full-title] Progress in neurobiology
  • [ISO-abbreviation] Prog. Neurobiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  •  go-up   go-down


88. Wang T, Hui XH, Zhou LX, Ju Y, Rong HT, Zhang Q: [Expression of CXCR4 and VEGF in hemangioblastomas of the central nervous system and its relation to tumor angiogenesis]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2010 May;41(3):420-3
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of CXCR4 and VEGF in hemangioblastomas of the central nervous system and its relation to tumor angiogenesis].
  • OBJECTIVE: To evaluate the relationships of CXCR4 (chemokine stromal cell-drived factor-1 receptor) and VEGF (vaseular endothelial growth factor) expression to tumor angiogenesis in hemangioblastomas of the central nervous system.
  • The endothelial cells of blood vessels within the tumor were labeled by CD34, then the microvessel density (MVD) was calculated.
  • CXCR4 expression was located in the nucleus of tumor stromal cells.
  • VEGF expression was located in the cytoplasm and membrane of tumor stromal cells and some endothelial cells.
  • But there is no significant difference between the cystic and solid tumors, VHL disease and sporadic disease on the expression level of CXCR4, VEGF and MVD (P > 0.05).
  • [MeSH-major] Brain Neoplasms / blood supply. Hemangioblastoma / blood supply. Neovascularization, Pathologic / metabolism. Receptors, CXCR4 / metabolism. Vascular Endothelial Growth Factor A / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20629312.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CXCR4 protein, human; 0 / Receptors, CXCR4; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


89. Acciarri N, Galassi E, Giulioni M, Pozzati E, Grasso V, Palandri G, Badaloni F, Zucchelli M, Calbucci F: Cavernous malformations of the central nervous system in the pediatric age group. Pediatr Neurosurg; 2009;45(2):81-104

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cavernous malformations of the central nervous system in the pediatric age group.
  • OBJECTIVE: The main clinico-diagnostic features, risk factors and associated diseases of cavernous malformations (CMs), also called cavernous angiomas or cavernomas, of the central nervous system (CNS) in children are described, and the most relevant differences compared to the affected adult population are pointed out, focusing on the management of pediatric patients harboring cranial and spinal CMs.
  • The results were compared with those found in the most recent literature dealing with pediatric CMs of the CNS.
  • CONCLUSION: CMs represent the most common CNS vascular lesion in children, although their incidence is 4 times lower than that of the adult population.
  • The natural history of pediatric CMs throughout the neuraxis seems to be more aggressive than in adult patients; these lesions have higher rates of growth and hemorrhage, larger dimensions and often atypical radiological pictures at diagnosis.
  • Beside the familial form of the disease, which is more often associated with multiple lesions and an earlier age of clinical presentation, the major risk factor for CMs in children seems to be radiotherapy for CNS tumors.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Central Nervous System Neoplasms / surgery. Hemangioma, Cavernous, Central Nervous System / diagnosis. Hemangioma, Cavernous, Central Nervous System / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 S. Karger AG, Basel.
  • (PMID = 19307743.001).
  • [ISSN] 1423-0305
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


90. Mondin V, Ferlito A, Devaney KO, Woolgar JA, Rinaldo A: A survey of metastatic central nervous system tumors to cervical lymph nodes. Eur Arch Otorhinolaryngol; 2010 Nov;267(11):1657-66
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A survey of metastatic central nervous system tumors to cervical lymph nodes.
  • There are, of course, less frequently encountered differential diagnostic possibilities; one of the most uncommon of all is the possibility of metastasis from an intracranial tumor.
  • Intracranial tumors rarely give rise to cervical node metastases.
  • The present review examines the published experience with 128 tumors that gave rise to cervical node metastases in both adult and in pediatric patients.
  • While it is presumed that the blood-brain barrier blocks the spread of most tumors beyond the intracranial locale, this is speculative.
  • Cervical node metastases may arise from glial tumors (including glioblastoma multiforme, in both adult and pediatric patients) and non-glial tumors (such as medulloblastoma in pediatric patients).
  • The history of a previous intracranial lesion is often the key to correct diagnosis, since, without prompting, neither the pathologist nor the radiologist is likely to think of a cervical node metastasis from a brain tumor when assessing a cervical mass of unknown etiology.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Head and Neck Neoplasms / secondary. Lymphatic Metastasis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1980 Oct;53(4):562-5 [7420182.001]
  • [Cites] Radiology. 1966 Jul;87(1):55-63 [4287332.001]
  • [Cites] Acta Neuropathol. 2003 Apr;105(4):309-27 [12624784.001]
  • [Cites] Neurol Med Chir (Tokyo). 2007 Jun;47(6):273-7 [17587781.001]
  • [Cites] Neurochirurgie. 1976;22(6):653-69 [193060.001]
  • [Cites] J Korean Med Sci. 2004 Dec;19(6):911-4 [15608410.001]
  • [Cites] Acta Neurochir (Wien). 1981;57(1-2):99-105 [6267905.001]
  • [Cites] Hum Pathol. 1979 Jul;10(4):453-67 [381159.001]
  • [Cites] Neuropathology. 2003 Jun;23 (2):146-9 [12777104.001]
  • [Cites] J Neurooncol. 1988;6(1):53-9 [3294352.001]
  • [Cites] J Neurooncol. 2006 Sep;79(2):187-90 [16645723.001]
  • [Cites] Arch Anat Cytol Pathol. 1995;43(5-6):342-9 [8729851.001]
  • [Cites] W V Med J. 1998 Sep-Oct;94(5):276-8 [9803886.001]
  • [Cites] Cancer. 1990 Jul 1;66(1):180-4 [2162242.001]
  • [Cites] J Neurosurg. 1974 Feb;40(2):206-12 [4809119.001]
  • [Cites] Taiwan Yi Xue Hui Za Zhi. 1975 Mar;74(3):220-8 [167101.001]
  • [Cites] Genes Chromosomes Cancer. 2009 Mar;48(3):229-38 [19025795.001]
  • [Cites] J Cancer Res Ther. 2007 Apr-Jun;3(2):102-4 [17998733.001]
  • [Cites] Am J Med Sci. 1989 Aug;298(2):109-18 [2669475.001]
  • [Cites] Cytopathology. 1997 Dec;8(6):421-7 [9439895.001]
  • [Cites] Arch Pathol. 1962 Mar;73:223-9 [14461268.001]
  • [Cites] J Neurol. 1982;227(3):151-5 [6181222.001]
  • [Cites] Cancer. 1993 Jun 15;71(12):4111-7 [8508376.001]
  • [Cites] Neuro Oncol. 2003 Jan;5(1):14-8 [12626129.001]
  • [Cites] Tumori. 1984 Aug 31;70(4):389-92 [6474586.001]
  • [Cites] J Neurosurg. 1991 Jun;74(6):872-7 [2033446.001]
  • [Cites] Acta Neuropathol. 1981;54(4):269-73 [7270083.001]
  • [Cites] Acta Neurochir (Wien). 2008 Jul;150(7):699-702; discussion 702-3 [18548193.001]
  • [Cites] J Pathol. 1973 Apr;109(4):335-43 [4720914.001]
  • [Cites] Brain. 1961 Jun;84:301-9 [13733291.001]
  • [Cites] Pediatr Neurosurg. 1994;20(4):269-71 [8043466.001]
  • [Cites] Neurology. 1989 Dec;39(12):1593-6 [2685656.001]
  • [Cites] Neoplasma. 1962;9:585-92 [13991553.001]
  • [Cites] Br J Neurosurg. 1994;8(1):87-92 [8011201.001]
  • [Cites] Cancer. 1984 Feb 15;53(4):974-81 [6692295.001]
  • [Cites] Pathology. 1984 Apr;16(2):217-21 [6087260.001]
  • [Cites] J Neurooncol. 2010 May;97(3):451-7 [19898745.001]
  • [Cites] Indian J Pathol Microbiol. 2007 Apr;50(2):422-5 [17883098.001]
  • [Cites] J Neurosurg. 1961 May;18:313-30 [13761772.001]
  • [Cites] Surg Neurol. 1977 Nov;8(5):347-9 [199955.001]
  • [Cites] Neurol Neurochir Pol. 1971 Sep-Oct;5(5):753-7 [5161087.001]
  • [Cites] Cancer. 1976 Mar;37(3):1577-83 [177171.001]
  • [Cites] Acta Cytol. 1993 Nov-Dec;37(6):938-42 [8249517.001]
  • [Cites] Pathology. 2009 Feb;41(2):197-9 [19152196.001]
  • [Cites] Neurol Neurochir Pol. 2009 Mar-Apr;43(2):183-90 [19484696.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1992 Jul;118(7):755-6 [1320896.001]
  • [Cites] J Neurosurg. 1974 Nov;41(5):607-9 [4371027.001]
  • [Cites] Duodecim. 1974;90(24):1744-8 [4374348.001]
  • [Cites] Cancer. 1980 Jan 1;45(1):112-25 [6985826.001]
  • [Cites] Zentralbl Neurochir. 1975;36(1):27-36 [1224866.001]
  • [Cites] Acta Neurochir (Wien). 2001;143(6):575-86 [11534674.001]
  • [Cites] Br J Neurosurg. 2005 Aug;19(4):348-51 [16455543.001]
  • [Cites] No Shinkei Geka. 1979 Oct;7(10 ):1005-10 [522948.001]
  • [Cites] Clin Neuropathol. 2005 Nov-Dec;24(6):247-51 [16320817.001]
  • [Cites] Cancer. 2005 Apr 1;103(7):1427-30 [15690330.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1982 Fall;4(3):259-62 [7149167.001]
  • [Cites] Br J Surg. 1951 Jul;39(153):56-65 [14858828.001]
  • [Cites] Arkh Patol. 1960;22(4):78-80 [13804641.001]
  • [Cites] Brain. 1964 Jun;87:379-412 [14188281.001]
  • [Cites] Cancer Radiother. 2006 May;10(3):107-11 [16600659.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1969 Jun;32(3):249-53 [5795118.001]
  • [Cites] Hum Pathol. 1987 Jan;18(1):90-2 [3817801.001]
  • [Cites] No Shinkei Geka. 1986 Jan;14(1):59-65 [3951664.001]
  • [Cites] Vopr Onkol. 2009;55(2):230-6 [19514382.001]
  • [Cites] Neurosurgery. 1981 Mar;8(3):391-6 [7242888.001]
  • [Cites] J Histochem Cytochem. 1998 May;46(5):585-94 [9606106.001]
  • [Cites] J Clin Neurosci. 2009 Nov;16(11):1485-6 [19581092.001]
  • [Cites] Diagn Cytopathol. 1996 Jul;15(1):60-5 [8807254.001]
  • [Cites] Arch Neurol. 1968 Jun;18(6):649-53 [5652993.001]
  • [Cites] Am J Otolaryngol. 1983 Sep-Oct;4(5):297-324 [6416092.001]
  • [Cites] Arkh Patol. 1958 Jun;20(6):83-6 [13560319.001]
  • [Cites] J Lancet. 1964 Jul;84:227-9 [14153500.001]
  • [Cites] J Neurosurg. 1969 Jul;31(1):50-8 [4307543.001]
  • [Cites] Neurol Med Chir (Tokyo). 2010;50(2):161-4 [20185886.001]
  • [Cites] Neurol Med Chir (Tokyo). 2004 Dec;44(12):669-73 [15684601.001]
  • [Cites] J Neurosurg. 1970 Jul;33(1):88-94 [4316740.001]
  • [Cites] Pathologe. 1993 Dec;14(6):386-90 [8121896.001]
  • [Cites] J Neurosurg. 1967 Dec;27(6):568-73 [6065130.001]
  • [Cites] Arkh Patol. 1979;41(11):68-70 [518368.001]
  • [Cites] Acta Neurochir (Wien). 2001;143(1):25-9 [11345714.001]
  • [Cites] J Pathol Bacteriol. 1959 Jul;78:187-95 [14439916.001]
  • [Cites] J Neurosurg. 1973 Feb;38(2):226-31 [4540397.001]
  • [Cites] Zhonghua Yi Xue Za Zhi (Taipei). 1992 May;49(5):354-64 [1320996.001]
  • [Cites] Mayo Clin Proc. 2007 Oct;82(10):1271-86 [17908533.001]
  • [Cites] Ann Saudi Med. 1997 May;17(3):340-3 [17369737.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1991 Jan;54(1):80-6 [2010766.001]
  • [Cites] Diagn Cytopathol. 1994;11(1):68-73 [7956665.001]
  • [Cites] Acta Neurochir (Wien). 1976;35(4):247-59 [998355.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Nov-Dec;17 (10 ):1929-31 [8933881.001]
  • [Cites] Rev Esp Otoneurooftalmol Neurocir. 1951 Sep-Oct;10(57):313-6 [14920995.001]
  • [Cites] J Laryngol Otol. 1991 Mar;105(3):229-31 [2019817.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1975 Nov;38(11):1133-5 [1206423.001]
  • [Cites] Pediatr Dev Pathol. 2009 May-Jun;12(3):244-8 [19086745.001]
  • [Cites] Neurosurgery. 2008 Oct;63(4):720-6; author reply 726-7 [18981882.001]
  • [Cites] Childs Nerv Syst. 1990 May;6(3):179-82 [2162735.001]
  • [Cites] J Neurosurg. 1977 Nov;47(5):766-70 [908941.001]
  • [Cites] Acta Neurochir (Wien). 1959;7:263-73 [13805555.001]
  • [Cites] Can J Neurol Sci. 1981 May;8(2):115-9 [7296419.001]
  • [Cites] Arch Derm Syphilol. 1949 Jun;59(6):626-35 [18151073.001]
  • [Cites] Z Krebsforsch. 1955;60(5):590-6 [13300505.001]
  • [Cites] Am J Otolaryngol. 1983 Jan-Feb;4(1):74-6 [6324605.001]
  • [Cites] No To Shinkei. 1972 Mar;14 (3):339-51 [4335553.001]
  • [Cites] Psychiatr Neurol Med Psychol (Leipz). 1971 Mar;23(3):167-74 [4330749.001]
  • [Cites] Surg Neurol. 1979 Oct;12(4):337-9 [524254.001]
  • [Cites] Zentralbl Neurochir. 1952;12(6):347-56 [13091280.001]
  • [Cites] J Oral Pathol Med. 1997 Sep;26(8):388-92 [9379431.001]
  • [Cites] Cancer. 1958 Sep-Oct;11(5):888-94 [13585341.001]
  • [Cites] J Neurosurg. 1973 May;38(5):631-4 [4351224.001]
  • [Cites] Clin Neuropathol. 1988 May-Jun;7(3):131-3 [3203482.001]
  • [Cites] Klin Padiatr. 1987 Jan-Feb;199(1):19-21 [3560762.001]
  • [Cites] No Shinkei Geka. 1985 Nov;13(11):1245-50 [4088447.001]
  • [Cites] J Neurosurg. 1974 Feb;40(2):255-9 [4809126.001]
  • [Cites] Pathol Res Pract. 2009;205(7):502-7 [19410385.001]
  • [Cites] J Neurosurg. 1985 Jun;62(6):918-21 [2987441.001]
  • [Cites] Am J Clin Pathol. 1963 Feb;39:148-60 [13939379.001]
  • [Cites] J Neurooncol. 2004 Feb;66(3):265-71 [15015656.001]
  • [Cites] Ann Neurol. 1980 Feb;7(2):113-7 [7369716.001]
  • [Cites] J Neurosurg. 1967 May;26(5):542-7 [6025328.001]
  • [Cites] Psychiatr Neurol Neurochir. 1967 Jul-Aug;70(4):245-59 [6052791.001]
  • [Cites] J Comput Assist Tomogr. 1990 Mar-Apr;14(2):294-6 [2312862.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64(3):294-8 [5855579.001]
  • [Cites] Tumori. 2008 Jan-Feb;94(1):40-51 [18468334.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Dec;59(12):1044-50 [11138924.001]
  • (PMID = 20694730.001).
  • [ISSN] 1434-4726
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  •  go-up   go-down


91. Altundag K, Bondy ML, Mirza NQ, Kau SW, Broglio K, Hortobagyi GN, Rivera E: Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis. Cancer; 2007 Dec 15;110(12):2640-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis.
  • BACKGROUND: Breast cancer is the second most common cause of central nervous system (CNS) metastases.
  • Several risk factors for CNS metastases have been reported.
  • The objective of the current study was to describe clinicopathologic characteristics and prognostic factors in breast cancer patients with CNS metastases.
  • METHODS: The authors retrospectively evaluated clinical data from 420 patients who had been diagnosed with breast cancer and CNS metastasis between 1994 and 2004 at the University of Texas M. D.
  • Most patients had invasive ductal histology (91.2%), grade 3 tumors (81.4%) (using the modified Black nuclear grading system), T2 tumor classification (40.1%), and N1 lymph node status (59.7%) diagnosis.
  • CNS metastasis was the site of first recurrence in 53 patients (12%).
  • The median time from breast cancer diagnosis to CNS metastasis was 30.9 months (range, from -5 months to 216.7 months).
  • The median follow-up after a diagnosis of CNS metastasis was 6 months (range, 7-95.9 months).
  • CONCLUSIONS: The current results indicated that the prognosis remains patients with breast cancer metastatic to the CNS.
  • More effective treatment approaches are needed for patients with CNS metastases, even for those with favorable prognostic factors, such as ER-positive tumors or younger age.
  • [MeSH-major] Breast Neoplasms / pathology. Central Nervous System Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Middle Aged. Prognosis. Retrospective Studies. Survival Rate. Time Factors


92. Lim M, Cheshier S, Steinberg GK: New vessel formation in the central nervous system during tumor growth, vascular malformations, and Moyamoya. Curr Neurovasc Res; 2006 Aug;3(3):237-45
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New vessel formation in the central nervous system during tumor growth, vascular malformations, and Moyamoya.
  • In the normal adult brain, blood vessel formation is tightly down-regulated.
  • However, pathologic processes such as brain tumors can increase the proportion of endothelial cells involved in angiogenesis.
  • In this review, we will describe the process of angiogenesis in the central nervous system.
  • We will also look into their significance in disease processes such as neoplasms, arteriovenous malformations (AVM), and Moyamoya disease.
  • [MeSH-major] Brain / blood supply. Brain Neoplasms / blood supply. Central Nervous System Vascular Malformations / pathology. Moyamoya Disease / pathology. Neovascularization, Pathologic. Neovascularization, Physiologic

  • Genetic Alliance. consumer health - Vascular Malformations.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16918387.001).
  • [ISSN] 1567-2026
  • [Journal-full-title] Current neurovascular research
  • [ISO-abbreviation] Curr Neurovasc Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Angiopoietins; 0 / Integrins; 0 / Platelet-Derived Growth Factor; 0 / Vascular Endothelial Growth Factor A; 62031-54-3 / Fibroblast Growth Factors
  • [Number-of-references] 98
  •  go-up   go-down


93. Liao W, Liu Y, Wang X, Jiang X, Tang B, Fang J, Chen C, Hu Z: Differentiation of primary central nervous system lymphoma and high-grade glioma with dynamic susceptibility contrast-enhanced perfusion magnetic resonance imaging. Acta Radiol; 2009 Mar;50(2):217-25
Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation of primary central nervous system lymphoma and high-grade glioma with dynamic susceptibility contrast-enhanced perfusion magnetic resonance imaging.
  • BACKGROUND: Preoperative differentiation of primary central nervous system lymphomas (PCNSLs) from other tumors is important for presurgical staging, intraoperative management, and postoperative treatment.
  • Microvessel density (MVD) was evaluated using immunohistochemical staining of surgical specimens with anti-CD34, and MVDs of the two tumor groups were compared by using Student's t test.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Glioma / diagnosis. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Contrast Media. Diagnosis, Differential. Female. Gadolinium DTPA. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19096950.001).
  • [ISSN] 1600-0455
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


94. Lonser RR, Vortmeyer AO, Butman JA, Glasker S, Finn MA, Ammerman JM, Merrill MJ, Edwards NA, Zhuang Z, Oldfield EH: Edema is a precursor to central nervous system peritumoral cyst formation. Ann Neurol; 2005 Sep;58(3):392-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Edema is a precursor to central nervous system peritumoral cyst formation.
  • Despite the common occurrence and frequent clinical effects of peritumoral cysts in the central nervous system (CNS), the mechanism underlying their development and evolution is not understood.
  • Because they commonly produce peritumoral cysts and because serial magnetic resonance imaging (MRI) is obtained in von Hippel-Lindau disease patients, hemangioblastomas provide an opportunity to examine the pathophysiology of CNS peritumoral cyst formation.
  • Serial MRI was correlated with the clinical findings in 16 von Hippel-Lindau disease patients with 22 CNS hemangioblastomas (11 spinal cord; 11 cerebellar) that were associated with the appearance and evolution of peritumoral cysts.
  • MRI clearly showed peritumoral edema that developed and slowly and progressively evolved into enlarging hemangioblastoma-associated cysts in all tumors (mean follow-up, 130 +/- 38 months; mean +/- standard deviation).
  • CNS peritumoral cyst formation is initiated by increased tumor vascular permeability, increased interstitial pressure in the tumor, and plasma extravasation with convective distribution into the surrounding tissue.
  • When the delivery of plasma from the tumor exceeds the capacity of the surrounding tissue to absorb the extravasated fluid, edema (with its associated increased interstitial pressure) and subsequent cyst formation occur.
  • [MeSH-major] Brain Neoplasms / pathology. Central Nervous System Cysts / pathology. Edema / pathology
  • [MeSH-minor] Adult. Autopsy / methods. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging / methods. Male. Time Factors. Vascular Endothelial Growth Factor A / blood. Vascular Endothelial Growth Factor A / cerebrospinal fluid

  • Genetic Alliance. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Edema.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16130092.001).
  • [ISSN] 0364-5134
  • [Journal-full-title] Annals of neurology
  • [ISO-abbreviation] Ann. Neurol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


95. Agrawal M, Uppin MS, Patibandla MR, Bhattacharjee S, Panigrahi MK, Saradhi V, Rani JY, Purohit AK, Challa S: Teratomas in central nervous system: a clinico-morphological study with review of literature. Neurol India; 2010 Nov-Dec;58(6):841-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Teratomas in central nervous system: a clinico-morphological study with review of literature.
  • AIMS: To study the demographic, clinico-morphological and follow-up data of central nervous system (CNS) teratomas.
  • MATERIALS AND METHODS: Cases diagnosed as mature or immature teratomas in the CNS over a 20-year period were included in the study.
  • RESULTS: A total of 14 tumors were diagnosed as teratomas.
  • Of these, 11 were mature cystic teratomas; and 1 case each, of teratoma with malignant transformation, terato-carcinoma and mixed germ cell tumor (immature teratoma with germinoma).
  • Radiologically, contrast enhancement with predominantly solid component was suggestive of malignancy or an aggressive tumor.
  • Excision was curative or provided symptomatic relief in most cases; terato-carcinoma and mixed germ cell tumor patients needed adjuvant radiotherapy.
  • CONCLUSION: CNS teratomas are rare.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Central Nervous System Neoplasms / surgery. Teratoma / diagnosis. Teratoma / surgery
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Infant. Infant, Newborn. Magnetic Resonance Imaging. Male. Middle Aged. Neurosurgery. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21150046.001).
  • [ISSN] 0028-3886
  • [Journal-full-title] Neurology India
  • [ISO-abbreviation] Neurol India
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] India
  •  go-up   go-down


96. Fogh S, Machtay M, Werner-Wasik M, Curran WJ Jr, Bonanni R, Axelrod R, Andrews D, Dicker AP: Phase I trial using patupilone (epothilone B) and concurrent radiotherapy for central nervous system malignancies. Int J Radiat Oncol Biol Phys; 2010 Jul 15;77(4):1009-16
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial using patupilone (epothilone B) and concurrent radiotherapy for central nervous system malignancies.
  • PURPOSE: Based on preclinical data indicating the radiosensitizing potential of epothilone B, the present study was designed to evaluate the toxicity and response rate of patupilone, an epothilone B, with concurrent radiotherapy (RT) for the treatment of central nervous system malignancies.
  • Eligible patients had recurrent gliomas (n = 10) primary (n = 5) or metastatic (n = 17) brain tumors.
  • Primary central nervous system malignancies received RT to a median dose of 60 Gy.
  • Central nervous system metastases received whole brain RT to a median dose of 37.4 Gy, and patients with recurrent gliomas underwent stereotactic RT to a median dose of 37.5 Gy.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Brain Neoplasms. Epothilones / adverse effects. Glioma. Maximum Tolerated Dose. Radiation-Sensitizing Agents / adverse effects
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy / methods. Drug Administration Schedule. Female. Hemorrhage / chemically induced. Humans. Lung Diseases / chemically induced. Male. Middle Aged. Pneumonia / chemically induced. Radiotherapy Dosage. Tubulin Modulators / administration & dosage. Tubulin Modulators / adverse effects. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 19879067.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA056036-08
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Epothilones; 0 / Radiation-Sensitizing Agents; 0 / Tubulin Modulators; UEC0H0URSE / epothilone B
  •  go-up   go-down


97. Nicholson HS, Kretschmar CS, Krailo M, Bernstein M, Kadota R, Fort D, Friedman H, Harris MB, Tedeschi-Blok N, Mazewski C, Sato J, Reaman GH: Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer; 2007 Oct 1;110(7):1542-50
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
  • BACKGROUND: Effective chemotherapy is lacking for most types of central nervous system (CNS) tumors in children.
  • Temozolomide, an agent with activity against adult brain tumors, was investigated in children and adolescents with recurrent CNS tumors.
  • RESULTS: The cohort comprised 122 patients, including 113 with CNS tumors.
  • Among 104 evaluable patients with CNS tumors, 5 PRs and 1 CR were observed.
  • PRs occurred in 1 of 23 evaluable patients with high-grade astrocytoma, 1 of 21 with low-grade astrocytoma, and 3 of 25 with medulloblastoma/primitive neuroectodermal tumor (PNET).
  • No responses were observed in patients with ependymoma, brain-stem glioma, or other CNS tumors.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Administration, Oral. Adolescent. Adult. Astrocytoma / drug therapy. Central Nervous System Neoplasms / drug therapy. Child. Child, Preschool. Drug Administration Schedule. Ependymoma / drug therapy. Female. Humans. Infant. Male. Medulloblastoma / drug therapy. Neuroectodermal Tumors, Primitive / drug therapy. Treatment Outcome


98. Tehrani M, Friedman TM, Olson JJ, Brat DJ: Intravascular thrombosis in central nervous system malignancies: a potential role in astrocytoma progression to glioblastoma. Brain Pathol; 2008 Apr;18(2):164-71
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravascular thrombosis in central nervous system malignancies: a potential role in astrocytoma progression to glioblastoma.
  • We investigated whether intravascular thrombosis was more frequent or prominent in GBM than other central nervous system (CNS) malignancies and considered its prognostic significance in anaplastic astrocytoma (AA; WHO grade III), which lacks necrosis.
  • Histologic sections were examined for thrombosis, necrosis and microvascular hyperplasia from each of 297 CNS tumors, including 103 GBMs, 46 AAs, 20 diffuse astrocytoma (DAs; WHO grade II), eight anaplastic oligodendrogliomas (AOs; WHO grade III), 20 oligodendrogliomas (ODs; WHO grade II), 49 metastatic carcinomas (METs), 31 primary central nervous system lymphomas (PCNSLs) and 20 medulloblastomas (MBs).
  • Among newly diagnosed tumors, thrombosis was present in 92% of GBM resections, significantly greater than other types of CNS malignancies.
  • Of tumors with thrombosis, GBMs had a higher frequency of affected vessels than AAs, DAs, AOs, ODs and MBs, but had a frequency similar to METs and PCNSLs.
  • The sensitivity of thrombosis for the diagnosis of GBM in this set of tumors was 92% and the specificity was 91%.
  • Thus, intravascular thrombosis is more frequent in GBM than other CNS malignancies.

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Thrombosis.
  • MedlinePlus Health Information. consumer health - Blood Clots.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89 [15977639.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2584-91 [16510576.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Jun;65(6):529-39 [16783163.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Sep;65(9):846-54 [16957578.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10643-6 [17108099.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 May;62(2):126-36 [17293122.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Proc Staff Meet Mayo Clin. 1949 Feb 2;24(3):71-5 [18111063.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2606-18 [10861440.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Mar;60(3):248-62 [11245209.001]
  • [Cites] Thromb Res. 2001 Jun 15;102(6):V215-24 [11516455.001]
  • [Cites] Curr Opin Pulm Med. 2001 Sep;7(5):326-31 [11584184.001]
  • [Cites] J Neurosurg. 1991 Mar;74(3):480-6 [1899696.001]
  • [Cites] Nature. 1992 Oct 29;359(6398):845-8 [1279432.001]
  • [Cites] Neurosurgery. 1995 Feb;36(2):375-80; discussion 380-1 [7731519.001]
  • [Cites] Cancer. 1996 Mar 15;77(6):1161-6 [8635139.001]
  • [Cites] Noshuyo Byori. 1996 Nov;13(2):115-8 [8958516.001]
  • [Cites] J Pathol Bacteriol. 1954 Jul;68(1):231-3 [13212575.001]
  • [Cites] Acta Pathol Microbiol Scand. 1950;27(1):51-64 [15406242.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1406-13 [15735028.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Neuro Oncol. 2005 Apr;7(2):122-33 [15831231.001]
  • [Cites] Trends Mol Med. 2002;8(4 Suppl):S62-7 [11927290.001]
  • [Cites] Clin Biochem. 2002 Jun;35(4):321-5 [12135696.001]
  • [Cites] Neurosurgery. 2002 Jul;51(1):2-12; discussion 12-3 [12182418.001]
  • [Cites] Ann Intern Med. 2003 Apr 15;138(8):659-68 [12693889.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):920-7 [14871821.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1147-52 [15001257.001]
  • [Cites] Lab Invest. 2004 Apr;84(4):397-405 [14990981.001]
  • [Cites] Cancer. 1983 Aug 1;52(3):550-4 [6305479.001]
  • [Cites] Cancer. 1987 May 1;59(9):1617-25 [3030531.001]
  • [Cites] Cancer. 1988 Nov 15;62(10):2152-65 [3179928.001]
  • (PMID = 18093251.001).
  • [ISSN] 1015-6305
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS053727-01; United States / NINDS NIH HHS / NS / R01 NS053727; United States / NINDS NIH HHS / NS / NS053727; United States / NINDS NIH HHS / NS / R01 NS053727-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Switzerland
  • [Other-IDs] NLM/ NIHMS82090; NLM/ PMC2610479
  •  go-up   go-down


99. Neder L, Scheithauer BW, Turel KE, Arnesen MA, Ketterling RP, Jin L, Moynihan TJ, Giannini C, Meyer FB: Desmoplastic small round cell tumor of the central nervous system: report of two cases and review of the literature. Virchows Arch; 2009 Apr;454(4):431-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Desmoplastic small round cell tumor of the central nervous system: report of two cases and review of the literature.
  • Desmoplastic small round cell tumor (DSRCT) is a malignant tumor often involving the abdominal and/or pelvic peritoneum.
  • Only one fully documented example has arisen in the central nervous system (CNS).
  • In conclusion, CNS DSRCT follows a similar aggressive course as do peritoneal examples.
  • Although rare, DSRCT warrants consideration in the differential diagnosis of "malignant small blue cell tumors" of the CNS.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Cerebellar Neoplasms / pathology. Cerebellopontine Angle / pathology
  • [MeSH-minor] Adult. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Magnetic Resonance Imaging. Male. Oncogene Proteins, Fusion / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Desmoplastic Small Round Cell Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1992 Oct;16(10):998-1006 [1384373.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Am J Surg Pathol. 1998 Nov;22(11):1303-13 [9808123.001]
  • [Cites] Am J Surg Pathol. 1990 Jul;14(7):633-42 [2356923.001]
  • [Cites] J Clin Oncol. 1998 Sep;16(9):3028-36 [9738572.001]
  • [Cites] Diagn Mol Pathol. 1998 Feb;7(1):24-8 [9646031.001]
  • [Cites] Am J Surg Pathol. 1996 Jan;20(1):112-7 [8540602.001]
  • [Cites] Hum Pathol. 1997 Apr;28(4):502-9 [9104953.001]
  • [Cites] Cancer Cell. 2002 Dec;2(6):497-505 [12498718.001]
  • [Cites] Arch Pathol Lab Med. 2006 May;130(5):728-32 [16683894.001]
  • [Cites] Hum Pathol. 1992 Apr;23(4):454-64 [1563748.001]
  • [Cites] Arch Pathol Lab Med. 1989 Sep;113(9):1019-29 [2505732.001]
  • [Cites] Am J Surg Pathol. 2002 Jul;26(7):823-35 [12131150.001]
  • [Cites] Am J Surg Pathol. 1989 May;13(5):413-21 [2469334.001]
  • [Cites] Nature. 1990 Jul 12;346(6280):194-7 [2164159.001]
  • [Cites] Am J Surg Pathol. 1995 Jun;19(6):659-65 [7755152.001]
  • [Cites] Diagn Mol Pathol. 2005 Mar;14(1):23-8 [15714060.001]
  • [Cites] Am J Surg Pathol. 1999 Nov;23(11):1408-13 [10555010.001]
  • [Cites] Cancer Genet Cytogenet. 1993 Aug;69(1):17-21 [8374894.001]
  • [Cites] Exp Cell Res. 2001 Mar 10;264(1):74-99 [11237525.001]
  • [Cites] Acta Cytol. 1995 Mar-Apr;39(2):377-8 [7887076.001]
  • [Cites] J Surg Oncol. 1999 Aug;71(4):269-72 [10440769.001]
  • [Cites] J Neurosurg. 1996 Jul;85(1):56-65 [8683283.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Acta Cytol. 1993 Jan-Feb;37(1):77-82 [7679537.001]
  • [Cites] Semin Diagn Pathol. 1996 Aug;13(3):204-12 [8875710.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Feb 14;92(4):1028-32 [7862627.001]
  • [Cites] Am J Surg Pathol. 2004 May;28(5):644-50 [15105654.001]
  • [Cites] Virchows Arch. 1998 Feb;432(2):135-41 [9504858.001]
  • [Cites] Mod Pathol. 1999 Jul;12(7):729-34 [10430278.001]
  • [Cites] Ultrastruct Pathol. 2000 Sep-Oct;24(5):333-7 [11071572.001]
  • [Cites] Hum Pathol. 1999 Apr;30(4):430-5 [10208465.001]
  • [Cites] Pediatr Pathol. 1989;9(2):177-83 [2473463.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1991;418(3):207-14 [1900966.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):2837-40 [8187063.001]
  • [Cites] Am J Surg Pathol. 1991 Jun;15(6):499-513 [1709557.001]
  • [Cites] Gynecol Oncol. 2000 Oct;79(1):124-8 [11006044.001]
  • [Cites] Arch Pathol Lab Med. 2002 Oct;126(10):1226-8 [12296765.001]
  • [Cites] Semin Cancer Biol. 2005 Jun;15(3):197-205 [15826834.001]
  • [Cites] Semin Diagn Pathol. 2003 Feb;20(1):25-45 [12693673.001]
  • [Cites] Pediatr Blood Cancer. 2008 Oct;51(4):545-8 [18561179.001]
  • (PMID = 19263077.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / EWS1-WT1 fusion protein, human; 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


100. Agarwal PA, Menon S, Smruti BK, Singhal BS: Primary central nervous system lymphoma: a profile of 26 cases from Western India. Neurol India; 2009 Nov-Dec;57(6):756-63
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary central nervous system lymphoma: a profile of 26 cases from Western India.
  • BACKGROUND: Primary central nervous system (CNS) lymphoma (PCNSL) is a rare malignant non-Hodgkin's lymphoma and it accounts for 1% of all intracranial tumors.
  • [MeSH-major] Central Nervous System Neoplasms. Lymphoma
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD / metabolism. Antiretroviral Therapy, Highly Active / methods. Enzyme-Linked Immunosorbent Assay / methods. Female. HIV Seropositivity / drug therapy. Humans. India / epidemiology. L-Lactate Dehydrogenase / blood. Magnetic Resonance Imaging / methods. Male. Mental Status Schedule. Middle Aged. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20139505.001).
  • [ISSN] 0028-3886
  • [Journal-full-title] Neurology India
  • [ISO-abbreviation] Neurol India
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antigens, CD; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down






Advertisement